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Owing to its strategic location in the body along with performing over 500 daily 
functions, liver health is indispensable to survival. Following any form of acute or chronic 
hepatic injury, a repair process is induced which, if successful, restores histology and function. 
However, continuous insult can lead to unremitting immune response, hepatocyte death, 
proliferation, wound healing, and sets the stage for DNA damage and errors, eventually leading 
to dysplasia and neoplasia. Wnt/β-catenin signaling is implicated in a variety of processes to 
maintain liver homeostasis and promote regeneration, but its dysregulation is often evident in 
chronic liver diseases and cancer. To further understand the role and regulation of the Wnt/β-
catenin pathway in hepatic pathophysiology, we focused on studying this pathway in a model of 
chronic iron overload replicating hereditary hemochromatosis (HH), hepatocellular carcinoma 
(HCC), a primary liver tumor with rising incidence, and in metabolic zonation and liver 
regeneration (LR) after partial hepatectomy (PH), two fundamental attributes innate to the liver. 
The underlying goal of our studies was to address the role of β-catenin in hepatocyte biology, 
and identify the cell source and identity of Wnt ligands that regulate β-catenin signaling in 
hepatocytes, both in hepatic health and in disease. HH is a genetic iron overload disorder with no 
cure, invasive treatments, and no representative animal models that recapitulate human disease. 
β-Catenin knockout mice (bKO), when subjected to chronic iron overload led to remarkable 
hepatic injury compared to control mice (bCON) and displayed inflammation, steatosis and 
fibrosis due to enhanced oxidative stress and lipid peroxidation. This led us to identify an 
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important role of β-catenin in regulating the redox state of hepatocytes as we alleviated the 
pathology by supplementing the antioxidant N-acetyl-L-cysteine to bKO while challenging them 
with iron overload. Additionally, bKO on high iron diet serve as a novel animal model that 
robustly mimic disease development and progression of an HH patient. Chronic injury like HH 
often progresses to HCC accompanied by ongoing hepatocyte death and proliferation, along with 
infiltration of immune cells including macrophages. We next assessed if hepatocytes and 
macrophages could be the source of Wnt ligands that may activate non-mutated β-catenin in 
hepatocytes to contribute to injury, inflammation and HCC. We generated hepatocyte-specific 
(HP-KO) and macrophage-specific (MP-KO) Wntless knockout mice, unable to secrete Wnts 
from respective cell types and subjected them to diethylnitrosamine/carbon tetrachloride 
(DEN/CCl4). This model yields non-β-catenin mutated HCC with 100% penetrance by five 
months. HP-KO and respective controls (HP-CON) had comparable tumor burden albeit with 
some distinct signaling indicating overall that hepatocytes are not a major contributor of Wnts in 
HCC in this model. MP-KO displayed two distinct, litter-specific phenotypes. In one group, MP-
KO had greater tumor burden than control mice (MP-CON), and in another group MP-KO had 
reduced tumor burden compared to MP-CON. We revealed different HCC phenotypes in MP-
CON from both groups, suggesting MP Wnts will promote or suppress tumors depending on the 
underlying oncogenic and inflammatory milieu. Finally, we queried the role of cell-specific Wnts 
in metabolic zonation and LR. Using endothelial cell-specific Wntless knockout mice (EC-KO), 
we confirmed EC to be the source of Wnt ligands that directed β-catenin activation in pericentral 
hepatocytes. Also, EC lining sinusoids regulated Cyclin D1 expression and eventually 
hepatocyte proliferation during LR after PH. We next identified Wnt2 and Wnt9b as the Wnts 
chiefly from EC to be regulators of hepatic zonation and during LR after PH. Finally, we provide 
 vi 
in vitro evidence that shear stress produced after PH may initiate Wnt expression in EC and 
hence may initiate the process of LR. Overall, our data elucidates the role and regulation of 
Wnt/β-catenin signaling and begins to outline the complex paracrine cell-molecule circuitry of 
this intricate pathway in hepatic health and disease. 
 vii 
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1.0  INTRODUCTION 
The liver is a vital organ unique in its ability to regenerate when up to 70% is removed or acute 
hepatic injury is sustained. However, during chronic liver diseases the ability to regenerate is 
impaired, and instead the hepatic injury progresses to fibrosis and hepatocellular carcinoma. 
Therapies for chronic liver diseases and liver cancer are limited and ineffective, so current 
studies aim to understand regeneration kinetics to eventually shift injured livers towards 
regeneration and away from fibrosis and cancer (Fig.1). A major signaling pathway in liver 
homeostasis and disease is the Wnt/β-catenin pathway. This dissertation focuses on the role of β-
catenin in a specific chronic liver disease (Aim 1), namely hereditary hemochromatosis, 
hepatocellular carcinoma after chronic hepatic injury (Aim 2), and liver regeneration in the 
context of a healthy liver (Aim 3). We will show the importance of Wnt/β-catenin in each arm of 
the liver disease dogma and provide insights that will lead to further understanding of signaling 
in disease and health and to eventual therapeutic options. For a list of all animal models used in 
this study, please refer to Appendix A. 
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Figure 1: Central dogma of liver injury and regeneration. 
(A) During chronic liver disease, the liver loses its ability to regenerate, and hepatic injury 
progresses to fibrosis and hepatocellular carcinoma. (B) Current studies to understand liver 
regeneration will lead to improved therapies for chronic liver diseases and induce hepatocyte 
repopulation while preventing fibrosis and hepatocellular carcinoma. This proposal focuses on 
the chronic liver disease hereditary hemochromatosis (Aim 1), hepatocellular carcinoma (Aim 
2), and liver regeneration (Aim 3). 
1.1 WNT/Β-CATENIN SIGNALING OVERVIEW 
1.1.1 Canonical Wnt signaling “on” and “off” 
Canonical Wnt signaling is a highly regulated pathway functioning in processes ranging from 
development to cancer (Fig.2). Wnt ligands are insoluble secreted glycoproteins that require 
palmitoylation by Porcupine O Acyltransferase (PORC) in the endoplasmic reticulum, enabling 
Wnt interaction with Wntless (Wls) in the Golgi. Wls acts as a cargo receptor and modulates 
vesicular transport of Wnts outside the cell (1), making both Wls and PORC necessary for Wnt 
function and secretion. As Wnts are insoluble and hydrophobic, they likely travel short distances 
to target cells (2), although a complete understanding of the Wnt morphogen gradient is lacking. 
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Additional studies have suggested Wnts travel via exosomes, requiring Wls, and remain on 
exosomal membranes to interact with target cells (3, 4). It is also likely Wnts can remain tethered 
to their parent cell membrane.  
In the absence of Wnt, β-catenin is bound by the “destruction complex” in the cytoplasm, 
composed primarily of Adenomatous Polyposis Coli (APC), Axin, Casein Kinase I alpha 
(CKIα), and Glycogen Synthase Kinase 3β (GSK3β) (5). This causes β-catenin phosphorylation 
at serine 45 by CKIα (6), which primes β-catenin phosphorylation by GSKβ3 at serines 33, 37, 
and threonine 41 (7). This results in β-catenin ubiquitination and subsequent proteasome-
mediated degradation (8). When Wnt is present, it interacts with a Frizzled receptor (Fzd) and 
Low-Density Lipoprotein Receptor-Related Protein 5 or 6 (LRP) coreceptor. This complex 
recruits Dishevelled (Dsh) to the membrane, where it mediates Axin removal from the 
destruction complex and causes the complex to dissociate. β-Catenin stabilizes and levels 
increase in the cytoplasm, leading to translocation into the nucleus where it interacts with 
transcription factors to transcribe target genes (9) (Fig.2). There are 19 Wnts and 10 Fzds in the 
mammalian genome (10), with several of them being expressed in the different hepatic cell 
populations (11). 
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Figure 2: Schematic of canonical Wnt signaling pathway. 
(A) In the absence of Wnts, the pathway is turned off. β-Catenin is bound by the destruction 
complex, leadings to subsequent phosphorylation and degradation via the proteasome. (B) When 
activated, a Wnt ligand binds an LRP5/6 and Frizzled coreceptor, recruiting Dishevelled to the 
membrane. Dishevelled recruits Axin and leads to dissociation of the destruction complex. β-
Catenin then accumulates in the cytoplasm and translocates into the nucleus, where it interacts 
with various transcription factors and cofactors to transcribe target genes. Fzd, Frizzled; Lrp5/6, 
Low-density lipoprotein receptor-related protein 5/6; APC, Adenomatous polyposis coli; CKIα, 
Casein kinase I alpha; GSK3β, Glycogen synthase kinase beta; Dvl, Dishevelled; TF, 
transcription factor; CF, cofactor. 
1.1.2 Wnts and accompanying agonists and antagonists  
There is extensive questioning into whether the 19 Wnts have redundant or unique roles, 
considering Wnts and Wntless are evolutionarily conserved across mammals (12, 13). 
Developmental loss-of-function studies have revealed roles of specific Wnts, including Wnt1’s 
role in midbrain development, Wnt2’s and Wnt7b’s roles in placental development, and 
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Wnt10b’s and Wnt16’s roles in bone development (14-18). However, the role of specific Wnts in 
liver pathobiology lacks characterization. Recent literature from us and others identify Wnt2 
being important for liver regeneration (19), Wnt2 and Wnt9b important for hepatic zonation (20), 
Wnt5a important for termination of liver regeneration (21), and Wnt7b and Wnt10a to promote 
cholangiocyte proliferation (22). Challenges remain in studying liver-specific Wnts, including a 
lack of robust Wnt antibodies available, and the ability of hepatic cell populations to compensate 
for one another when Wnts are mutated or lost.  
There are several known families of Wnt antagonists composed of secreted or 
transmembrane proteins, all being characterized to different extents. The Dickkopf proteins 
(Dkks) represent the most extensively studied group, and are composed of four secreted 
glycoproteins (Dkk1-4) that bind to Lrp6 and Wnt and inhibit their interaction (23, 24). The 
largest family of Wnt antagonists, secreted frizzled-related protein (sFrp), contains 5 members 
and binds to Wnts, sequestering them and preventing interaction with Fzd or Lrp5/6 receptors 
(24, 25). More recently identified, the E3 ubiquitin ligases Zinc Ring finger 3 (Znfr3a) and Ring 
finger 43 (Rnf43) promote internalization and endocytosis of Fzd and Lrp receptors (26, 27), 
although this is inhibited by the secreted Wnt agonist R-spondin (Rspo) (28). Intriguingly, 
Znfr3a and Rnf43 are Wnt targets, suggesting a negative feedback loop. Further, the enzyme 
Notum is able to remove palmitoleate groups from Wnts, inhibiting their interaction with Wls 
(29) 
Additional lesser understood Wnt modulators include antagonists Wnt-inhibitory factor 1 
(Wif1), Insulin-like growth factor binding protein 4 (IGFBP4), and transmembrane proteins 
Shisha, Adenomatosis polyposis coli down-regulated 1 (Apcdd1), and Waif1a, (24), and the 
agonist Norrin, which can bind and activate select Fzd receptors (1).  
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1.1.3 β-Catenin as a transcription cofactor  
While β-catenin is not a bona fide transcription factor, it regulates transcription by serving as a 
scaffold for transcription factors and cofactors to bind (9, 30). Targets genes involved in several 
different cellular functions. The following is a partial list of known liver-specific β-catenin target 
genes: 
Table 1: List of select beta-catenin target genes 
Function Target Genes Citations 
Cell cycle/proliferation cMyc, Cyclin D1, Egfr, Tgfα, S100A6, Smp30 (context 
dependent) 
(31-38) 
Metabolism & Zonation  GS, Slc1a2, Oat, Rhbg, Cyp1a2, Cyp2e1, S100A6, 
cMyc (context dependent), Smp30, Lect2 
(38-45) 
Transcription factor Lef1, Tcf1 (46, 47) 
Angiogenesis & fibrosis Vegf, Vegfr2, MMP7, MMP14, uPAR, CD44, PAI1, 
fibronectin 
(42, 48-53) 
Adult stem cell marker EpCAM, Lgr5 (54, 55) 
Negative feedback Axin2, sFrp2, Dickkopf (56-58) 
Antiapoptosis Bcl2, Survivin (48) 
 
Below is a list of transcriptional cofactors β-catenin can interact with, emphasizing 
interactions in the liver. We do not fully understand the spatial and temporal regulation of these 
interactions, or their comprehensive target genes. 
Table 2: partial list of transcriptional regulators β-catenin can interact with in the liver 
Cofactor Notes Citations 
Tcf4 Most common; Can differentially interact with Cbp or P300; Known 
target Cyclin D1 
(40, 59, 
60) 
Lef1 Known target Cyclin D1; may serve mutually exclusive role with Tcf4 (32, 61) 
Klf4 Transcription factor that inhibits Wnt signaling when interacting with 
β-catenin 
(62) 
Hnf4α Can compete with β-catenin by binding to Tcf4  (63) 
Cbp Histone acetyl transferase; May promote growth genes (ex. Cyclin D1, 
Survivin) 
(64-66) 
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P300 Histone acetyl transferase; may promote differentiation genes (ex. 
cMyc) 
(65, 66) 
Hif1α During hypoxia, competes with Tcf4 for β-catenin interaction; 
promotes hepatocyte survival under hypoxia 
(67, 68) 
FoxO3 Competes with Tcf4; during oxidative stress, interacts with β-catenin to 
inhibit proliferation and resist oxidative damage 
(69) 
1.1.4 Noncanonical β-catenin and noncanonical Wnt  
Although Wnt-mediated nuclear translocation of β-catenin is the most common activation 
method, β-catenin signaling can be propagated through other Wnt-independent mechanisms. β-
Catenin complexes with the receptor tyrosine kinase c-Met on hepatocyte membranes. The c-Met 
ligand, Hepatocyte growth factor (HGF), can cause β-catenin/c-Met dissociation, β-catenin 
phosphorylation at tyrosines 654 and 670, and subsequent nuclear translocation (70-72). 
Alternatively, V-Akt Murine Thymoma Viral Oncogene (AKT) downstream of growth factor 
receptors (73) or tyrosine kinase receptors (74) can initiate β-catenin nuclear translocation 
through inhibition of GSK3β (74, 75) or through direct phosphorylation of β-catenin at serine 
552 (73, 76). Furthermore, G-protein coupled receptors can activate Protein Kinase A (PKA) to 
phosphorylate β-catenin at serine 675, leading to its activation (77, 78). 
Wnt acts independently of β-catenin in the noncanonical planar cell polarity (PCP) 
pathway and the Wnt-calcium pathway. PCP regulates cell polarity through Wnt interaction with 
Fzd and another receptor, likely ROR2, although this is not clearly defined (79, 80). This 
activates Dishevelled, leading to activation of small GTPases Rho and Rac, subsequently 
modulating the actin cytoskeleton through JNK (81, 82). The Wnt-calcium pathway plays roles 
in development including dorsal axis formation and ventral cell fate. Noncanonical ligands 
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including Wnt5a and Wnt11 can induce calcium release from the ER by activating PKC and 
CamKII (83, 84). 
1.2 WNT/Β-CATENIN SIGNALING IN LIVER PATHOBIOLOGY 
1.2.1 Role in liver development 
During prenatal development, the endoderm consists of the foregut, midgut, and hindgut. The 
liver is derived from the foregut endoderm during gastrulation. Wnts from the mesoderm signal 
to the posterior endoderm to promote hindgut fate thus inhibiting foregut development. 
Concurrently, the anterior endoderm secretes Wnt antagonists to suppress β-catenin signaling 
and maintain foregut identity and allow liver development (85, 86). Upon conclusion of foregut 
development, Wnt/β-catenin activation is required for liver specification around embryonic day 
8.5 (E8.5). When β-catenin is removed from hepatoblasts using Foxa3-Cre recombinase, mice 
have suboptimal liver development by E12 and lethality is observed by E17 resulting from 
increased oxidative stress, hepatocyte apoptosis, and lack of hepatocyte growth (87). The switch 
from repressing foregut development to being required for embryonic liver specification 
highlights a necessary temporal regulation of Wnt signaling. 
Postnatally, β-catenin activation correlates with increased hepatic cell proliferation of 
developing livers up to 20 postnatal days, while β-catenin-null mice have lower liver weight to 
body weight ratios throughout their lifespan. Concomitantly, mice with hyperactivated β-catenin 
develop larger livers before one month of age resulting from increased cell cycle entry and 
proliferation (31, 88, 89).  
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1.2.2 Role in liver regeneration after acute liver failure 
The contributions of Wnt/β-catenin during liver regeneration (LR) after partial hepatectomy (PH) 
will be discussed extensively in section 6.0. β-Catenin is also required for liver regeneration after 
acute liver failure from acetaminophen (APAP) overdose. APAP is metabolized by cytochrome 
P450 enzymes Cyp2e1 and Cyp1a2, which create a toxic metabolite N-acetyl-p-benzoquinone 
imine, which causes hepatocyte death. Cyp2e1 and Cyp1a2 are β-catenin target genes. 
Furthermore, hepatocyte-specific β-catenin-null mice, lacking these two enzymes, are completely 
protected from APAP-induced liver injury. Despite this, β-catenin is activated within one hour 
after a sub-lethal APAP injection in mice, and is required for hepatocyte proliferation after 
APAP injury. Indeed, patients with increased β-catenin activation exhibit improved LR after 
APAP overdose (90). 
1.2.3 Role in oxidative stress, inflammation, and hepatic fibrosis 
β-Catenin regulates production of the antioxidant ascorbic acid through target genes including 
Regulcalcin, which negatively regulates oxidative stress (36, 91). Consequentially, mice lacking 
liver-specific β-catenin develop increased reactive oxygen species and DNA breaks after injuries 
including ionizing radiation, diethylnitrosamine-induced HCC, and 3,5-diethoxycarbonyl-1,4-
dihydrocollidine (DDC) diet (92-94).  
Oxidative stress leads to hepatic fibrosis through various mechanisms including 
macrophage and stellate cell activation (95). In vitro studies suggest Wnt/β-catenin is activated in 
and necessary for stellate cell activation and thus fibrosis (96-98). Whether hepatocyte-specific 
β-catenin is required for fibrosis is unclear. While Wnt5a contributes to fibrosis and is 
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upregulated in fibrotic livers, it can activate or repress β-catenin depending on the specific Fzd 
receptor involved (96, 99).  
Furthermore, our lab has shown the p65 subunit of NFκB interacts with β-catenin which 
prevents NFκB activation (100). During lipopolysaccharide-induced hepatotoxicity, p65 
dissociates from β-catenin to transcribe genes including various cytokines, antiapoptotic factors 
and growth factors (100, 101), overall suggesting β-catenin is a negative regulator of 
inflammation.  
β-Catenin is also protective against ischemia/reperfusion injury and the development of 
hepatic steatosis (67, 102). However, aberrant activation such as during chronic liver disease and 
hepatocarcinogenesis, often contributes to disease progression. Further understanding of β-
catenin during pathogenesis is required, and we attempt to elucidate its role during the chronic 
liver disease hereditary hemochromatosis, as discussed in detail in section 2.0.  
1.2.4 Role in oval cell response and tumorigenesis  
Oval cells, or hepatic progenitor cells, do not contribute to liver homeostasis or liver regeneration 
unless hepatocyte proliferation is blocked, such as during chronic liver disease. Models including 
the 3,5-diethoxycarbonyl-1, 4-dihydrocollidine (DDC) diet or the 2-acetylaminofluorine (2-
AAF)/partial hepatectomy model, force the liver to regenerate but prevent hepatocyte 
proliferation, and hence force oval cells to activate and differentiate into hepatocytes. After both 
DDC and 2-AAF/PH, nuclear β-catenin accumulation and upregulation of several Wnts is 
observed (103, 104), and β-catenin is recruited to the promoter regions of genes including cMyc 
to a greater extent during DDC-induced oval cell induction (105). Blocking β-catenin, such as 
with β-catenin knockout mice, leads to a blunted oval cell response after DDC (106). After a 
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choline-deficient ethionine-supplemented diet (CDE), another injury model leading to increased 
oval cell response, macrophage-specific Wnts activate oval cell-specific β-catenin and lead to 
hepatocyte differentiation (107).   
Hepatocellular carcinoma (HCC) expressing progenitor-like cells often lead to poorer 
prognosis. While one study suggested oval cells compose up to 5% of a tumor, there was a 
strong positive correlation between stem-cell marker OV6 and Wnt/β-catenin activation. In vitro 
analysis confirmed β-catenin activation increases the number of OV6+ cells in various HCC cell 
lines (105) suggesting β-catenin is important for oval cell expansion.  
Further roles of β-catenin in tumorigenesis are discussed in sections 4.0 and 5.0.  
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2.0  MICE LACKING LIVER-SPECIFIC Β-CATENIN DEVELOP STEATOHEPATITIS 
AND FIBROSIS AFTER IRON OVERLOAD 
In this section we utilize liver specific β-catenin knockout mice (bKO) to elucidate the role of β-
catenin in hepatic iron metabolism by subjecting bKO and littermate controls to iron overload 
diet for three months (Fig.3). We predict loss of β-catenin in bKO will lead to increased hepatic 
injury after iron overload, and will discuss our results, interpretations, and future directions in 
detail. This work was published in the Journal of Hepatology PMID: 28341391 (108). As first 
author, the publisher Elsevier has granted full permission to reuse the manuscript in this 
dissertation. 
 
Figure 3: Schematic representation of iron overloading study. 
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2.1 ABSTRACT 
Iron overload disorders such as hereditary hemochromatosis are a common cause of morbidity 
from liver diseases and increase risk of hepatic fibrosis and hepatocellular carcinoma (HCC). 
Once iron-induced damage occurs, treatment options are limited partly because of the lack of 
animal models recapitulating human disease, which do not exhibit relevant sequelae after chronic 
iron overload. Since liver-specific β-catenin knockout mice (bKO) are susceptible to injury, 
fibrosis and tumorigenesis following chemical carcinogen exposure, iron-overload diet was 
administered to KO and littermate control (bCON) mice for various times. To ameliorate an 
oxidant-mediated component of tissue injury, N-Acetyl-L-(+)-cysteine (NAC) was added to 
drinking water of mice on iron overload diet. bKO on iron diet (bKO+Fe) exhibited remarkable 
inflammation, followed by steatosis, oxidative stress, fibrosis, regenerating nodules and 
occurrence of occasional HCC. Increased injury in bKO+Fe was associated with activated AKT, 
ERK, and NFκB, along with reappearance of β-catenin and target gene Cyp2e1, which promoted 
lipid peroxidation and hepatic damage. Addition of NAC to drinking water protected bKO+Fe 
from hepatic steatosis, injury and fibrosis, and prevented activation of AKT, ERK, NFκB and re-
appearance of β-catenin. In summary, we provide evidence that absence of hepatic β-catenin 
predisposes mice to hepatic injury and fibrosis following iron overload, which was reminiscent 
of hemochromatosis and associated with enhanced steatohepatitis and fibrosis. Disease 
progression was notably alleviated by antioxidant therapy, which supports its chemopreventive 
role in the management of chronic iron overload disorders. 
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2.2 BACKGROUND 
2.2.1 Hereditary Hemochromatosis 
The most common iron overload disorder is hereditary hemochromatosis (HH), occurring 
in approximately 1 in 200 Caucasians and 40% of healthy population in the US carries a 
mutation predisposing them to iron overload (109). This leads to an excess in hepatic iron stores, 
from 300mg-1g in adults to 25-30g in HH patients, with very limited methods of excreting iron 
which then accumulates in the parenchyma of organs including the liver, heart, and pancreas 
(110, 111). Early symptoms are nonspecific and include joint pain, fatigue, and palpitations, 
although this can progress into potentially fatal heart failure, diabetes, liver cirrhosis, or 
hepatocellular carcinoma (112). Because symptoms can be broad and generic, HH diagnosis 
requires assessing levels of iron content, which is performed by measuring serum ferritin levels.  
Generally, levels above 200-300 μg/L suggest elevated serum ferritin, and patients can have 
levels as high as 1000 μg/L, which likely indicates increased disease severity (111).  
There are four main types of familial HH (113), characterized by various mutations in 
iron-regulatory genes (Table 3). 
Table 3: Hemochromatosis types and corresponding mutations 
Type Mutation Reference 
Type 1 HFE gene (C282Y or H63D) (113) 
Type 2 (Juvenile) Hepcidin (93delG or C166T) or hemojuvelin (G320V) (113-115) 
Type 3 Transferrin receptor 2 (Y250X) (113, 116) 
Type 4 Ferroportin (A77D) (113, 117) 
 
HFE gene, or the hemochromatosis protein, binds the transferrin receptor to inhibit 
cellular uptake of transferrin-bound iron. The mutated version loses binding affinity for 
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transferrin receptor and is unable to limit iron entrance, leading to cellular iron accumulation and 
overload (118, 119). Hepcidin promotes the internalization of ferroportin, which transports iron 
out of the cells including hepatocytes and macrophages (120). Hepcidin mutations are loss-of-
function and lead to increased ferroportin-mediated iron export into circulation. Intriguingly, this 
leads to iron overload likely through excessive hepatocyte uptake of plasma non-transferrin 
bound iron that exceeds the rate of iron export (121). Hemojuvelin mutations similarly cause iron 
overload through downregulation of hepcidin expression (122). Transferrin receptor 2 is the 
liver-specific isoform, and mutations are predicted to be loss-of-function, again leading to 
decreased hepcidin expression (123, 124). Lastly, ferroportin mutants are unable to export iron 
(125). 
Patients with type 1 or 3 experience a relatively minor phenotype, as HJV is able to 
compensate to an extent for loss of hepcidin activity. Type 2, the juvenile form, is the most 
severe and is associated with the most robust hepcidin inactivity leading to increased iron 
loading in the liver and in parenchymatous organs (126). Type 4 is milder than type 1 (127). 
2.2.2 Impact on liver 
Liver is one of the major organs affected by HH and around 75% of clinically affected 
hemochromatosis patients have evidence of liver disease at presentation. Iron localization is 
predominantly periportal in hepatocytes, as iron enters the liver through portal circulation (128). 
Kupffer cells also retain iron, often resulting from phagocytosing dead iron-rich hepatocytes. 
Intriguingly, in patients a strong positive correlation has been shown with iron overload in 
Kupffer cells, and ICAM-1 expression in hepatocytes, leading to increased fat deposition and 
fibrosis (129). The liver is the source of hepcidin production (126), and almost all HH types lead 
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to decreased hepcidin expression as described above, also explaining the increased hepatic insult 
compared to other organs. 
Excess iron deposition in hepatocytes is also associated with hepatomegaly, elevated liver 
enzymes, oxidative stress, steatosis, inflammation, fibrosis, and cancer (130, 131). In fact, 50% 
of HH-related deaths result from hepatic cirrhosis or hepatocellular carcinoma, and HH patients 
are 200 times more likely to develop hepatocellular carcinoma (132, 133). 
2.2.3 Current treatments for HH 
Presently, recurrent phlebotomy is the only effective way to prevent chronic iron overload in 
patients with HH, baring absence of hepatic cirrhosis. In most cases, 400-500 mL of blood is 
removed weekly to reduce serum ferritin levels and hence, iron levels (111, 132, 134). 
Strikingly, phlebotomy has been the standard of care for HH patients since 1950 (111), highlight 
a lack of therapeutic advancement. Transplant is another therapeutic option for patients with liver 
complications, and five-year survival rates post liver transplant for HH patients are comparable 
to rates from non-HH liver recipients (135), although longitudinal studies did not control for HH 
type. Further, like any chronic liver disease, donor organs are severely lacking and liver 
transplant is an uncommon option for HH patients.  
2.2.4 Animal models of hemochromatosis 
One major obstacle in studying cellular and molecular mechanisms underlying hemochromatosis 
disease progression is the lack of relevant animal models. Rodents fed high iron diet do not 
display injury or disease progression like patients. Transgenic models, including an HFE-
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deficient mouse, Trf2-mutated mouse, Trf1-mutated mouse, and hepcidin-knockout mouse 
inexplicably have no effect on iron loading, or exhibit increased iron stores with no associated 
injury (136-141).  
Hepcidin knockouts fed 3% carbonyl iron diet displayed mild hepatic inflammation, 
apoptosis, and twelve-month old hepcidin knockouts developed liver fibrosis (but not six-month 
old) (136). Further, disrupting both HFE and Trf2 via double knockout lead to increased iron-
induced hepatic injury in the form of inflammation and fibrosis compared to a single knockout or 
wildtype animal (142). However, further investigation identifies marginal inflammation and 
fibrosis, and steatosis is absent in this model. Thus there is a significant need for development of 
relevant animal models that can mimic human disease. 
2.2.5 Role of Wnt/β-catenin in hemochromatosis  
Studies assessing the role of Wnt and/or β-catenin in iron metabolism are limited, however one 
study identified a Wnt/β-catenin inhibitor in vitro that worked through chelating iron (143), 
suggesting iron can activate Wnt/β-catenin signaling. Another group demonstrated that increased 
cellular iron leads to elevated Wnt/β-catenin activity as measured by TOPFLASH reporter assay 
(144). This link has not been investigated further, or in the context of HH.  
  We hypothesize β-catenin is required for response to hepatic iron overload in vivo. Our 
lab has previously identified β-catenin to be a primary regulator of the antioxidant response 
through target gene regucalcin-dependent production of ascorbic acid (36). As mentioned, 
oxidative stress is present in HH patients (145) and likely an early symptom of disease onset 
(146). We have also identified β-catenin knockout mice (bKO) to have higher tumor burden and 
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fibrosis after diethylnitrosamine-induced oncogenesis due to increased inflammation and 
oxidative stress (94). We predict a similar phenotype in bKO mice after chronic iron overload. 
 
2.3 METHODS 
2.3.1 Animals 
All animal work was performed in accordance with the University of Pittsburgh 
Institutional Animal Care and Use Committee. Liver-specific β-catenin knockout mice (bKO) 
were generated as previously described (89). Briefly, mice expressing Cre recombinase under the 
Albumin promoter were crossed with animals carrying LoxP sites flanking β-catenin.  
One to three month old male and female bKO and littermate controls (bCON) were used 
in this study, n=3-5 for each condition. Mice were subjected to a 1% carbonyl 10,000ppm iron 
diet (Harlan Laboratories) (bCON+Fe, bKO+Fe) or basal diet (bCON–Fe, bKO–Fe) for three 
months. Male and female mice were also used for 4 week and 5 day timepoints, n=3-4. As no 
differences were observed in male versus female mice, and considering males are affected by 
iron overload more frequently than females (147), male mice were used for subsequent 
antioxidant studies (n=3-4). N-Acetyl-L-(+)-cysteine (NAC, 2g/kg, Fisher Chemical) was 
administered to mice on iron diet via drinking water for three months. For all studies, iron diet 
was replaced every two weeks, and NAC was replaced every week.  
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2.3.2 Immunohistochemistry 
Four micron paraffin sections were dehydrated with xylene and graded ethanol, and 
rinsed in PBS. Heat-mediated antigen retrieval was performed and slides were inactivated for 
endogenous peroxidases. Unless mentioned, slides were blocked with Super Block (ScyTek 
Laboratores). The following antibodies used citrate buffer in microwave: β-Catenin, Cyclin D1, 
Glutamine Synthetase, Cyp2e1, 4-Hydroxynonenal, Malondialdehyde, α-Smooth Muscle Acin 
which required use of a Mouse On Mouse Kit (Vector). Ki67, used Tris EDTA in microwave. 
Sox9, used citrate buffer in pressure cooker. CD45 and CK19 required DAKO antigen retrieval 
in pressure cooker. F480 required proteinase K digestion for antigen retrieval. See Table 4 for 
antibody information. Secondary antibodies were purchased from Millipore and used at 1:400. 
Sections stained with antibodies were incubated with streptavidin-biotin and signal was detected 
with DAB. 
Table 4: Antibodies used in Section 2.0 
Name Use and dilution Supplier Cat no. 
β-catenin IHC: 1:100 Santa Cruz Sc-7199 
Cyclin D1 IHC: 1:200 Neomarkers RB-9041-P 
Glutamine Synthetase (GS) IHC: 1:50 Santa Cruz Sc-9067 
Cytochrome p450 2e1 (Cyp2e1) IHC: 1:500 Sigma Aldrich HPA009128 
4-Hydroxynonenal (4HNE) IHC: 1:2000 Millipore 393207 
Malondialdehyde (MDA) IHC: 1:200 Abcam Ab6463 
α-Smooth muscle actin (αSMA) IHC: 1:200 Dako M0851 
Sox9 IHC: 1:10,000 Abcam AB5535 
CD45 IHC: 1:100 Santa Cruz sc-53665 
CK19 IHC: 1:10 DSHB TROMA-III-S 
β-catenin WB: 1:1000 BD 
Biosciences 
610154 
Hypo-phosphorylated β-catenin at 
Ser33/Ser37/Thr41 
WB: 1:1000 Cell Signaling 4270s 
Regucalcin WB: 1:1000 Santa Cruz sc-130344 
Cytochrome p450 1a2 (Cyp1a2) WB: 1:200 Santa Cruz sc-53241 
Peroxisome proliferator-activated WB: 1:200 Santa Cruz sc7273 
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receptor γ (PPARγ) 
Phosphorylated Extracellular signal–
regulated kinase (ERK) (T202/T204) 
WB: 1:1000 Cell Signaling 4370 
Extracellular signal–regulated kinase 
(ERK) 
WB: 1:1000 Cell Signaling 4695 
Phosphorylated Protein Kinase B 
(AKT) (T308) 
WB: 1:1000 Cell Signaling 13038 
Protein Kinase B (AKT) WB: 1:1000 Cell Signaling 4685 
Phosphorylated Nuclear factor kappa-
light-chain-enhancer of activated B 
cells (NFκB) (Ser536) 
WB: 1:1000 Cell Signaling 3033 
Nuclear factor kappa-light-chain-
enhancer of activated B cells (NFκB) 
WB: 1:200 Santa Cruz Sc-372 
α-Smooth muscle actin (αSMA) WB: 1:1000 Abcam ab5694 
Platelet Derived Growth Factor 
Receptor Beta (PDGFRB) 
WB: 1:200 Santa Cruz Sc-432 
Interleukin 6 (IL6) WB: 1:1000 Abcam ab7737 
C-C Motif Chemokine Ligand 2 
(CCL2) 
WB: 1:200 Santa Cruz Sc-1785 
Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) 
WB: 1:200 Santa Cruz Sc-25778 
Actin WB: 1:1000 Millipore MAB1501 
Ki-67 IHC: 1:100 Thermo Fisher RM-9106-S0 
F480 IHC: 1:100 Serotec MCA497A488 
 
2.3.2.1 Special stains 
For assessing collagen deposition, sections were deparaffinized and stained with 
picrosirius red (Biorad) for 1 hour, then dipped in acidified water (5ml acetic acid in 1L H2O) 
and dehydrated. Prussian blue stain was performed by the Research Histology Services at the 
University of Pittsburgh. For terminal deoxynucleotidyl transferase dUTP nick end labeling 
(TUNEL), ApopTag peroxidase kit (Intergen) was used under the manufacturer’s protocol. 
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2.3.3 Protein extraction and western blotting 
Protein extraction from frozen liver tissue was performed using RIPA buffer with 
protease and phosphatase inhibitors (Sigma). Forty micrograms of protein were resolved by 
SDS-PAGE on a 7.5% precast gel (Biorad) and transferred to nitrocellulose membranes using 
semi-dry Trans-Blot Turbo Transfer System (Biorad). Antibodies used are available in Table 4. 
Horseradish peroxidase-conjugated secondary antibodies were purchased from Millipore.  
2.3.4 Fatty acid and iron profiles 
For triglyceride and cholesterol ester profiles, snap-frozen tissue was sent to the Hormone Assay 
and Analytical Services Core at Vanderbilt University for analysis. 
For serum iron profiles, serum was collected through retro-orbital cavity and was 
analyzed according to manufacturer’s instructions using the Iron-SL kit (Seikisui, Cat# 157-30, 
Lexington, MA). Briefly, 20l serum samples or standard (provided in the kit) was added to 
260l R1 buffer and A595 measured with a 96 well plate reader [A1]. R2 buffer was added to 
bring the volume to 340l, incubated at room temperature for 5 minutes then measured again at 
the same wavelength [A2]. The serum iron concentration (M) was calculated with the following 
formula: (A2 –A1 Sample/A2-A1 Standard)*35 
Liver tissue was weighed (mg) and homogenized in 1ml protein precipitation solution 
(0.53N HCl and 5.3% trichloroacetic acid in HPLC grade water using a Pro Gen PRO200 
homogenizer (Pro-Scientific, Oxford, CT). Iron Standard (Ricca Chemical Company, Arlington, 
TX) was diluted in protein precipitation solution to generate a standard series from 5 – 0.08mM. 
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75l of each standard was diluted to 1ml with protein precipitation solution in a microtube. 
Samples and standards were boiled for 60 minutes then centrifuged for 10 min at 14,000xg. 
The Iron-SL iron kit was used as follows: 30l sample and standards were placed in 
duplicate wells in a 96 well plate, 150l R1 and then 40l R2 buffers were added, mixed for 5 
minutes at 330RPM then A595 measured and mM concentrations determined using the standard 
curve. Iron by weight was calculated using the following formula: g/g Non-Heme Iron = [Iron 
mM/weight(mg)] x 75 x 55.5 
2.3.5 RNA extraction and qPCR analysis 
RNA was extracted from frozen liver using Trizol (Invitrogen) and 2g of RNA was 
reverse-transcribed using Super Script III first strand kit (Invitrogen). Real-time PCR was ran 
using SYBR Green (Thermo) and all values were normalized to GAPDH. See Table 5 for primer 
information. 
Table 5: Primer sequences for qPCR in Section 2.0 
Name Sequence Supplier 
GAPDH forward primer AACTTTGGCATTGTGGAAGG Integrated DNA 
Technologies 
GAPDH reverse primer ACACATTGGGGGTAGGAACA Integrated DNA 
Technologies 
Ceruloplasmin (CP) forward 
primer 
TCCCTGGAACATACCAACC Integrated DNA 
Technologies 
Ceruloplasmin (CP) reverse 
primer 
ATTTATTTCATTCAGCCAGACTTAG Integrated DNA 
Technologies 
Ferroportin (FP) forward 
primer 
CTCTGTCAGCCTGCTGTTTG Integrated DNA 
Technologies 
Ferroportin (FP) reverse primer TCAGGATTTGGGGCCAAGATG Integrated DNA 
Technologies 
Transferrin receptor 1 (TRF1) 
forward primer 
ATAAGCTTTGGGTGGGAGGC Integrated DNA 
Technologies 
Transferrin receptor 1 (TRF1) CTTGCCGAGCAAGGCTAAAC Integrated DNA 
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reverse primer Technologies 
Transferrin receptor 2 (TRF2) 
forward primer 
GTTGCTGAGCTGAACTTGGC Integrated DNA 
Technologies 
Transferrin receptor 2 (TRF2) 
reverse primer 
TGAGTTCCATGGGGCAGAAC Integrated DNA 
Technologies 
Hepcidin (HAMP) forward 
primer 
TGTCTCCTGCTTCTCCTCCT Integrated DNA 
Technologies 
Hepcidin (HAMP) reverse 
primer 
CTCTGTAGTCTGTCTCATCTGTTG Integrated DNA 
Technologies 
Hemojuvelin (HJV) forward 
primer 
GGGAGTCACGTGGAGATTCG Integrated DNA 
Technologies 
Hemojuvelin (HJV) reverse 
primer 
ACGCAGGATTGGAAGTAGGC Integrated DNA 
Technologies 
Human hemochromatosis 
protein (HFE) forward primer 
GCAATGGCTACAGGGTGACT Integrated DNA 
Technologies 
Human hemochromatosis 
protein (HFE) reverse primer 
CTGGTCATCCACATAGCCCC Integrated DNA 
Technologies 
 
2.3.6 Proinflammatory cytokine analysis 
To assess cytokine levels in 5 day iron-fed mice, the V-PLEX Proinflammatory Panel 1 Kit 
(MesoScale) was used per the manufacturer’s instructions to assess TNFα, IL6, and KC/Gro. 
Duoset Kit (R&D) was used to assess CCL2/MCP1, CCL5, and CXCL10 per the manufacturer’s 
instructions. 
2.3.7 Statistics 
Data presented as mean and individual data points. Graphs were generated using GraphPad 
Prism 7 and comparisons between two groups were performed using Student’s T Test. Two-
tailed P values of <0.05 (*) and <0.01 (**) or less were considered significant. 
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2.4 RESULTS 
2.4.1 Mice lacking beta-catenin in liver epithelial cells develop steatohepatitis and fibrosis 
after iron overload 
Iron overload diet was fed for 3 months to bKO (KO+Fe) and bCON (bCON+Fe). While 
both groups tolerated the treatment, bKO+Fe livers showed evidence of gross injury showing 
pale discoloration and rigidity (not shown). Serum ALT levels trended higher in bKO+Fe 
although the differences were not significant (Fig.4A). bKO-Fe had significantly lower basal 
liver weight to body weight ratio (LW/BW) when compared to the bCON-Fe group as reported 
previously (Fig.4B) (89). Intriguingly, both bCON+Fe and bKO+Fe showed comparable and 
significantly higher LW/BW ratio than their respective controls (Fig.4B).  
Liver histology revealed notable macrovesicular steatosis and inflammation in bKO+Fe 
only (Fig.4C). To confirm hepatic steatosis, we examined levels of hepatic lipids. bCON+Fe and 
bKO+Fe had significantly greater hepatic triglycerides and cholesterol esters than respective 
controls although bKO+Fe showed highest and most significant increase (Fig.4D, E). PPAR, a 
known adipogenic factor negatively regulated by -catenin (148), was marginally increased in 
KO basally but was further induced in bKO+Fe (Fig.4F). KO-Fe livers show a small increase in 
CD45-positive inflammatory cells as reported previously (100).  
Iron diet led to more pronounced inflammation in bKO along with F480-positive 
macrophage infiltration (Fig.5A, B). Enhanced inflammation in bKO+Fe was further verified by 
the presence of increased inflammatory markers IL-6 and CCL2 by Western blots (WB), both of 
which migrate slower likely due to glycosylation (149, 150) (Fig.5C). Presence of steatohepatitis 
was also associated with increased fibrosis as revealed by Sirius Red staining showing extensive 
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collagen accumulation in bKO+Fe only (Fig.5D and Fig.7A). This was further validated by the 
presence of activated myofibroblasts seen by increased -smooth muscle actin (-SMA) by both 
WB and IHC in KO+Fe only (Fig.5E, F). Presence of fibrosis was further supported by elevated 
PDGFR levels (Fig5E).  
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Figure 4: Chronic iron overload causes steatohepatitis in β-catenin knockout mice. 
 (A) Serum ALT levels reflect a modest but insignificant increase in bKO+Fe as compared to 
other groups. (B) Iron causes increased liver weight to body weight ratio (LW/BW) in bCON+Fe 
and bKO+Fe. At baseline, bKO show significantly lower LW/BW than bCON. (C) 
Representative H&E staining (100x) shows mild hepatic steatosis in bCON+Fe and more 
profound hepatic steatosis and inflammation in bKO+Fe. (D) Increased hepatic triglycerides 
(TG) (p=0.0524) in bKO+Fe as compared to bCON+Fe. (E) Cholesterol esters (CE) were 
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comparably increased after iron in bKO and bCON. (F) Representative WB showing increase in 
PPAR in bKO+Fe as compared to other groups. *p<0.05 using Student’s T test.  
 
Figure 5: bKO+Fe have increased hepatic inflammation and fibrosis after chronic iron overload. 
(A) Representative IHC images demonstrate increased CD45-positive inflammatory cells in 
bKO+Fe as compared to other groups. (B) Representative IHC images demonstrate increased 
F480-positive macrophages in bKO+Fe only. (C) Representative WB shows bKO+Fe have 
increased inflammatory markers including IL-6 and CCL2. IL-6 and CCL2 appear to be 
migrating slower due to glycosylation. (D) bKO+Fe have increased Sirius Red staining 
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suggesting increased collagen deposition. (E). WB show increased levels of α-SMA and 
PDGFR substantiating presence of fibrosis. (F) IHC for -SMA also confirms presence of 
activated myofibroblasts in bKO+Fe only. (Image magnification: 100x) 
2.4.2 bKO display enhanced ductular reaction in response to injury due to iron overload. 
We next investigated cellular injury and repair in bKO+Fe. A marginal increase in cell 
death as seen by TUNEL staining was evident in bCON+Fe, which was exacerbated in bKO+Fe 
(Fig.6A). This was associated with modest but comparable increase in S-phase marker Ki-67, in 
hepatocytes in bCON+Fe and bKO+Fe (Fig.6B). Likewise, a mid-zonal increase in Cyclin D1 
expression was evident in bCON+Fe, which was reduced in bKO+Fe and instead observed in 
periportal hepatocytes (Fig.6B). Chronic hepatic injury can lead to progenitor cell response in the 
form of ductular reaction, especially if hepatocyte proliferation is disproportionally lower than 
ongoing death (151). Indeed, bKO+Fe uniquely showed increased sox-9, EpCAM and CK19 
positive ductular reaction (Fig.6D-F).  
Continued injury in bKO+Fe led to development of bridging fibrosis outlining 
regenerating nodules (Fig.7A). We also observed occurrence of occasional HCC nodule in 
bKO+Fe (Fig.7B). Intriguingly, tumors were -catenin and GS-positive (Fig.7B).  
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Figure 6: Analysis of cell death, proliferation and ductular reaction in bCON and bKO on normal 
and high iron diet. 
(A) Representative images of TUNEL staining shows marginal increase in cell death in 
bCON+Fe, but a greater increase in bKO+Fe. (B) Ki-67 IHC demonstrates comparable and 
increased number of cells in S-phase after iron overload in both bCON+Fe and bKO+Fe. (C) 
Cyclin D1 staining is increased in midzonal hepatocytes in bCON+Fe compared tob CON-Fe. 
bKO+Fe exhibit less Cyclin D1 staining in periportal hepatocytes and in ductular cells. (D) 
bKO+Fe have increased ductular reaction as evident by IHC for Sox9. (E) Increased ductular 
reaction in bKO+Fe was confirmed by EpCAM staining.  (F) Increased ductular reaction in 
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bKO+Fe was also confirmed by IHC for CK19. (Image magnification:100X, except 
EpCAM:200x). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 31 
 
Figure 7: bKO+Fe display increased bridging fibrosis and development of HCC. 
 (A) Additional images of Sirius red staining showing bridging fibrosis in bKO+Fe. (100x). (B) 
Image of HCC observed in a subset of bKO+Fe mice. Sirius red staining shows tumor nodule 
lacking intratumoral fibrosis. H&E identifies HCC. IHC for β-catenin shows HCC to be 
composed of -catenin-positive cells. IHC for Glutamine Synthetase (GS) also shows HCC to be 
positive for this -catenin target. (100x). 
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2.4.3 Comparable hepatic iron accumulation in bKO and bCON following iron overload. 
Next, we addressed if iron metabolism is altered in bKO+Fe. Prussian blue staining 
revealed iron accumulation in bCON+Fe predominantly in the periportal region (Fig.8A). Iron 
accumulation showed a more pan-zonal distribution in bKO+Fe (Fig.8B). An increase in 
aggregates of iron pigment in bKO+Fe reminiscent of iron-laden macrophages was also observed 
(Fig.8B). However, both bCON+Fe and bKO+Fe had an increase in total liver iron content 
compared to respective controls, and differences in the hepatic iron content between bCON+Fe 
and bKO+Fe were insignificant (Fig.8C). Interestingly, bKO+Fe showed increased serum iron 
when compared to bKO-Fe, whereas bCON+Fe and bCON-Fe showed no differences (Fig.8D).  
Next, we determined expression levels of genes commonly mutated in hemochromatosis 
or otherwise involved in iron metabolism by RT-PCR. Hepcidin, a gene that inhibits iron export 
from a cell (152) was comparably induced in bCON and bKO after iron overload as reported 
previously (153) (Fig.9A). Human hemochromatosis protein and hemojuvelin, two genes 
frequently mutated in different hemochromatosis subtypes (142), demonstrated no significant 
differences in expression (Fig.9B,C). Expression of ceruloplasmin, which converts toxic ferrous 
form to a nontoxic ferric form (154), was increased in bKO+Fe as compared to bCON+Fe, with 
an insignificant increase compared to bKO-Fe (Fig.9D).  Transferrin receptors 1 and 2 are cell 
surface receptors required for iron entry into cells (124, 155). Although TRF1 expression is low 
in the liver (124), we saw a further reduction in bCON+Fe and bKO+Fe compared to bCON-Fe 
and bKO-Fe (Fig.9E). TRF2 was not significantly altered in bCON+Fe compared to bCON-Fe, 
as also reported elsewhere (124). Interestingly, a modest but statistically significant decrease in 
TRF2 was observed in bKO+Fe when compared to bKO-Fe (Fig.9F). Ferroportin, the iron export 
protein negatively regulated by hepcidin (120), is increased in bCON and bKO after iron 
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although increase is significantly greater in bKO+Fe (Fig.9G). Overall, our data suggests that 
major iron regulatory genes are unaffected by β-catenin signaling basally, but bKO+Fe livers 
show altered expression of some iron regulatory genes, likely in an attempt to compensate for 
increased hepatic injury after high iron diet. 
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Figure 8: Comparable hepatic iron levels in bCON+Fe and bKO+Fe, despite increased serum iron 
and altered iron zonation in bKO+Fe. 
(A) Prussian blue staining (100x) shows iron accumulation is periportal in bCON+Fe. In 
bKO+Fe, iron deposition is pan-zonal. Aggregates of iron pigment resembling iron-laden 
macrophages were observed in bKO+Fe (B) A Periportal Prussian blue staining in periportial 
region in bCON+Fe versus more pan-zonal staining in bKO+Fe can be appreciated in lower 
magnification (50x). (C) Liver iron levels increase comparably in bCON+Fe and bKO+Fe 
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compared to bCON-Fe and bKO-Fe. (D) Serum iron levels are increased in bKO+Fe compared to 
bKO-Fe, but there is no difference between bKO+Fe and bCON+Fe. *p<0.05 using Student’s T 
test. 
 
 
Figure 9: Changes in the expression of iron regulatory genes in bKO and bCON, on control or high 
iron diet. 
RT-PCR displaying comparison of mRNA fold change of major iron regulatory genes in bCON-
Fe, bKO-Fe, bCON+Fe, and bKO+Fe, including Hepcidin (HAMP) (A), Human 
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hemochromatosis protein (HFE) (B), Hemojuvelin (HJV) (C), Ceruloplasmin (CP) (D), 
Transferrin Receptor 1 (TRF1) (E), Transferrin Receptor 2 (TRF2) (F), and Ferroportin (FP) (G). 
Expression was normalized to bCon-Fe for each gene. *p<0.05, **p<0.01 using Student’s T test.  
2.4.4 Iron overload decreases β-catenin signaling in bCON but induces other cell survival 
and mitogenic signaling in bKO 
Next, we asked if chronic iron overload impacts -catenin signaling in the liver. Livers 
from mice fed high iron diet or basal diet were assessed for liver-specific -catenin targets. 
Intriguingly, we observed a decrease in Glutamine synthetase (GS), Cyp1a2 and Cyp2e1 
(Fig.10A.B). In the absence of any evidence of -catenin activation by iron overload, the 
mechanism of worse injury in high iron-fed bKO mice required additional investigation.  
We first assessed factors like Protein Kinase B (Akt), extracellular signal-regulated 
kinase 1/2 (Erk1/2), and nuclear factor kappa-light-chain-enhancer of activated B cells (NFB). 
Akt, which is involved in cell survival, migration, and proliferation (156), showed increased 
phosphorylation in bKO+Fe compared to other groups (Fig.10C). Erk1 phosphorylation, which 
is associated with hepatic fibrosis (157), was increased at baseline in bKO-Fe, was induced by 
iron in both bCON and bKO, and was highest in bKO+Fe (Fig.10C). Erk2 phosphorylation 
showed only a modest increase in bKO-Fe with no notable differences between bCON+Fe or 
bKO+Fe (Fig.10C). NFB, which regulates genes involved in inflammation (158), proliferation 
and survival (159), showed increased phosphorylation in bKO+Fe compared to other groups 
(Fig.10C). Taken together, these data suggest that iron overload leads to decreased -catenin 
signaling but in its absence, leads to activation of Akt, Erk and NFB, which may contribute to 
greater hepatic injury and repair response in bKO+Fe. 
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2.4.5 Evidence of increased hepatic oxidative stress and β-catenin activity in bKO after iron 
overload. 
Since -catenin has been shown to regulate redox homeostasis in hepatic tissue through 
multiple mechanisms (68, 87, 94), we next investigated if -catenin-deficient livers are inept at 
counteracting oxidative stress generated normally by iron accumulation and inflammation, and 
known to contribute to chronic injury, fibrosis and cancer (160, 161). Indeed, increased oxidative 
stress in the form of lipid peroxidation was seen in bKO+Fe by IHC for both 4-hydroxynonenal 
(4HNE) and malondialdehyde (MDA) (Fig.10D). Predictably, lipid peroxidation products were 
visible in and around areas of steatosis in the bKO+Fe.  
Since Cyp2e1 has been implicated in contributing to harmful reactive oxygen species 
(ROS) (162) and regulated by -catenin signaling in liver (89, 163), we assessed its expression in 
bCON and bKO after iron. Decrease in Cyp2e1 staining and its localization to sparse areas of 
steatosis was observed in bCON+Fe as compared to bCON-Fe (Fig.11A). Intriguingly, while no 
Cyp2e1 was detected in bKO-Fe, iron overload led to an unexpected increase, which was 
localized to steatotic areas in bKO+Fe (Fig.11A). The reappearance of Cyp2e1 was also 
confirmed by WB (Fig.11B). Likewise, while total -catenin levels decreased in bCON+Fe, its 
levels increased in bKO+Fe (Fig.11B-D). Similarly, GS staining decreased and was irregular in 
bCON+Fe as compared to uniform pericentral staining in hepatocytes in bCON-Fe (Fig. 11E), 
However, while GS was absent in bKO-Fe, we observed occasional areas of GS-positive 
hepatocytes especially in steatotic and even periportal areas in bKO+Fe (Fig.11E). Thus, 
presence of chronic injury in KO after iron overload led to some repopulation by -catenin-
positive hepatocytes, which led to reappearance of Cyp2e1. 
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Figure 10: Chronic iron overload affects β-catenin signaling in bCON+Fe, but induces AKT, ERK, 
and NFκB signaling and lipid peroxidation in bKO+Fe. 
 (A) Representative WB show a decrease in hepatic levels of Cyp1a2 and Cyp2e1 levels after 
iron overload. (B) Representative IHC for GS shows decreased uniformity of GS staining in 
pericentral hepatocytes in bCON after iron overload (100x). (C) Representative WB show 
greater increases in pAKT (Thr308) and pERK1 (Thr202/Thr204) in KO+Fe as compared to 
bCON+Fe. pNFB (Ser536) is induced only in bKO+Fe. (D) Representative IHC images show 
increased staining for lipid peroxidation markers 4-hydroxynonenal (4HNE) and 
malondialdehyde (MDA) in bKO+Fe. (50x). 
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Figure 11: Reappearance of β-catenin and its targets following chronic iron overload in bKO. 
 (A) IHC for Cyp2e1 shows decrease in pericentral staining for Cyp2e1 in bCON after iron diet. 
bKO lack Cyp2e1 basally, however bKO+Fe show its re-appearance particularly in areas of 
steatosis. (B) WB confirm increases in levels of Cyp2e1, β-catenin, and Cyclin D1 in bKO+Fe 
compared to bKO-Fe. (C) Representative IHC images of β-catenin also confirm re-expression of 
-catenin especially in steatotic areas in bKO+Fe (100x). (D) Higher magnification image of -
catenin IHC from bKO+Fe liver shows positive staining (200x). (E) Representative IHC of GS 
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shows decreased staining in bCON livers after iron diet, however in bKO which lack GS basally, 
show re-appearance of GS (50x).  
2.4.6 N-Acetyl-L-(+)-cysteine (NAC) protects bKO after iron overload against injury and 
fibrosis. 
Since increased lipid peroxidation appeared to be associated with steatohepatitis and fibrosis in 
bKO+Fe, we next administered NAC, an antioxidant, to bCON+Fe and bKO+Fe via drinking 
water for 3 months. NAC alleviated lipid peroxidation as observed by IHC for MDA and 4-HNE 
in KO+Fe (Fig.12). Simultaneously, we observed a modest decrease in steatosis, which was also 
reflected by a partial reduction in PPAR levels (Fig.12,13A). NAC also led to a pronounced 
decrease in -SMA IHC along with a dramatic decrease in fibrosis by Sirius Red staining 
(Fig.12). This was verified by decreased PDGFR and -SMA protein levels (Fig.13A). 
Although numbers of CD45-positive cells remained unaffected by NAC in bKO, inflammation 
markers IL-6 and MCP1 lowered to match bCON+Fe+NAC levels (Fig.13A). Zonal iron 
distribution was also partially restored in bKO+Fe+NAC group (Fig.12).  
Since we considered resurgence of -catenin and its targets Cyp2e1 and GS as injury 
responses, we next posited that NAC may prevent such increase if injury is successfully 
alleviated. Indeed, levels of total β-catenin, Cyclin D1 and Cyp2e1 were diminished to non-
existent levels as basal bKO, following NAC treatment as also verified by IHC (Fig.13B,C). 
NAC also prevented activation of AKT and NF-B although pERK1 remained higher in 
bKO+Fe+NAC (Fig.13D). Intriguingly, pERK2 levels were markedly increased in both bCON 
and bKO after iron and NAC treatment (Fig.13E). Lastly, normalization of LW/BW ratio was 
evident in bKO+Fe+NAC group which was significantly lower than bCON+Fe+NAC (Fig.13F). 
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Thus, alleviating oxidative stress by NAC prevented several relevant complications of chronic 
iron overload in bKO. 
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Figure 12: Inclusion of N-Acetyl-L-(+)-cysteine (NAC) in drinking water normalizes histology and 
affects oxidative stress, steatosis, fibrosis and iron staining in bKO+Fe, while inflammation remains 
unaltered. 
Representative images from livers of bKO+Fe, bCON+Fe+NAC, and bKO+Fe+NAC mice 
showing a profound effect of NAC in reducing overall hepatic injury in bKO+Fe, which is 
depicted by decrease in staining for 4HNE, MDA, Sirius Red and SMA. H&E shows 
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normalization of histology along with an overall decrease in steatosis. Prussian blue staining 
shows shift of pan-zonal staining to periportal staining after NAC treatment of bKO+Fe. No 
quantitative differences in the numbers of CD45 cells were seen. (100x). 
 
 
 
Figure 13: NAC rescues injury phenotype in bKO+Fe. 
 (A) WB confirms lack of increase in fibrosis markers α-SMA and PDGFR-, and inflammation 
markers IL-6 and CCL2 in bKO+Fe+NAC. PPAR levels are partially restored in 
bKO+Fe+NAC. (B) WB shows NAC treatment reduces levels of β-catenin, Cyp2e1, and Cyclin 
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D1 in bKO+Fe+NAC. (C) IHC shows absence of GS and Cyp2e1 in bKO+Fe+NAC (50x). (D) 
WB for total and activated ERK, AKT, and NFB show lack of activation after NAC treatment. 
(E) WB shows pERK in bCON and bKO at baseline, with iron, and with iron and NAC. Same 
blot shown in Figure 13C and Figure 16D, shown here for direct comparison of pERK1 and 
pERK2 between NAC and non-NAC-treated groups. (F) LW/BW is decreased in bKO+Fe+NAC 
and is now similar to baseline bKO-Fe. *p<0.05 using Student’s T test. 
2.4.7 Inflammation precedes steatosis, which precedes fibrosis in bKO after iron overload. 
To address the disease development in KO+Fe, we subjected bCON and bKO mice to 4-week 
iron-overload diet. Notable steatosis was evident in bKO+Fe, but not in bCON+Fe (Fig.14A). An 
associated increase in CD45- and F480-positive cells was also observed in bKO+Fe only along 
with mild fibrosis (Fig.14A). These observations suggest that fibrosis follows inflammation and 
steatosis in bKO+Fe.  
 We next challenged bKO and bCON with high iron diet for 5 days. No steatosis or 
fibrosis was evident in either group (Fig.14B). While no discernible differences in CD45-positive 
cells were evident, a small increase in F480-positive infiltrate was evident in bKO+Fe (Fig.14B). 
To more conclusively address differences, we assessed these livers for pro-inflammatory 
cytokines. A significant upregulation of CCL5, CXCL10, IL-6, and TNF- was seen in bKO+Fe 
as compared to bCON+Fe (Fig.14C).  
Thus, iron-overload in absence of -catenin in liver leads to sequential increase in 
inflammation followed by steatosis and fibrosis. 
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Figure 14: Increased levels of inflammatory cytokines precede steatohepatitis and fibrosis in 
bKO+Fe as shown by time course after iron-feeding. 
 (A) H&E, Sirius Red and IHC for CD45 and F480 in bCON and bKO livers after 4-week iron 
diet shows presence of steatohepatitis in bKO+Fe and initiation of fibrosis. (B)  H&E, Sirius Red 
and IHC for CD45 and F480 in bCON and bKO livers after 5-day iron diet. bCon+FE and 
bKO+Fe lack steatosis and fibrosis while CD45-positive inflammatory cells and F480-
macrophages appear to be comparably increased in both groups. (C) Cytokine assay using liver 
lysates from 5-day bCON+Fe and bKO+Fe reveals comparable increased protein levels of 
CCL5, CXCL10, IL-6, TNF, and KC/Gro in BKO+Fe but no change in CCL2. *p<0.05, 
**p<0.01, #p<0.005, ##p<0.001 using Student’s T test. (Image magnification: 100x) 
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2.5 DISCUSSION 
Wnt/-catenin signaling plays diverse roles in liver pathobiology (164), although its role in iron 
metabolism in the liver remains unknown. A previous study reported increased Wnt signaling 
after addition of cellular iron to APC-mutant cell lines (144). We used previously characterized 
liver-specific -catenin KO (89, 163) to determine any changes in the expression of key iron-
metabolism genes. None of the major genes were differentially expressed between bCON and 
bKO. To determine if iron had an impact on -catenin signaling, control mice were fed a diet 
with excessive iron content. Two groups had individually identified iron chelators that inhibited 
Wnt signaling in different cancer models (143, 165). Interestingly, we observed decreased β-
signaling after high iron diet as indicated by decreased expression of target genes Cyp2e1, 
Cyp1a2 and GS. Intriguingly, despite decreased signaling, a complete lack of β-catenin was a 
greater detriment to mice after hepatic iron overload, which exhibited activation of AKT, ERK, 
and NFB, steatohepatitis, fibrosis, HCC and progenitor response, which led to re-appearance of 
-catenin and its targets inadvertently making the injury worse. Thus overall, bKO on high iron 
diet recapitulated hemochromatosis-like disease. Addition of antioxidant NAC abrogated hepatic 
damage and normalized histology and cell signaling in bKO+Fe.  
There was differential regulation of a few iron metabolism genes between bKO and 
bCON after high iron diet. We noted decreased transferrin receptor 2 mRNA levels while 
ferroportin and ceruloplasmin mRNA levels were increased in bKO+Fe. Since transferrin 
receptor 2 allows entry of iron into hepatocytes and ceruloplasmin converts toxic ferrous form to 
a nontoxic ferric form, the changes in bKO are likely compensatory to limit injury in bKO. This 
could also explain increased serum iron levels in bKO+Fe, which however could simply reflect 
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an increase in overall hepatic injury in bKO. Ferroportin mRNA is increased in bKO+Fe and 
bCON+Fe. Ferroportin is negatively regulated by hepcidin at a posttranslational level (120). 
Hepcidin binds to ferroportin to induce its internalization and degradation (152). Thus, we 
believe that increase in ferroportin mRNA in bKO+Fe and bCON+Fe is in response to its 
enhanced degradation by increased hepcidin. However, a significantly greater increase in 
ferroportin in bKO+Fe versus bCON+Fe may be due to additional mechanisms like 
inflammation and IL-6, which occur in bKO+Fe and have been shown to induce hepcidin 
expression (166). 
Progression of injury in bKO after iron overload lends insights into pathogenesis of 
disease like hemochromatosis. Increase in inflammatory cytokines like CCL5, CXCL10, IL-6, 
and TNF appear to be the first molecular event following iron overload in the absence of -
catenin in hepatocytes, which was evident at 5 days after iron diet. We believe that NFB 
activation is responsible for inflammation in bKO+Fe (167). We have previously shown that β-
catenin associates with NFB to prevent its nuclear translocation, and -catenin loss accelerates 
NFB activation (100).  
Steatosis follows inflammation as seen by the presence of steatohepatitis at 4 weeks. 
Steatosis in bKO is likely due to inflammation and also due to increased hepatic PPAR, master 
regulator of adipogenesis (168). -Catenin signaling suppress adipogenesis while its inhibition 
promotes pre-adipocyte differentiation to adipocyte through activation of lipogenic factors 
PPAR and CEBP (169). How iron overload induces PPAR uniquely in bKO remains under 
investigation.  We also observe activation of AKT, ERK, and NFB after long term iron diet 
administration to bKO. AKT activation impacts proteins involved in survival, cell cycle, 
autophagy, and protein synthesis (170, 171), including FoxO, which normally inhibits cell 
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growth and/or induces apoptosis (171). AKT phosphorylates and inhibits FoxO (172). 
Intriguingly, β-catenin can also act as a transcriptional cofactor for FoxO (67). While further 
studies are required to precisely address the role of AKT in bKO+Fe, we posit that excess iron 
enhances β-catenin and FoxO to induce apoptotic genes to clear damaged cells, thereby 
promoting proliferation of healthy cells. However, when β-catenin is absent, AKT 
phosphorylates and inactivates FoxO, allows persistence of damaged cells, eventually leading to 
HCC. We also observe increased ERK1 in bKO+Fe compared to bCON+Fe. Whether ERK1 and 
ERK2 have distinct roles is controversial (157). A rat study showed ERK1 upregulation 
augmented fibrosis and its suppression decreased fibrosis and increased hepatocyte proliferation 
(173). Therefore, it is likely that ERK1 activation in bKO+Fe contributes to fibrosis. Phospho-
ERK2 levels increased in bCON and bKO after iron and NAC treatment. Since silencing ERK2, 
but not ERK1, affected hepatocyte proliferation (174), we believe that NAC-induced ERK2 
activation contributes to hepatic regenerative response after iron overload. NFB can also be 
activated by inflammation and lipid peroxidation (175). As a transcription factor, it regulates 
expression of a number of inflammatory cytokines and chemokines and also Cyclin D1 (176). 
This may explain in part the Cyclin D1 induction seen in bKO+Fe. Eventually steatohepatitis 
leads to cell death, stellate cell activation, fibrosis, and occasionally to development HCC.  
The presence of increased oxidative stress appears to be chief perpetrator in disease 
progression in bKO+FE. We observe both increased MDA and 4HNE, especially in the areas of 
steatotic hepatocytes. Indeed, iron overload in genetically obese mice is associated with 
oxidative stress, injury and a NASH-like phenotype (177). Since mice are notoriously resistant to 
injury after high iron diet, we posit that lack of notable oxidative stress after iron feeding may 
explain the absence of a phenotype in control mice. Cyp2e1 is typically associated with 
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excessive lipid peroxidation and hepatic injury following iron overload, alcohol and high fat diet 
(162, 178-180). Cyp2e1 is a bona fide -catenin target in pericentral hepatocytes (89, 163, 181). 
Our study shows that feeding high iron diet to control mice leads to decreased Wnt/-catenin 
signaling and as a result, lowers Cyp2e1 levels. This may be the protective mechanism, which 
limits generation of oxidative stress to make mice resistant to iron overload injury.  
Despite lack of Cyp2e1 in bKO, these mice showed worse injury to iron overload. This is 
likely a consequence of enhanced inflammation due to NFB activation and dearth of -catenin-
dependent anti-oxidant mechanisms. Loss of -catenin in liver is associated with enhanced 
oxidative stress following ischemia-reperfusion injury and chemical carcinogenesis (68, 94, 
182). This is due to the lack of adequate glutathione content resulting from altered expression of 
several glutathione S-transferases, regucalcin (required for ascorbic acid biosynthesis) and 
interactions with HIF1 (36, 68, 87, 183). However, another unexpected and paradoxical event 
in bKO+Fe further underscores the importance of Cyp2e1 and oxidative stress as a mediator of 
iron-induced hepatic injury. Due to enhanced injury in bKO+Fe, we observed progenitor 
response characterized by Sox9, EpCAM, and CK19-positive ductular reaction (151). As a 
consequence, there is re-appearance of -catenin-positive hepatocytes in bKO+Fe, along with 
targets like Cyp2e1 especially in the steatotic areas. A caveat is that as progenitor cells would 
differentiate into hepatocytes, they will re-express albumin which would lead to expression of 
cre-recombinase and β-catenin deletion. It is likely hepatocyte differentiation is suboptimal and 
hence these “hepatocyte-like” cells may not have optimum albumin-cre expression. Another 
possibility is repopulation by -catenin-positive hepatocytes due to suboptimal deletion by 
‘leaky’ albumin-cre, which has been reported during chronic injuries like 3,5-diethoxycarbonyl-
1, 4-dihydrocollidine (DDC) diet (184). In the current study however, the survival advantage 
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attributed to the -catenin deletion-escaped hepatocytes comes at an unexpected cost of 
reappearance of Cyp2e1, which is normally downregulated following iron overload in controls. 
This pivots the balance towards greater lipid peroxidation, injury and disease progression.  
Alleviation of oxidative stress and lipid peroxidation in -catenin KO with NAC 
following iron overload had a dramatic effect on the disease process. While inflammation was 
unaffected quantitatively, NAC treatment led to notable decreases in pro-inflammatory 
cytokines, steatosis, stellate cell activation and fibrosis, thus normalizing histology and 
phenotype and making bKO+Fe indistinguishable in phenotype from bCON+Fe. It may be 
beneficial to examine any role of antioxidants for chemopreventive use in iron overload 
disorders. A summary of our findings is presented in Figure 15. 
 
Figure 15: Schema of β-catenin’s role in protection against hepatic iron overload. 
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3.0  HEPATOCYTE WNTS ARE DISPENSABLE DURING DIETHYLNITROSAMINE 
AND CARBON TETRACHLORIDE-INDUCED INJURY AND HEPATOCELLULAR 
CANCER 
In section 3, we used a phenotypically relevant chemical carcinogenic model to induce 
hepatocellular carcinoma in the context of hepatic injury and fibrosis. We first confirm efficacy 
and relevance of the model, then apply it using hepatocyte-specific Wntless knockout mice to 
assess the role of hepatocyte Wnts in tumor progression. The work in this section was published 
in Gene Expression-The Journal of Liver Research, PMID: 29519268 (185). The publisher, 
Cognizant, has granted permission for reuse of the manuscript in this dissertation. 
3.1 Abstract 
Activation of the Wnt/-catenin signaling is reported in large subsets of hepatocellular 
carcinoma (HCC). Upregulation of Wnt genes is one contributing mechanism. In the current 
study, we sought to address the role of hepatocyte-derived Wnts in a model of hepatic injury, 
fibrosis and carcinogenesis. We subjected hepatocyte-specific Wntless knockout mice (HP-KO), 
unable to secrete Wnts from hepatocytes, and littermate controls (HP-CON), to 
diethylnitrosamine and carbon tetrachloride (DEN/CCl4) and harvested at 3, 5, and 6 months for 
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histological and molecular analysis. Analysis at 5 months displayed increased hepatic expression 
of several Wnts and upregulation of some but not all -catenin targets, without mutations in 
Ctnnb1. At 5 months, HP-CON and HP-KO had comparable tumor burden and injury, however 
HP-KO uniquely showed small CK19-positive foci within tumors. At 6 months both groups were 
moribund with comparable tumor burden and CK19-positivity. While HCC histology was 
indistinguishable between the groups, HP-KO exhibited increased active-β-catenin, and 
decreased cMyc, Brd4, E-Cadherin, and others. Hepatic injury, inflammation and fibrosis were 
also indistinguishable at 3 months between both groups. Thus, lack of Wnt secretion from 
hepatocytes did not affect overall injury, fibrosis or HCC burden although there were protein 
expression differences in the tumors occurring in the two groups. 
3.2 BACKGROUND 
3.2.1 Introduction to liver cancer 
HCC, the most common type of liver cancer, is the fourth most common cancer worldwide, with 
incidence rates ranging from 4.6 per 100,000 in North America to 80 per 100,000 in Asia (186-
188). The frequency and cause of HCC clearly varies per region, with higher prevalence in 
developing countries (189), however incidence rates are rising in the US with increases in liver 
diseases including Hepatitis C and Non Alcoholic Fatty Liver Disease (190). It is the third most 
common global cancer death, and the ninth most common in the US (191). Additionally, fibrosis 
or cirrhosis is a prerequisite to HCC in 70-90% of cases (189, 192). Therefore, understanding 
what initiates and sustains tumorigenesis after fibrosis will not only have therapeutic potential 
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for HCC patients, but can aim to prevent HCC in patients with chronic liver diseases, which are 
both major concerns considering two thirds of patients are diagnosed at advanced stages of HCC 
(193). 
3.2.2 Etiology of HCC 
3.2.2.1 Fibrosis and Cirrhosis 
Fibrosis is characterized by increased extracellular matrix collagen deposition after sustained 
hepatic injury (86, 87), leading to scar formation and gradual loss of functional hepatic tissue. 
Fibrosis may be reversible (88, 89), or it can progress to hepatocyte dysfunction, nodule 
development, and decreased blood flow, defined as cirrhosis (90). Fibrosis almost always 
accompanies chronic liver injury (91), and is the product of inflammation resulting from 
macrophages phagocytosing dead hepatocytes, which leads to increased reactive oxygen species 
(ROS) (92) and macrophage-specific TGFβ1 secretion (93). These responses activate hepatic 
stellate cells (HSC) to transdifferentiate into myofibroblasts and produce excess collagen (94, 
95), leading to fibrosis. Macrophages also secrete profibrinogenic proteins including matrix 
metalloprotease inhibitors, which prevent extracellular matrix degradation (93).  
Other potential mechanisms leading to fibrosis include increased growth factor signaling 
through extracellular matrix interactions or reduced natural killer T cell function (92). In this 
milieu of activated myofibroblasts, chronic inflammation, ongoing hepatocyte death and 
existence of ROS, hepatocytes may incur enough DNA damage and mutations which promote 
their survival and expansion and eventually lead to HCC development (91).  
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3.2.2.2 Hepatitis 
Hepatitis B Virus (HBV) commonly leads to HCC, with 30-50% of HBV-related mortality 
resulting from HCC (100). HBV is a hepatotropic DNA-integrating virus encoding its own 
replication machinery (101) and contributes to HCC transformation by transcriptionally 
activating oncogenes (102) and inactivating tumor suppressors (103, 104). Additionally, viral-ER 
interactions can induce oxidative stress (105), leading to several responses such as activating 
HSCs (94, 95) leading to fibrosis. 
Hepatitis C Virus (HCV), the most common cause of cirrhosis and chronic liver disease 
(106), also leads to HCC (107). As an RNA virus, it exhibits greater propensity than HBV to 
develop chronic infection and cirrhosis (108). Although less is known about the progression of 
HCV to HCC (109), the mechanism by which HCV contributes to HCC onset are similar to HBV 
(95) and include inducing ER-related oxidative stress and regulating cell proliferation (110, 111). 
HCV is accompanied by chronic inflammation, leading fibrosis through HSC activation (112-
114). 
3.2.2.3 Chronic alcohol consumption 
In the US, over 18 million adults abuse alcohol, making it five times more common than HCV 
(115). The direct methods by which alcohol causes HCC are not well known, and given to 
rodents alone is not enough to induce carcinogenesis (115, 116). One theory is Cytochrome P450 
2E1 (Cyp2E1), a β-catenin target gene, is induced during heavy alcohol use in order to 
metabolize ethanol (117, 118) and produces reactive oxygen species when activated (119), 
leading to HSC activation and DNA damage in hepatocytes (120). 
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3.2.2.4 Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) 
With obesity rates rising, NAFLD incidence is increasing with 25% of Americans currently 
suffering. Of this population, approximately 25% have NASH, a more severe form of hepatic 
steatosis, or fatty liver (121, 122). The number of HCC cases resulting from NAFLD ranges from 
4 to 22% and is steadily rising in Western countries (123-125). Non-adipose tissues such as liver 
are unable to effectively store and metabolize increased triacylglyceride (TAG) content, and 
TAG overload leads to increased lipotoxicity, elevated ROS, and increased DNA damage (126-
128). 
 A summary of HCC development is presented in Figure 16.  
 
Figure 16: Progression from chronic liver injury to HCC. 
Chronic liver diseases, including HBV, HCV, ALD, or NAFLD/NASH, lead to increased hepatic 
inflammation, oxidative stress, and hepatic stellate cell activation. This causes collagen 
deposition and fibrosis, which can progress into hepatocyte damage and dysfunction, leading to 
cirrhosis. Cirrhosis often leads to HCC. HBV, hepatitis B virus; HCV, hepatitis C virus; ALD, 
alcoholic liver disease; NAFLD/NASH, Nonalcoholic Fatty Liver Disease/Nonalcoholic 
Steatohepatitis; HSC, hepatic stellate cells; HCC, hepatocellular carcinoma. 
3.2.3 Current treatments for hepatocellular carcinoma 
The only curative treatment for HCC is liver transplant, which leads to a low recurrence rate and 
a high long-term survival rate (194). However, patients with several large tumor nodules, 
vascularized tumors, or metastatic HCC are ineligible for transplants (195).  Surgical resection, 
where part of the liver is removed, is also promising for certain HCC patients although the 
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regenerative capacity of the remaining liver is usually unsatisfactory (196). If recurrence occurs 
after resection, the standard is to repeat resection, thereby requiring the injured liver to 
regenerate further (197).  
To date, only three chemotherapeutic drugs are Food and Drug Administration (FDA) 
approved for unresectable HCC. Sorafenib, a multikinase inhibitor that inhibits tumor 
proliferation and angiogenesis, only extends patient survival by approximately three months 
(198). The multikinase inhibitor Lenvatinib has an FDA application pending for approval, but 
patient survival was comparable to Sorafenib in clinical trials (199). Recently Regorafenib, 
another multikinase inhibitor, was approved for patients who have tumor progression during 
Sorafenib treatment, however patient survival was only extended another three months during a 
phase 3 trial (200). Another second-line therapeutic, the Programmed Death-1 inhibitor 
Nivolumab, was also recently approved for patients experiencing recurrence after Sorafenib, but 
a response was observed in only 15-20% of patients during clinical trials (201, 202). Additional 
trials are continuously surfacing, including the second-line kinase inhibitor Cabozantinib with 
improved overall survival of 11.5 months (201, 203). 
Transarterial chemoembolization may improve survival for patients in early disease 
stages by inducing tumor necrosis, although improvement is marginal (204). It is, therefore, of 
utmost importance to better understand underlying mechanisms of HCC initiation, progression, 
and advancement to provide better treatment options for patients with all liver diseases. 
3.2.4 Mutated β-catenin in hepatocellular carcinoma 
β-Catenin signaling is overactive in 20 to 90% of HCC patients (205). Approximately 8-44% of 
patients exhibit increased β-catenin signaling resulting from mutations (164). The most common 
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β-catenin mutations are found in exon 3 (corresponding exon 2 in mice) (206), which typically 
are single nucleotide substitutions that prevent β-catenin ubiquitination and degradation (207, 
208), classically through alteration of the GSK3β phosphorylation sites (209). Furthermore, Axin 
and APC, parts of the β-catenin destruction complex, have been individually mutated in subsets 
of HCC patients rendering them defective and allowing constitutive β-catenin activity (209-211). 
Although mutated β-catenin alone is insufficient to induce HCC, it can cooperate with other 
signaling pathways including mutated Ha-ras (212), Met (213), P53 (214), or TERT (215), and is 
often associated with better prognosis and well-differentiated HCC (216). 
3.2.5 Nonmutated β-catenin in hepatocellular carcinoma 
Approximately 35 to 80% of HCC patients have increased β-catenin accumulation but do not 
display any related mutations. Studies show this aberrant accumulation is due in part to 
overexpression of Wnt and/or Fzd (217). In fact, overexpression of many Wnts and Fzds has 
been implicated in different cancers including HCC (192, 217, 218) as well as several HCC cell 
lines (219). These modifications result in increased nuclear accumulation of β-catenin (220), 
leading to transcriptional upregulation of target genes and promotion of tumorigenesis. When 
Wnt antagonist fusion proteins are injected into an orthotopic HCC model harboring wildtype β-
catenin, animal survival and apoptosis increases, and tumor volume, β-catenin activity, and 
angiogenesis decreases (221), suggesting that Wnts may be a promising therapeutic target. 
Furthermore, patients with activated wild-type β-catenin resulting from upstream Wnt or Fzd 
activation have more aggressive, dedifferentiated tumors (218) and poorer prognosis than those 
with mutated β-catenin (222, 223), yet less is known about the mechanism of wild-type β-catenin 
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in tumor progression. Considering HCC arises from hepatocytes (224), we hypothesized they are 
a main cellular source of Wnts that contribute to tumor pathogenesis. 
3.3 Methods 
3.3.1 Animals 
Animal work was performed in accordance with the Institutional Animal Care and Use 
Committee at the University of Pittsburgh. Albumin-Cre Wntless knockout mice were generated 
as described previously(40). Male pups (HP-KO, HP-CON) were injected with 25mg/kg 
diethylnitrosamine (Sigma) at 14-16 days prepared in sterile 0.9% saline. Animals were 
transferred to a BSL2+ facility and injected with 0.5ml/kg carbon tetrachloride (CCl4) twice per 
week from week 8 to 22, prepared in corn oil. Three days after the last injection, animals were 
sacrificed (n=4) and livers were harvested. Livers were also harvested from a pre-cancer time-
point of 3 months (n=3) and advanced-cancer time-point of 6 months (n=4). Animals were 
monitored daily for signs of morbidity. At time of sacrifice, liver weights (LW) and body 
weights (BW) were assessed for LW/BW and differences tested for significance by Student’s T 
Test with p<0.05 to be considered significant. Blood was collected from the inferior vena cava 
and serum was sent to the University of Pittsburgh Medical Center Clinical Laboratory for ALT, 
AST, and ALP testing. 
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3.3.2 Immunohistochemistry 
Paraffin sections were processed as described elsewhere (108). Sirius Red, Ki67, H&E, CD45, 
CK19 and GS staining was performed as also described in detail previously (108) in section 
2.3.2. 
3.3.3 Protein isolation and analysis 
Protein was extracted in RIPA buffer, quantified, and 30µg was loaded onto a precast 
BioRad SDS gel. Gels were transferred using BioRad semi-dry transfer system. Antibody 
information can be found in Table 6. Horseradish peroxidase conjugated secondary antibodies 
(Invitrogen) were used. Ponceau or Gapdh was used as a loading control. Densitometric analysis 
was performed with ImageJ and normalized to housekeeping control. Statistics were calculated 
using One-way ANOVA with multiple comparisons and P values less than 0.05 were considered 
significant. 
 For reverse phase protein array (RPPA) analysis, samples were prepared via instructions 
from the MD Anderson Cancer Center RPPA Core Facility, and sent for analysis. Data was 
analyzed via Student’s t-test, and select proteins with statistically significant differences were 
validated by western blot. 
Table 6: List of antibodies used for western blot in section 3.0 
Antibody Company Catalog number 
GS Santa Cruz Sc74430 
cMyc Santa Cruz Sc764 
Hypo phosphorylated β-catenin Cell Signaling  4270 
PCNA Santa Cruz Sc56 
Cyp2e1 Atlas Antibodies  HPA009128 
β-catenin BD Biosciences 610154 
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Gapdh Proteintech 60004-1-Ig 
Wee1 Cell Signaling 4936 
Yap Cell Signaling 4912 
Erk1/2 Cell Signaling 4695 
Bax Cell Signaling 2772 
Cdc25 Cell Signaling 4688 
Brd4 Cell Signaling 13440 
E cadherin Cell Signaling 3195 
PKAa Cell Signaling 5675 
 
3.3.4 RNA isolation and qPCR 
RNA was extracted from DEN/CCl4 treated control livers and untreated livers (n=3) using Trizol 
(Thermo Fisher), and after DNAse treatment (Thermo Fisher) 2µg of RNA was reverse 
transcribed using Superscript III (Thermo Fisher). Samples were pooled together and Sybr Green 
(Thermo Fisher) was used for qPCR. Ct values were normalized to GAPDH, and primer 
sequences are included in Table 7. 
Table 7: qPCR primers used in Section 3.0 
Primer 
(Mouse) 
Forward Sequence Reverse Sequence 
Gapdh AACTTTGGCATTGTGGAAGG ACACATTGGGGGTAGGAACA 
Wnt1  ATCCATCTCTCCCACCTCCTAC GAATCTTTCTCTCACCCTCTGG 
Wnt2 TCTGTCTATCTTGGGCATTCTG TTCCTTCGCTATGTGATGTTTC 
Wnt2b ACCTTCCTCTACCCTCAATCCT TCACTCAGCCTCCTAAATCCAT 
Wnt3 GTCTGCTAATGCTGGCTTGAC TAGGAAGGGATGGGAGGTGT 
Wnt4 AGAACTGGAGAAGTGTGGCTGT AAAGGACTGTGAGAAGGCTACG 
Wnt6  TTTACACCAGCCCACGAAAG ACTCACCCATCCATCCAAGTA 
Wnt8b  GTTTGCTTGGGACCGTTG TCCATTTCGGGAGTCATCA 
Wnt9a ATGGTGTGTCTGGCTCCTG CAGTGGCTTCATTGGTAGTGCT 
Wnt9b GGGTGTGTGTGGTGACAATCT GGTCCTTGCTTCCTCTCTTG 
Wnt10a TCCTGTTCTTCCTACTGCTGCT ACGCACACACACCTCCATC 
Wnt10b CCACTACAGCCCAGAACCTC GGAGAGACCCTTTCAACAACTG 
Wnt11 CCCTGGAAACGAAGTGTAAATG AGGTAGCGGGTCTTGAGGTC 
Wnt16 GCTGTAACCTCCTCTGCTGTG GTGGACATCGGTCATACTTTCA 
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3.3.5 DNA extraction and Ctnnb1 sequencing 
gDNA was isolated from livers (XNAT, Sigma), and primers flanking intron-exon junctions of 
Ctnnb1 exon 2 (forward primer TACAGGTAGCATTTTCAGTTCAC, reverse primer 
TAGCTTCCAAACACAAATGC) (206) were used in PCR. Product was gel purified and 
sequenced by the Genomics Research Core at University of Pittsburgh. Sequences were 
validated using ApE Software. Tumors in HP-CON and HP-KO at 5 and 6 months (N=3) were 
sequenced. 
3.4 Results 
3.4.1 DEN/CCl4 leads to wildtype Ctnnb1 and upregulation of several Wnts 
To develop an injury-based carcinogenesis model, we adapted the DEN/CCl4 protocol 
used to induce inflammation, fibrosis, and tumors (225, 226). This model utilizes one injection of 
diethylnitrosamine at day 15, and biweekly injections of carbon tetrachloride from week 8 to 
week 22 (DEN/CCl4) (Fig.17A). DEN/CCl4 shows 100% penetrance at 5 months for HCC in 
conjunction with fibrosis and inflammation, thereby representing what is seen in patients 
(Fig.17B, 18F).  
This model is known to cause HCC without β-catenin mutations as confirmed through 
sequencing and supported by lack of GS staining (227), which is a surrogate, albeit debated, for 
mutated β-catenin (216, 228). Via immunohistochemistry, all tumors were GS-negative 
(Fig.17C). Further, tumors were sequenced for mutations in exon 2 of Ctnnb1, analogous to exon 
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3 in humans. This is home to GSK3β phosphorylation sites and the most frequent activating 
mutations in HCC (206, 229). Wildtype Ctnnb1 was identified in all tumors (Fig.17D).  This was 
also corroborated using microarray data obtained from Gene Expression Omnibus 
(http://www.ncbi.nlm.nih.gov/geo/), accession number GSE33446, comparing data from 
DEN/CCl4 treated animals to untreated animals (225). We queried the data and noted no change 
in expression of Glul, gene encoding for GS, after DEN/CCl4. However, several -catenin targets 
were upregulated as listed in Table 8 suggesting that modest activation of the pathway does 
occur despite absent Ctnnb1 mutations. 
Next, we assessed whether Wnts were overexpressed after DEN/CCl4, and tested mRNA 
expression of select Wnts in livers after DEN/CCl4 compared to untreated livers. Wnt1, Wnt6, 
Wnt10a, Wnt10b, Wnt11, and Wnt16 showed upregulation of at least two-fold in DEN/CCl4 
livers versus control livers (Fig.17E). We hypothesized that some of these may be originating 
from hepatocytes and hence interrogated tumorigenesis in mice lacking ability to secrete all 
Wnts from hepatocytes owing to Wntless loss. 
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Figure 17: DEN/CCl4 model of HCC shows Wnt upregulation but non-mutated β-catenin. 
 (A) Schematic of DEN/CCl4 injection protocol, beginning at day of birth and concluding at 5 
months of age. (B) High magnification (200x) Hematoxylin and Eosin stain (H&E) highlighting 
intratumoral dysplastic hepatocytes. (C) Assessing GS staining in tumors in DEN/CCl4 model of 
HCC. No GS-positive tumors were observed, suggesting wildtype β-catenin. (D) Representative 
sequencing of β-catenin exon 2, focusing on GSK3β phosphorylation motifs, displays non-
mutated and identical sequence between tumors (Tu.) and wildtype (WT). (E) RT-PCR analysis 
showing upregulation in the transcript levels of several Wnts at 5 months of age after continued 
DEN/CCl4 treatment in mice as compared to untreated controls.  
 
 64 
 
Table 8: List of beta-catenin target genes altered in DEN/CCl4 
Gene Probe (from 
GSE33446) 
Log2 Fold 
Change 
Adjusted P 
value 
Reference 
CD44 1434376_at 3.55382771 8.71e-03 (230) 
Survivin 1424278_a_at 3.36261188 6.73e-04 (231) 
EGFR 1432647_at 2.58970608 3.94e-05 (31) 
Ccnd1     (Cyclin D1) 1417419_at 2.46649404 4.01e-09 (89) 
S100A6 1421375_a_at 2.40064056 8.99e-03 (232) 
Ctnnb1         (-catenin) 1430533_a_at 2.112623 5.53E-06  
MMP14 1448383_at 2.06551913 4.32e-06 (233) 
Vegfa 1451959_a_at 0.7674417 2.87e-03 (234) 
Tgfα 1450421_at 0.50142774 6.94e-04 (35) 
Axin2 1436845_at 0.39369432 7.48e-01 (235) 
Lef1 1421299_a_at 0.11541357 4.32e-01 (236) 
Glul (GS) 1426236_a_at -1.21199767 2.21e-01 (237) 
Regucalcin 1448852_at -1.28147025 7.64e-02 (36) 
Lect2 1449492_a_at -1.35084301 3.03e-01 (238) 
3.4.2 HP-KO and HP-CON have comparable tumor burden at 5 months, although HP-KO 
have more CK19+ nodules after DEN/CCl4. 
To assess the role of Wnts from hepatocytes, we subjected previously described hepatocyte-
specific Wntless KO referred henceforth as HP-KO and littermate controls (HP-CON) to 
DEN/CCl4 (40). Mice sacrificed at 5 months exhibited comparable tumor burden reflected by 
similar LW/BW between the two groups (Fig.18A,B). Serum analysis revealed comparable and 
modestly elevated ALT, AST, and ALP in HP-CON and HP-KO (Fig.18C-E). H&E staining 
verified these tumors to be similar HCCs as reflected by well-circumscribed lesions composed of 
hepatocytes with basophilic cytoplasm, some pleomorphic nuclei, and mitotic figures in HP-
CON and HP-KO (Fig.18F). Further, we noted no differences in fibrosis via Sirius red or α-SMA 
(Fig.18F and data not shown), or inflammation, vascularization, or proliferation, via assessment 
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of CD45, CD31, and Ki67, respectively (Fig.18F and data not shown). We also validated 
wildtype Ctnnb1 in HP-CON and HP-KO (Fig.18G). 
 To further characterize the tumor phenotype, we queried the differentiation status and 
assessed the dedifferentiation marker CK19, as it positively correlates with poor prognosis, 
increased tumor size and invasiveness (239). Immunohistochemistry revealed small CK19-
positive foci in all HP-KO mice, while expression was restricted to bile ducts in HP-CON mice 
(Fig.19A). Not all nodules in HP-KO were CK19-positive, however large tumors frequently 
contained smaller foci of heterogeneous CK-19-positive cells. These overall findings indicated 
that HCC occurring in absence of Wnts from hepatocytes were comparable to controls, other 
than the occurrence of small CK19-positive areas within tumors. 
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Figure 18: HP-CON and HP-KO have comparable tumor burden after 5 months of DEN/CCl4. 
(A) Representative gross images of HP-CON and HP-KO at 5 months. (B) HP-CON and HP-KO 
have comparable liver weight to body weight ratios after DEN/CCl4. (C-E) Serum analysis 
reveals comparable Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and 
Alkaline Phosphatase (ALP) in HP-CON and HP-KO. (F) Representative images of hematoxylin 
and eosin (200x), CD45, Sirius Red, and Ki67 (50x) reveal comparable tumors and injury burden 
in HP-CON and HP-KO. (G) Representative sequencing shown for HP-CON and HP-KO 
tumors, which are both CTNNB1 wildtype. 
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3.4.3 No difference in tumor burden in HP-KO versus HP-CON at advanced stages 
We predicted CK19-positive foci in HP-KO to develop into more aggressive tumors than 
HP-CON. To test this, we followed an independent cohort for an additional timeframe. However, 
by 6 months, all mice became moribund and required euthanasia. Grossly, livers from both 
groups were excessively stiff and showed sizable tumor burden (Fig.19B). LW/BW at 6 months 
failed to show significant differences between the two groups and both groups showed increased 
ratios over the 5-month time-point (Fig.19C). Mutations in Ctnnb1 were still absent at 6 months 
(Fig.19D). Intriguingly, at 6 months, both HP-CON and HP-KO displayed comparable, diffuse, 
and broader staining for CK19 within tumors (Fig.19E). Similar to 5-month time-point, 
comparable fibrosis, inflammation and proliferation was observed as seen by Sirius red 
(Fig.19E), CD45, and Ki67 staining, respectively (data not shown). Thus, there were no 
phenotypic differences in HCC occurring in HP-CON and HP-KO at 6 months after DEN/CCl4. 
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Figure 19: HP-KO have CK19-positive foci absent in HP-CON at 5 months, however HCC is 
comparable in HP-CON and HP-KO at 6 months after DEN/CCl4. 
(A) CK19 staining is positive in biliary epithelial cells in HP-CON and HP KO, but is evident in 
small tumor foci within larger tumors in HP-KO at 5 months. (B) Gross images show advanced 
HCC in both HP-CON and HP-KO at 6 months after DEN/CCl4. (C) Liver weight to body 
weight ratios are comparable at 6 months after DEN/CCl4. (D) At 6 months, HP-CON and HP-
KO have wildtype CTNNB1. (E) Representative H&E (200x), Sirius Red (50x), and CK19 (50x) 
suggest similar tumor composition, fibrosis, and CK19 pattern, respectively, in HP-CON and 
HP-KO at 6 months. 
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3.4.4 HP-CON and HP-KO after DEN/CCl4 show distinct temporal protein expression 
Despite comparable tumor burden and histology in HP-CON and HP-KO at 5 and 6 months, we 
queried whether there are differences in protein expression, likely correlating with altered 
signaling patterns, as a result of absent Wnt secretion from hepatocytes. First, we assessed 
proliferation markers and relevant β-catenin activation markers via western blot (Fig.20A,C). 
Hypo-phosphorylated β-catenin, suggesting activation, was comparable at 5 months and 
significantly upregulated in HP-KO at 6 months. GS was variable, while Cyp2e1, a -catenin 
target altered by CCl4, was lower in HP-KO at 5 months, although levels in both HP-CON and 
HP-KO were comparably reduced at 6 months. Total levels of β-catenin were comparably 
reduced at 6 months compared to 5 months. Cyclin D1 was increased at 6 months compared to 5 
months in both groups. PCNA remained comparably high at all times in both groups. 
Intriguingly, cMyc was reduced in HP-KO at both 5 and 6 months. Thus, overall hepatocyte-
specific loss of Wnts appears to promote β-catenin hypo-phosphorylation and decrease cMyc 
levels after DEN/CCl4. 
 We sought a holistic approach to assess protein levels, and performed Reverse Phase 
Protein Array to assess expression of over 240 proteins involved in cancer as described in 
Methods. Several proteins had significant differences between HP-CON and HP-KO in the 5 
month or 6 month time-point, and select proteins were confirmed by western blot (Fig.20B,D). 
Intriguingly, at 5 months HP-KO had significantly less expression of ERK1/2, Bax, Brd4, and E-
cadherin than HP-CON. By 6 months, HP-KO had increased ERK1/2 and decreased Brd4, and 
comparable Bax and E-cadherin. Expression of Wee1, Yap, and Cdc25 were variable, and while 
PKAa expression was only evident at 6 months, there was no difference between HP-CON and 
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HP-KO (Fig.20B,D). Taken together, this suggests HP-specific Wnts temporally regulate 
expression of oncogenes including ERK1/2, Bax, E-cadherin, and Brd4. 
 
Figure 20: HP-CON and HP-KO have divergent protein expression patterns at 5 and 6 months. 
 (A) Western blot assessing glutamine synthetase (GS), cMyc, hypo-phosphorylated β-catenin, 
Cyclin D1, PCNA, Cyp2e1, and total β-catenin. Ponceau shows comparable loading. (B) 
Western blot assessing select proteins based off RPPA analysis including Wee1, Yap, Erk1/2, 
Bax, Cdc25, Brd4, E-cadherin, PKAa. Gapdh shows comparable loading. (C) Densitometry of 
western blot from figure A highlights significant changes between HP-CON and HP-KO at 5 and 
6 months. Relative expression was normalized to Ponceau. (D) Densitometry analysis of western 
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blot from figure B, normalizing values to Gapdh. Statistics performed with one-way ANOVA 
using multiple comparisons. *P<0.05, **P<0.01. 
3.4.5 Comparable onset and progression of injury in response to DEN/CCl4  
Lastly, we asked whether hepatocyte-Wnts contribute to DEN/CCl4-induced injury and hence the 
pre-tumoral microenvironment. We subjected HP-CON and HP-KO to this insult until 3 months 
of age, and noted no gross hepatic differences (Fig.21A). Histology showed comparable cell 
death, hepatocyte ballooning, inflammation, and scarring in HP-CON and HP-KO (Fig.21B). 
Further analysis revealed similar fibrosis, inflammation, and proliferation via Sirius red, number 
of CD45+ cells, and number of Ki67-positive hepatocytes in HP-CON and HP-KO (Fig.21C). 
We therefore concluded removing Wntless from HP insignificantly contributes to hepatic injury 
during DEN/CCl4 treatments. 
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Figure 21: Comparable injury in HP-CON and HP-KO at 3 months after DEN/CCl4. 
(A) Gross images of HP-CON and HP-KO livers at 3 months show similar stiffness and lack of 
gross tumors. (B) H&E staining shows similar histology in HP-KO and HP-CON with 
comparable cell death, hepatocyte ballooning, inflammation and fibrosis after 3 months of 
treatment with DEN/CCl4. (C) Representative images for Sirius red and immunohistochemistry 
for CD45 and Ki67, demonstrate comparable fibrosis, inflammation, and proliferation in HP-
CON and HP-KO at 3 months after DEN/CCl4 
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3.5 Discussion 
Activation of Wnt/-catenin signaling in HCC is due to various mechanisms (164, 205). 
Overexpression of Wnt and Fzd genes have been implicated as a contributor to β-catenin 
activation in a subset of HCC cases (217). In fact, patients with intratumoral overexpression of 
Wnt and/or Fzd have more dedifferentiated tumors correlating with aggressiveness (218). Wnt 
upregulation has also been reported in HCC cell lines including Hep3B cells (219). To address 
the role of hepatocyte-derived Wnts in hepatocarcinogenesis in a relevant model, we examined 
injury and tumorigenesis in control mice and mice lacking Wntless in hepatocytes, which 
disallows secretion of all Wnts from these cells due to loss of this cargo receptor specific and 
essential for Wnts (13, 40, 240).  
We studied the DEN/CCl4 model of tumorigenesis, as it leads to HCC following chronic 
injury and fibrosis, mimicking patient progression (226). More importantly, we confirmed 
DEN/CCl4-induced HCC provides evidence of -catenin activation without mutations in Ctnnb1. 
Indeed, microarray data available publicly via Gene Expression Omnibus (GSE33446), confirms 
β-catenin target genes including CD44, Cyclin D1, EGFR, and Survivin are induced in this 
model whereas β-catenin targets like GS and Regucalcin, which are associated with more 
sustained -catenin activation through mutations are unchanged. Further, when mRNA 
expression of several Wnts was assessed, Wnt1, Wnt6, Wnt10a, Wnt10b, Wnt11, and Wnt16 
were upregulated at least 2-fold in comparison to control livers. While in the current study, we 
addressed the loss of all hepatocyte-derived Wnts, studying the relevance of individual Wnts will 
be interesting, especially since Wnt6 and Wnt11 can act non-canoncially, independent of β-
catenin (241).  
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Upon challenging HP-CON and HP-KO with DEN/CCl4, comparable tumor burden was 
observed at 5 months. We noted similar injury, fibrosis, inflammation, and proliferation. 
However, in assessing tumor differentiation, we observed the presence of small but frequent 
CK19-positive foci within larger CK19-negative tumors, in HP-KO. Presence of CK19 in HCC 
is suggested to correlate with a more dedifferentiated phenotype, overall poor prognosis and 
worse outcome after surgery (242-244). Finding CK19-positive foci in HP-KO was surprising, 
since a positive correlation between Wnt/β-catenin activation and stem markers including CK19 
has been previously reported (245). However, since secretion of all Wnts is being disrupted, it is 
likely that the loss of non-canonical Wnts may be allowing for increased CK19 positivity. 
Indeed, hepatocytes and transformed hepatocytes are known to be a source of non-canonical 
Wnts that suppress β-catenin activity (219). Intriguingly, the increased numbers of CK19-
positive foci did not lead to an overall aggressive HCC in HP-KO at 6 months and both groups of 
mice succumbed to excessive tumor burden, and CK19 staining was comparable at this time-
point. These data suggest that the DEN/CCl4 model is too robust leading to an aggressive disease 
and a model with an indolent course may be more suitable to address the overall role of 
hepatocyte-derived Wnts.  
We also noted a reduction in cMyc in HP-KO at 5 months and 6 months. Wnt/β-Catenin 
activates cMyc, particularly during hepatocarcinogenesis (246). Therefore, a reduction in cMyc 
would likely suggest a reduction in β-catenin activity. While β-catenin target gene Cyp2e1 was 
reduced in HP-KO at 5 months, target gene GS and hypo-phosphorylated and total β-catenin 
levels were unchanged. Although at 6 months a reduced cMyc in HP-KO correlated with 
increased hypo-phosphorylated (and thus activated) β-catenin. cMyc can be upregulated in HCC 
independent of -catenin, for example by amplification (247). The mechanism by which cMyc is 
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downregulated in HP-KO remains unclear and will be elucidated in the future. Overall, 
decreased cMyc does not seem to be altering the overall tumor biology in HP-KO since 
comparable tumor burden is evident in HP-KO and HP-CON. However, cMyc upregulation in 
HP-CON does appear to be partially Wnt/-catenin dependent as shown previously (208, 246).  
 RPPA analysis further revealed altered protein expression in HP-KO versus HP-CON. 
While the relevance of these changes remains unclear, there are several intriguing relationships 
among these data. Bromodomain 4 (Brd4) is a transcription coactivator involved in many 
cancers. In HCC, Brd4 is overactive and its suppression correlates with cMyc suppression (248). 
At 5 month and 6 month timepoints, cMyc and Brd4 were both reduced in HP-KO. Whether HP-
Wnts regulate cMyc through Brd4 remains a plausible mechanism to assess. E-cadherin 
inversely correlates with aggressive HCC, as loss leads to increased epithelial to mesenchymal 
transition and invasiveness (249). Reduction of E-cadherin in HP-KO at 5 months, then 
comparable expression to HP-CON at 6 months, supports the findings that at 5 months HP-KO 
tumors began to dedifferentiate, but all differences are ablated by 6 months. This likely reaffirms 
the model is too hepatotoxic to appreciate contributions of HP Wnts, as other pathways are able 
to compensate. E-cadherin can activate ERK signaling in other cancers (250), which may explain 
why reduced E-cadherin correlates with reduced ERK1/2 at 5 months, however further studies 
are required to confirm pathway activation. Finally, the role of HP-Wnts in Bax expression is 
unclear, despite HP-KO having reduced Bax at 5 months. Overall, we conclude HP-Wnts 
contribute to protein expression, which likely corresponds to signaling changes but are 
insignificant to the overall tumor phenotype.  
Wnt signaling from hepatocytes also appears to not influence the overall pre-tumor 
environment. At 3 months, comparable injury, inflammation, and fibrosis was observed between 
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HP-CON and HP-KO.  This negative data is novel and important, as we provide in vivo evidence 
that targeting hepatocyte-specific Wnts will not be an effective clinical therapy, despite literature 
demonstrating increased Wnts in HCC and transformed hepatocytes in vitro. It will be of interest 
to assess Wnt contributions from additional cell types, including macrophages and endothelial 
cells, to identify roles to injury, fibrosis, and carcinogenesis.  
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4.0  MACROPHAGE-SPECIFIC WNTLESS LOSS IN MICE CAN PROMOTE OR 
SUPPRESS HEPATIC TUMORIGENESIS IN RESPONSE TO CHRONIC INJURY AND 
CHEMICAL CARCINOGENESIS 
Section 4.0 is a continuation from section 3.0, where we take macrophage-specific Wntless 
knockout mice (MP-KO) and subject them to DEN/CCl4. We noted two distinct phenotypes, 
namely MP-KO had greater tumor burden than littermate controls, or MP-KO had reduced tumor 
burden to littermate controls. We attempt to characterize this phenotype and provide a work-in-
progress mechanism, focusing on overall signaling differences, tumor immunology differences, 
and questioning the underlying factor responsible for the divergent phenotype. At the time of this 
thesis submission, the work in this section was submitted as a first-author manuscript to 
American Journal of Physiology and is currently under revision. 
4.1 ABSTRACT 
Hepatocellular carcinoma (HCC) remains an important unmet clinical need. Considering HCC 
occurs in fibrotic livers in 90% of cases, understanding the basis of injury progression and tumor 
development is therapeutically relevant. We previously reported Wnts to be upregulated in 
diethylnitrosamine-carbon tetrachloride (DEN/CCl4) induced model of hepatic injury, fibrosis, 
and tumorigenesis. In this model, we confirmed Wnts from hepatocytes to not contribute majorly 
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to HCC development. Here, we investigated if Wnts from macrophages are required for injury 
and HCC. We subjected macrophage-specific wntless knockouts (KO), unable to secrete Wnts 
from macrophages, and littermate controls (CON), to DEN/CCl4 for five months and assessed 
injury, inflammation and hepatocarcinogenesis. Exposure of MP-KO and MP-CON led to two 
distinct and litter-specific phenotypes. So-called Group A MP-KO had greater tumor burden than 
MP-CON A, while Group B MP-KO exhibited lesser HCC than MP-CON B. We therefore 
hypothesized that HCC occurring in Group A are phenotypically different from Group B and the 
macrophage-Wnts contribute disparately to tumor development based on underlying 
heterogeneity. Comparing MP-CON A and MP-CON B, we identified several epigenetic 
regulators and also signaling proteins including increased cMyc and P38 to be differentially 
expressed. Moreover, we identified MP-CON B to have increased M1 macrophages and 
infiltrating leukocytes. Elimination of Wnt secretion from macrophages thus had opposing 
consequences on HCC growth and development based on the molecular makeup of HCC, driven 
by divergent expression of epigenetic regulators, signaling and macrophage polarization. Our 
data suggests macrophage-Wnts can promote or suppress tumors, depending on the underlying 
cellular and molecular composition of HCC. 
4.2 BACKGROUND 
The incidence of hepatocellular carcinoma (HCC) has increased from 4.4 per 100,000 
people in 2000 to 6.7 per 100,000 people in 2012 in the US. Compared to 2000, there was a 
115% increase in reported HCC cases in 2012 (251). In areas of increased hepatitis infection 
including Eastern Asia, incidence is as high as 20 per 100,000 people. Furthermore, HCC occurs 
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in the context of chronic liver disease and fibrosis or cirrhosis up to 90% of the time (252). 
Therefore, despite advancement in understanding disease progression and mechanism, we still 
lack strong therapeutics to prevent and limit HCC.  
Activation of Wnt signaling is known to occur in a major subset of HCC (164). While 
occurrence of mutations in CTNNB1 gene is one major mechanism, upregulation of Wnt 
signaling, via overexpression of Wnt ligands or receptors, or downregulation of Wnt antagonists, 
is also evident in additional subsets of HCC patients (218). However, the source of Wnts in HCC 
development remains unclear. Using the diethylnitrosamine and carbon tetrachloride 
(DEN/CCl4) model, which causes injury and HCC, we previously confirmed tumors to harbor 
wildtype β-catenin (185). There was also an associated upregulation of several Wnts in this 
model. We provided evidence however, that hepatocyte-specific Wnts do not play a major role in 
injury progression, HCC development, or tumor advancement (Section 3.0) (185). However, 
several Wnts we identified to be upregulated after DEN/CCl4, including Wnt10a, Wnt10b, 
Wnt11, and Wnt16, are present in resting and activated Kupffer cells (11). Therefore, we 
hypothesized that macrophages (MP) may secrete Wnts necessary for tumorigenesis, and 
preventing MP from secreting Wnts may impact HCC development and progression.  
 We subjected MP-specific Wntless knockout mice, unable to secrete all Wnts form MP 
(40), to DEN/CCl4 for five months. Intriguingly we identified two distinct phenotypes that were 
litter-specific. Removal of MP Wnts acted as a tumor promoter or tumor suppressor. We provide 
evidence that these opposing roles of MP Wnts depends on underlying factors including 
oncogenic signaling, inflammatory milieu, and may be due to different epigenomes eventually 
leading to the two distinct HCC phenotypes.  
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4.3 METHODS 
4.3.1 Animals 
All animal use was performed in accordance with the Institutional Animal Care and Use 
Committee at the University of Pittsburgh, and animal husbandry was carried out by staff of the 
Division of Laboratory Animal Resources. Macrophage specific Wntless knockout mice, Lyz-
Cre+/-;Wlsfl/fl (MP-KO) were generated and bred as described previously5. Male MP-KO (n=9) 
and littermate control (CON, n=9) were subjected to DEN/CCl4 as previously described (185) in 
section 3.2.1. Briefly, mice were given 25mg/kg DEN in saline at two weeks of age, and given 
twice-weekly injections of 0.5ml/kg CCl4 from 2 months to 5 months of age. Animals were 
monitored for morbidity. At time of harvest, livers were dissected into small sections and placed 
in 10% formalin for 48 hours prior to paraffin embedding, placed in O.C.T. compound to create 
frozen tissue sections, or flash frozen for RNA and protein analysis. Blood was extracted and 
serum was sent to the University of Pittsburgh Clinical Laboratory for liver injury marker 
testing, and liver weight and body weight were recorded. 
4.3.2 Immunohistochemistry 
CD45 and PCNA staining, and special stains Sirius Red and terminal deoxynucleotidyl 
transferase dUTP nick end labeling (TUNEL) were performed as previously described (Section 
2.0) (108). For relevant antibody information, see Table 9. ImageJ was used for quantification. 
For Sirius Red and CD45, images were taken at 50x and for PCNA, images were taken at 100x. 
At least 3 fields were randomly imaged from at least 4 de-identified tissues per group were 
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imaged and relative intensities were measured. For TUNEL staining, positive cells were counted 
manually at magnification 100x from at least three images per de-identified sample, and from 
four samples per group. The average value for the three images was used as the final data point 
for statistical and graphical analyses. 
4.3.3 Immunofluorescence 
Liver lobes frozen in O.C.T. were used to cut 4μm sections. Sections were fixed in acetone and 
permeabilized with 0.1% Triton X-100. Slides were blocked in 5% serum in 0.5% BSA, and 
primary antibodies were incubated for one hour as per Table 9. Secondary antibodies conjugated 
to FITC or TRITC were used. After Dapi, coverslips were mounted with Gelvatol and slides 
incubated at 4° overnight. Images were taken on a Nikon Eclipse Ti microscope using NIS 
Elements version 4.4. For quantification, seven images per de-identified samples were taken and 
results presented as average. For CD68 and CD11b staining, positive cells were counted 
manually at 200x. For F4/80 staining, images were taken at 100x and intensity was measured 
with ImageJ Software. 
4.3.4 Protein analysis 
For Reverse phase protein array (RPPA) analysis, all samples were submitted to The University 
of Texas MD Anderson Cancer Center RPPA core facility. Protein lysates were prepared per the 
core facility instructions. For immunoblotting, protein was extracted in RIPA buffer, quantified, 
and 30µg was loaded onto a precast BioRad SDS gel. Gels were transferred using BioRad semi-
dry transfer system. See Table 9 for antibody information. To perform cytokine array (R&D, 
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Mouse Cytokine Antibody Array, Panel A) three RIPA lysates per group were pooled together 
and used per the manufacturer’s instructions. To quantify western blotting and cytokine array, 
ImageJ was used and mean intensities were normalized to housekeeping proteins. 
Table 9: List of antibodies used in section 4.0 
Protein Company Catalog No. Use Dilution  
CD11b Biolegend 101201 IF 1 to 100 
CD68 Abcam 125212 IF 1 to 250 
F4/80 Serotec mca497ga IF 1 to 500 
PCNA 
Use with Mouse On 
Mouse kit (Vector 
Laboratories) 
 
Santa Cruz SC-56 IHC/WB 1 to 50/1 to 200 
CD45 Santa Cruz SC-53665 IHC 1 to 100 
Cyclin D1 Thermo Fisher RB-9041-P WB 1 to 200 
Gapdh Proteintech 60004-1-Ig WB 1 to 10,000 
GS Santa Cruz SC-74430 WB 1 to 1000 
Cyp2e1 Sigma Aldrich HPA009128 WB 1 to 500 
P21 Santa Cruz SC-271532 WB 1 to 100 
pRb Cell Signaling 9308 WB 1 to 500 
pAKT Cell Signaling 13038 WB 1 to 1000 
pERK Cell Signaling 4370 WB 1 to 1000 
53BP1 Cell Signaling 4937 WB 1 to 750 
cMyc Santa Cruz SC-764 WB 1 to 200 
Bax Cell Signaling 2772 WB 1 to 750 
P38 Mapk Cell Signaling 9212 WB 1 to 1000 
AR Abcam ab129081 WB 1 to 1000 
Stat3 BD Bioscience 610189 WB 1 to 5000 
Smad3 Abcam ab40854 WB 1 to 1000 
Active beta-catenin Cell Signaling 4270 WB 1 to 1000 
Beta-catenin BD Bioscience 610154 WB 1 to 1000 
Cleaved Casp3 Abcam ab32042 WB 1 to 1000 
Cleaved Caps7 Cell Signaling 9491 WB 1 to 1000 
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4.3.5 RNA and Qiagen qPCR array 
RNA was extracted from three DEN/CCl4 treated control livers from Group A, and three from 
Group B using Trizol (Thermo Fisher), and after DNAse treatment (Thermo Fisher) 2µg of RNA 
was reverse transcribed using Superscript III (Thermo Fisher). Samples were then pooled 
together and Sybr Green (Thermo Fisher) was used for qPCR in the Mouse Epigenetic 
Chromatin Modification Enzymes PCR array (Qiagen). Ct values were normalized to several 
housekeeping genes within the array. 
4.3.6 Statistical analysis 
Graphs were generated with Microsoft Excel or Prism software. Student’s T Test or One-Way 
ANOVA with multiple comparisons (as distinguished in figure legends) was used to calculate 
statistics and described appropriately in figure legends. P values less than 0.05 were considered 
significant. 
4.4 RESULTS  
4.4.1 Removing Wntless from MP results in opposing response to DEN/CCl4 
To test whether preventing Wnt secretion from MP will impact tumorigenesis, we used MP-
specific Wntless knockout mice (MP-KO) (40), and subjected  MP-KO  and littermate controls 
(MP-CON) to DEN/CCl4 until 5 months of age as previously reported (185). Four separate litters 
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composed of 9 MP-CON and 9 MP-KO in total were exposed to the treatment. Intriguingly, we 
observed a litter-specific contrasting phenotype. MP-KO exhibited greater tumor burden and 
liver weight to body weight ratio than MP-CON in two litters (n=4, herein referred to as Group 
A), and MP-KO exhibited reduced tumor burden and liver weight to body weight ratio compared 
to MP-CON in two litters (n=5, herein referred to as Group B) (Fig.22A,B). While serum injury 
markers were variable, Group A MP-CON and MP-KO had comparable injury markers ALT, 
AST, ALP, and Bilirubin (Fig.22C, Fig.23A). Group B  MP-KO  overall trended towards less 
injury compared to Group B CON, as  MP-KO  B had significantly less ALT, and insignificant 
reductions in AST and total Bilirubin. Direct bilirubin and ALP were comparable in Group B 
MP-CON and MP-KO (Fig.22C, Fig.23A).  
Hematoxylin and Eosin staining was done on tissues sections to address histological 
differences between various groups. HCC occurring in the DEN/CCl4 model show both inter- 
and intra-animal tumor heterogeneity (Fig.22D,E, Fig.23B,C). There were areas of well-
differentiated HCC composed of larger hepatocytes containing glycogen (clear spaces) with 
normal-sized nuclei without notable pleomorphism and only few mitotic figures (Fig.22D,E: 
MP-CON A 3; MP-CON B 1. Fig.23B, C: MP-KO A 2; MP-KO B 2). However, both groups 
also showed areas of moderately-to-poorly differentiated HCC with features of high nuclear to 
cytoplasmic ratio, greater nuclear atypia and high mitotic index (Fig.22D,E: MP-CON A 1,2; 
MP-CON B 2. Fig.23B, C: MP-KO A 1,2;  MP-KO  B 1). Overall, there were indiscernible 
differences in HCC histology that could explain consistent differences in tumors between MP-
KO and MP-CON in Groups A and B. However, the data did suggest that Wnts from MP may 
act as tumor promoters or suppressors in a contextual manner. 
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Figure 22: MP-KO have increased tumors or decreased tumors compared to littermate MP-CON. 
 (A) Gross images of Group A, with MP-KO having increased tumor burden, and of Group B, 
with MP-KO having decreased tumor burden. (B) Liver weight to body weight ratios. MP-KO 
are significantly increased in Group A, and significantly decreased in Group B. (C) Serum 
alanine aminotransferase (ALT) and serum aspartate aminotransferase (AST) are comparable in 
Group A, but decreased in Group B MP-KO compared to MP-CON. (D) Representative 
hematoxylin and eosin staining of tumors of MP-CON in Group A and Group B. Each number 
corresponds to a different tumor. Images at 50x. (E) H&E images of tumors taken at 200x. Each 
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number corresponds to the same number in D. Statistical analyses performed with Student’s T 
Test. *P<0.05. 
 
 
Figure 23: MP-KO and MP-CON have insignificant differences in serum bilirubin or ALP, and MP-
KO display tumor heterogeneity similar to MP-CON. 
(A) Serum levels of total bilirubin, direct bilirubin, and alkaline phosphatase are similar in MP-
CON versus MP-KO in Group A and Group B. (B) Low magnification (50x) images of H&E 
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displaying different HCC subtypes. Each number corresponds to a dysplastic or tumor nodule. 
(C) High magnification (200x) images of tumors labeled in B. Statistics performed using 
Student’s T Test. *P<0.05, **P<0.01. 
4.4.2 Despite comparable fibrosis and cell death, MP-CON B has increased CD45-positivity 
while MP-CON A has increased nuclear PCNA positivity 
As eliminating Wnt secretion from MP had different effects on Group A versus Group B, 
we predicted controls in Group A would have phenotypically different tumors than controls in 
Group B. Therefore, we focused on controls first and assessed staining for various injury 
phenotypes. Sirius red staining was comparable in MP-CON A and MP-CON B, suggesting 
similar fibrosis (Fig.24A). Next, we stained for CD45, marker for immune cells, and noted 
increased levels in MP-CON B, approaching statistical significance (Fig.24A), possibly 
suggesting increased leukocyte infiltration in MP-CON B. Hepatocyte cell death assessed via 
TUNEL staining was comparable in MP-CON A and MP-CON B (Fig.24B). Intriguingly, 
despite heterogeneity in PCNA staining patterns, nuclear PCNA-positivity was quantified and 
significantly upregulated in MP-CON A compared to MP-CON B (Fig.24B). 
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Figure 24: MP-CON A and MP-CON B have comparable fibrosis and cell death, but MP-CON B has 
more CD45-positivity and MP-CON A has increased nuclear PCNA intensity. 
(A) Representative images of Sirius red and CD45 immunohistochemistry, taken at 50x. 
Quantification via ImageJ suggests similar Sirius red levels, and increased CD45 in MP-CON B. 
(B) 100x images of TUNEL and PCNA staining. Total number of TUNEL-positive cells were 
counted and numbers in MP-CON A and MP-CON B were comparable. For PCNA, nuclear 
intensity was measured and MP-CON A displayed increased levels. For all quantification, three 
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images per de-identified sample were taken and data presented as average. Statistics performed 
using Student’s T Test. *P<0.05, **P<0.01. 
4.4.3 Differential protein expression is observed in MP-CON A versus MP-CON B 
Next, we questioned whether differences in protein expression, likely leading to differential 
signaling, could be identified between Group A and Group B CON. We performed Reverse 
Phase Protein Array (RPPA), assessing over 240 proteins involved in cancer to identify relative 
protein expression levels. Select proteins with statistically significant differences, and other 
HCC-relevant proteins not included in the RPPA, were validated via western blot (Fig.25A,B). 
While some sample-to-sample variation was present, Group A MP-CON had increased androgen 
receptor and cleaved Caspase 3, and consistent upregulation of cMyc and P38 MAPK. Group B 
MP-CON had significant increase in glutamine synthetase, although active- and total-β-catenin 
levels were comparable in both groups, and an insignificant increase in cleaved Caspase 7. Taken 
together, contrast in protein expression including cMyc and P38 MAPK suggests HCC in Group 
A MP-CON and Group B MP-CON utilize differential molecular signaling. 
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Figure 25: MP-CON A and MP-CON B have differences in protein expression. 
(A) Western blot assessing proteins based on RPPA analysis and independent investigation. (B) 
Densitometric analysis suggests MP-CON A has increased androgen receptor (AR), cMyc, 
cleaved caspase 3, and P38 Mapk, while MP-CON B has increased glutamine synthetase (GS).  
Statistics performed using Student’s T Test. *P<0.05, **P<0.01, ***P<0.005. 
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4.4.4 MP-CON B have increased CD68 and CD11b single-positive MP and pro-
inflammatory cytokines, despite comparable MP numbers to MP-CON A 
Next, we assessed how the removal of MP Wnt secretion impacts MP phenotype, as several 
reports have suggested activated MP to secrete Wnts including during pathogenesis of chronic 
liver disease (107, 253). In a resting liver, majority of Kupffer cells are CD68+CD11b-, as 
CD11b+ monocytes typically enter the liver from circulation before differentiating into MP. 
While, various treatments can lead to increase in CD68+CD11b+ and/or CD68-CD11b+ 
macrophages (254), the significance of such alterations is incompletely understood. To elucidate 
MP phenotype in our models, we performed co-immunofluorescence of CD68 and CD11b 
(Fig.26A,B). We observed a large portion of double positive cells, although Group B MP-CON 
had more CD68-CD11b+, and CD68+CD11b- single positive cells than Group A CON, despite 
similar numbers of total positive cells. F4/80 immunofluorescence confirmed Group A MP-CON 
and Group B MP-CON have comparable numbers of macrophages (Fig.26C,D).  
 CD68-CD11b+ cells produce proinflammatory cytokines to a greater extent than 
CD68+CD11b- cells (254). Less is known about the CD68+CD11b+ fraction, as this only 
represents 6% of Kupffer cells at baseline (254). Considering proinflammatory cytokines lead to 
recruitment of leukocytes (255) we performed a protein-based cytokine array to further elucidate 
differences in the microenvironment in Group A and Group B CON. Of 40 cytokines, 29 were 
noticeably expressed in whole-liver lysates and four were expressed at least 1.5-fold higher in 
Group B MP-CON compared to Group A MP-CON (Fig.27A). These four, IL1α, IL1β, IL16, 
and CCL2, all suggest an increased M1 proinflammatory phenotype (256, 257) in Group B MP-
CON compared to Group A. Intriguingly, M2 markers IL4, IL13 (258), IL1Ra, and IL10 (259), 
were either unchanged or absent from both groups. Our data suggests that Group A MP-CON 
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have a different macrophage phenotype than Group B CON, and Group B MP-CON likely have 
increased M1 macrophages. Despite a more M1 phenotype of MP in Group B MP-CON when 
compared to Group A CON, there were insignificant differences in overall tumor burden 
between the two groups (Fig.23D). This suggests MP polarity to not be playing an exclusive role 
in contributing to the overall extent of HCC and other factors may also be instrumental. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 93 
 
Figure 26: Despite similar number of macrophages in both groups, MP-CON B has more CD68 and 
CD11b single-positive macrophages. 
(A) Double immunofluorescence of CD11b (red), CD68 (green), and Dapi (blue). Red arrows 
point to single-positive (CD11b or CD68) cells. (B) Quantification of total number of single 
positive (CD68-CD11b+ or CD68+CD11b-) or total number of all positive (single positive or 
double positive) cells. CD11b and CD68 were calculated by counting the number of single 
positive cells and dividing it by the number of total positive (double and single positive) cells. 
For each sample, seven images at 200x were taken and counted, and the average of seven images 
was used as a single data point. (C) F4/80 (green) immunofluorescence of MP-CON A and MP-
CON B. (D) Quantification of F4/80 intensity is comparable in MP-CON A and MP-CON B. 
Intensity was measured using ImageJ, and each data point is the average of seven images at 
100x. Statistics performed using Student’s T Test. *P<0.05, **P<0.01. 
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4.4.5 MP-CON A upregulates transcripts of several histone and chromatin modifying 
enzymes compared to MP-CON B 
We hypothesized the opposing phenotypes leading to differences in tumor burden between 
Group A versus Group B resulted from different upstream oncogenic events. While chemically-
induced oncogenic events are random, we predicted one underlying event was responsible for 
Group A and Group B. Chappell et al. assessed tumors from DEN/CCl4-treated mice and found 
no mutations in oncogenic hotspots including Ctnnb1, H-ras, and Hnf1α, all known to be 
mutated after chemical carcinogenesis (227). Further, they identified epigenetic changes after 
DEN/CCl4 including alterations in DNA and histone methylation, to play a role in tumorigenesis. 
Therefore, we asked whether Group A MP-CON and Group B MP-CON have different 
epigenetic signatures, and performed an mRNA-based array to assess expression of 84 different 
genes involved in chromatin or histone modification. Of 84 genes, 26 were >2-fold increased in 
Group A CON, and one was >2-fold increased in Group B MP-CON (Fig.27B). Moreover, 19/26 
genes increased in Group A MP-CON activate transcription (indicated in green), while 5/26 
repress transcription (indicated in red), and 2/26 are context-dependent (indicated in gray). A 
deeper analysis revealed that a majority of these activating marks included histone 
phosphorylation, DNA and histone methylation, and histone acetylation (Fig.27C). While future 
studies are required to confirm if these changes translate to altered epigenetic status, and to 
elucidate specific oncogenes that may be impacted, our data suggests that Group A MP-CON has 
increased transcript levels of several histone and chromatin modifiers compared to Group B 
CON. We predict these changes to lead to differing epigenomes resulting in disparate tumor 
burden in Group A versus Group B.  
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Figure 27: MP-CON B has increased levels of pro-inflammatory cytokines, while MP-CON A has 
increased transcript levels of several histone and chromatin modifying enzymes. 
(A) Protein-based cytokine array using whole-liver lysates identified IL1α, IL1β, IL16, and 
CCL2 to be at least 1.5-fold increased in MP-CON B versus MP-CON A. Values are normalized 
to housekeeping genes per the array instructions. (B) Of 84 DNA modification enzymes, 26 were 
upregulated via mRNA in MP-CON A, and one was upregulated in MP-CON B. Green genes are 
involved in modifications that activate transcription, red genes influence modifications that 
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repress transcription, and gray genes are context-dependent. Values were normalized to 
housekeeping genes per array instructions, and values are presented as relative fold change of 
MP-CON A over fold change of MP-CON B. (C) List of differentially regulated genes per 
function. 
4.4.6 Removing MP Wls further influences protein expression in Group A and Group B 
To determine how preventing MP Wnt secretion impacts Group A and Group B differently, we 
assessed whole-liver lysates for differences in protein expression. We began by validating 
proliferation markers, β-catenin target genes, and other cancer relevant markers (Fig.28A,C). In 
Group A, MP-KO had significantly more PCNA than CON, although Cyclin D1 was 
comparable. Further, MP-KO A expressed higher levels of GS and Cyp2e1, suggesting increased 
β-catenin activity. While P21 was trending upward, phosphorylated Rb was significantly 
upregulated in MP-KO A, while phosphorylated AKT and ERK were comparable to MP-CON 
A. Next, we assessed our RPPA data, and validated select proteins that appeared to be 
differentially expressed in Group A MP-CON versus MP-KO. Intriguingly, MP-KO A had 
greater 53BP1 and Bax, but lower cMyc expression than MP-CON A (Fig.28B,C). 
 In Group B, MP-CON and MP-KO had comparable PCNA and Cyclin D1, however MP-
KO B had increased GS and Cyp2e1, similar to the trend observed in Group A (Fig.28A,C). 
Moreover, Group B MP-KO had a significant reduction in P21, while phosphorylated Rb, AKT, 
and ERK were comparable. After analyzing our RPPA data, we validated cMyc and P38 MAPK. 
Although P38 MAPK levels were comparable, MP-KO B had significantly increased cMyc 
compared to controls (Fig.28B,C). Taken together, this data overall suggests that removing MP-
specific Wnts contributes to protein expression changes after DEN/CCl4 with divergent 
expression patterns in Group A and Group B. 
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Figure 28: MP-KO influences protein expression differently in Group A and Group B. 
 (A) Western blot assessing proteins involved in proliferation, β-catenin signaling, and 
oncogenesis. (B) Western blot assessing additional proteins deemed to have significant 
differences in MP-CON versus MP-KO via RPPA analysis. (C) Densitometric analysis of 
western blot from A reveals MP-KO A has increased PCNA, GS, Cyp2e1, phospho-
retinoblastoma protein (pRb), 53BP1, and Bax, and decreased cMyc compared to MP-CON A. 
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Further, MP-KO B has increased GS, Cyp2e1, cMyc, and decreased p21 compared to MP-CON 
B. Statistics performed using Student’s T Test. *P<0.05, **P<0.01, #P<0.005, ##P<0.001. 
4.4.7 Removing MP Wls does not majorly impact fibrosis, leukocyte or MP count, or cell 
death, but does influence PCNA positivity and MP polarization 
We queried whether removal of MP Wls impacts fibrosis, leukocyte count, or cell death 
and proliferation. Sirius red staining and TUNEL staining were comparable in all groups 
(Fig.29A, Fig.30A,B). While no statistically significant differences in CD45-positivity were 
observed, MP-KO B trended lower compared to MP-CON B, and MP-KO A had a larger spread 
than MP-CON A. Interestingly, MP-KO A had reduced PCNA compared to MP-CON A, while 
MP-CON B and MP-KO B were comparable.   
Lastly, we assessed how removing MP Wnts influences the immunological landscape 
after DEN/CCl4. We began by assessing CD68 and CD11b co-immunofluorescence, and F4/80 
fluorescence. Total number of CD68 and/or CD11b positive cells were comparable between MP-
CON and MP-KO from Group A and Group B, and relative F4/80 signal intensity was also 
comparable (Fig.29B, Fig.30C), suggesting overall similar number of macrophages. In Group A, 
we noted a large spread in MP-KO when assessing number of CD68+CD11b- or CD68-CD11b+ 
single positive cells. Intriguingly, Group B MP-KO had fewer single positive cells than Group B 
MP-CON (Fig.29B, Fig.30C). We predicted preventing MP-Wnt secretion from both groups 
therefore partially impacted MP phenotype, so we performed the cytokine array to compare MP-
CON and MP-KO. In Group A, M1 markers IL16 and CCL2 were increased in MP-KO at least 
1.5-fold, and M1 marker and chemokine CXCL9 (260) was reduced in MP-KO by 1.9-fold 
(Fig.29C). In Group B, MP-KO had reduced expression of several markers, with 1.57-2.15-fold 
reduction in IL1α, IL1β, IL16, IL17, IL27, and MIP2, compared to MP-CON (Fig.29C). This 
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data suggests MP from Group B MP-KO have reduced activation compared to CON. This 
suggests that differences in MP polarization between the Group A MP-KO and MP-CON as well 
as Group B MP-KO and MP-CON may be contributing to overall differences in the HCC burden, 
although further studies will be required.  
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Figure 29: Removing macrophage-Wntless influences PCNA-positivity and immunological milieu. 
 (A) Quantification from immunohistochemistry of Sirius red, CD45, TUNEL, and PCNA from 
Figure 31. MP-KO A has significantly less PCNA intensity than MP-CON A, while no other 
changes were statistically significant. (B) Quantification of immunofluorescent staining reveals 
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comparable number of CD68 and/or CD11b-positive cells and F4/80 intensity, suggesting 
comparable macrophage levels between all groups. MP-KO A had variable levels of CD68 or 
CD11b single positive cells, while MP-KO B had decreased single-positive cells compared to 
MP-CON B, although this was insignificant via one-way ANOVA. (C) Results from cytokine 
array. In Group A, MP-KO A had increased IL16, CCL2, and decreased CXCL9 at least 1.5-
fold. In Group B, MP-KO B had decreased IL1α, IL1β, IL16, IL17, IL27, and MIP2 at least 1.5-
fold compared to MP-CON B. Statistics performed using one-way ANOVA. *P<0.05, **P<0.01.  
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Figure 30: Immunohistochemical and immunofluorescent images of MP-CON and MP-KO from 
Group A and Group B as quantified in Figure 29. 
 (A) Images of Sirius red and CD45 staining of MP-CON and MP-KO from both groups, 50x. (B) 
Images from all groups of TUNEL and PCNA, taken at 100x. (C) 200x IF images of CD11b 
(red) and CD68 (green) co-stain (left), and of 100x images of F4/80 (green, right) stain.  
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4.5 DISCUSSION 
Previously we have shown that loss of Wnt secretion from hepatocytes has overall minor 
impact on hepatic injury progression and carcinogenesis (185). We verified that DEN/CCl4 
model of hepatic injury, fibrosis, and cancer led to HCC harboring wildtype-β-catenin, but 
showed overexpression of several Wnts in whole liver lysates. Knowing that multiple cell types 
within a liver express Wnts (11), and showing Wnts from hepatocytes are dispensable for 
tumorigenesis, we next queried MP for their role in Wnt secretion in this model of hepatic 
injury-driven HCC. Using MP-specific Wntless knockout mice, unable to secrete Wnts from all 
myeloid cells, at 5 months of age after DEN/CCl4 we observed two striking and opposing 
phenotypes that were litter-specific. In two separate litters (n=4), MP-KO had significantly more 
tumor burden than CON, termed Group A. In additional two litters (n=5), MP-KO had 
significantly reduced tumor burden, termed Group B. We therefore hypothesized Group A and 
Group B have different HCC subtypes, and may lead to phenotypically distinct tumors. 
 Focusing on MP-CON from Group A and Group B, our RPPA and independent analyses 
identified differences in protein expression. MP-CON A had significantly more androgen 
receptor, cleaved caspase 3, P38 MAPK, and cMyc than MP-CON B. Intriguingly, P38 MAPK 
can activate caspase 3 in hepatoma cell lines in vitro (261). However, caspase 3 activation does 
not always correlate with apoptosis in HCC (262), which is likely the case as our TUNEL 
staining was comparable in MP-CON A and MP-CON B, suggesting caspase 3 is playing non-
apoptosis related roles or tumors are evading apoptosis through adaptive mechanisms. P38 
MAPK can also activate androgen receptor, which in turn can activate cMyc in other systems 
including prostate cancer (263, 264). These relationships may suggest overexpression of P38 
MAPK is a central oncogenic event occurring in Group A that does not occur to the same extent 
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in Group B, although further studies are required to validate this significance. Remarkably, MP-
CON B had significantly more glutamine synthetase than MP-CON A, despite no increase in 
activated or total β-catenin levels. Several factors contribute to GS levels in HCC, including 
driver oncogenes, immunologic background and source of glutamine (265). Mitochondrial 
enzyme glutaminase can synthesize glutamine, and studies have identified roles for Myc in 
regulating expression of both GS and glutaminase. Intriguingly, one study suggests Myc-driven 
tumors suppress GS and upregulate glutaminase, which may explain increased Myc and lower 
GS levels found in MP-CON A (265). Our IHC analysis revealed increased PCNA in MP-CON 
A compared to all groups including MP-KO A and MP-CON B. However, western blot 
identified increased PCNA in MP-KO A compared to MP-CON A. We predict this discrepancy 
is because western blotting considers all nuclear and cytoplasmic PCNA, whereas our intensity 
threshold for IHC quantification was designed to only measure nuclear staining. Further, PCNA 
contributes to processes beyond proliferation, including DNA repair and apoptosis (266), 
suggesting the presence of significantly more PCNA in MP-CON A should be investigated 
further. 
 We also identified differences in MP phenotype and the resulting inflammation. While 
total numbers of MP were similar, MP-CON B had more CD68+CD11b- and CD68-CD11b+ 
single positive cells, compared to MP-CON A which had more double-positive cells. CD68+ 
MP, the resident Kupffer cells, are capable of optimal phagocytosis and are a known source of 
reactive oxygen species. CD11b+ MP are considered to be bone marrow-derived at baseline and 
known to produce cytokines. However, little is known about the CD68+CD11b+ population, 
which increases in frequency after hepatic injury and macrophage activation, likely resulting 
from CD11b+ infiltrating cells acquiring CD68-positivity (254). Both CD68 and CD11b can 
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exhibit M1 polarization based on expression of various markers (267, 268). Likewise, MP could 
exhibit both M1 and M2 polarization in injury states, such as after thioacetamide-induced 
cirrhosis (268). We identified MP in MP-CON B to exhibit a more M1-like phenotype compared 
to MP-CON A as supported by upregulation of inflammatory cytokines IL1α, IL1β, IL16, and 
CCL2 in MP-CON B. IL1α and IL1β are produced by activated MP, while various cell types 
including tumor cells produce CCL2 to attract T cells and monocytes capable of differentiating 
into tumor-associated MP. IL16 is produced by lymphocytes to activate monocytes to secrete 
proinflammatory cytokines, and is often implicated in cancer (269-274). Taken together, with the 
increase in CD45-positive leukocytes observed in MP-CON B compared to MP-CON A, it 
appears the inflammatory milieu between Groups A and B differ, with more M1 MP and 
leukocytes found in MP-CON B. As tumor-associated MP are typically M2, and M1 polarization 
suggests better prognosis in HCC patients (274), MP-CON B may have better survival in long-
term studies compared to MP-CON A. We recognize, however, that several pro-inflammatory 
cytokines were unchanged per the array, which is likely attributed to the use of whole-liver 
lysates and MP polarization existing as a spectrum more so than a dichotomy (275).  
 We therefore propose that Group A HCC relies on upregulation of oncogenic signaling, 
including P38 MAPK and cMyc pathways, suggested by increases in protein expression. 
Removing MP Wls causes increased tumor burden likely because further pathways are 
upregulated, evident through increased expression in MP-KO A of GS, Cyp2e1, phosphorylated 
Rb, 53BP1, and Bax. Moreover, we propose Group B HCC is dependent on the pro-
inflammatory and pro-tumorigenic microenvironment. M1 MP produce reactive oxygen species, 
which can lead to DNA damage and oncogenesis (254, 274). MP-KO B has fewer tumors 
because of fewer activated macrophages and recruited leukocytes, likely less oxidative damage, 
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and reduction in several cytokines compared to MP-CON B. The question remains, what leads to 
such dichotomy between the two groups? Although each animal displayed predictable 
heterogeneity in protein expression and overall phenotype, we predicted one single event may be 
common to Group A, and one to Group B. Chappell et al. sequenced tumors after DEN/CCl4 for 
common oncogenic mutations, and were unable to find any. Instead, they observed several 
epigenetic events, including genomic DNA demethylation and a decrease in the repressive mark 
histone 3 lysine 9 trimethylation (227). Therefore, we posited Group A has a different epigenetic 
signature from Group B, and our mRNA data suggests this is an appropriate future direction to 
pursue. Group A upregulated transcripts of several chromatin and histone modifying enzymes, 
including those involved in histone phosphorylation, methylation, acetylation, and DNA 
methylation. In fact, Ribosomal Protein S6 Kinase A5 and A3, both transcriptionally upregulated 
in MP-CON A, can activate P38 MAPK during stress (276). Our overall hypothesis is illustrated 
in Figure 31.  
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Figure 31: Overall hypothesis and summary of bimodal phenotype of MP-CON and MP-KO after 
DEN/CCl4. 
We predict two different oncogenic events, likely epigenetic modifications, occur after 
DEN/CCl4 to lead to Group A and Group B. In MP-CON A, we observed increased protein 
expression of several notable oncogenes compared to MP-CON B including cMyc, suggesting 
alterations in signaling, leading to HCC A. When macrophages cannot secrete Wnts, this 
promotes tumor growth further. In MP-CON B, we observed increased M1 macrophages and 
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CD45-positive leukocytes, potentially suggesting a tumor-promotive inflammatory milieu, 
leading to HCC B. When macrophages are unable to secrete Wnts, this acts as tumor 
suppressive. Identifying the epigenetic events responsible for Group A versus Group B, and 
identifying the mechanism by which macrophage Wnts contribute to HCC differentially, will be 
of interest for future studies.  
 
Because the entire MP-KO in a litter conformed to the same phenotype of either less or 
more tumors than their MP-CON littermates, we speculate the divergent epigenetic status results 
from differences in breeding pairs. The role of DNA modifications in the Cre-recombinase 
system is unclear, and the epigenome of pups from a mother with Cre and father with a floxed 
gene may differ from the reverse breeding scenario. Indeed, many foreign DNA sequences 
inserted into mice become heavily methylated dependent on the breeder strain(277). While the 
animals used in this study are primarily C57BL/6, the floxed Wntless animals were originally in 
a 129 background. It is possible different litters retain a different fraction of 129 to C57BL/6, 
explaining why our phenotype is litter-specific. Recent studies have even identified different 
responses to a single CCl4 dose in C57/BL6 N versus J mice (278). Furthermore, the liver is a 
notoriously sexual dimorphic organ. Addition of foreign DNA, as in a transgenic animal, may 
alter epigenetic statuses of surrounding genes to different extents in males and females (279). 
Therefore, if the mother carried the Cre Recombinase and the father carried the floxed Wntless, 
the epigenome of resulting pups may differ from breeders of the reverse genotype. Hence, it may 
be advantageous for investigators using DEN/CCl4 method of hepatocarcinogenesis on 
genetically manipulated animals to be mindful of the breeders. In addition to the novel 
observation that DEN/CCl4 can produce phenotypically distinct HCC subsets, we provide 
evidence that macrophage-specific Wnts can be tumor promoting or tumor suppressing, likely 
depending on the signaling and immunological milieu of the cancer.  
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5.0  ENDOTHELIAL WNTS REGULATE Β-CATENIN SIGNALING IN MURINE LIVER 
ZONATION AND REGENERATION 
In section 5 we focus on the cellular source, identity, and initiating factors of Wnts required for 
liver regeneration after partial hepatectomy. This work is an extension of previously published 
data from our lab (40, 89), described below. Our work focusing on endothelial cells was 
modified for this dissertation from a manuscript recently accepted in Hepatology 
Communications, and our work focusing on hepatic stellate cells is still ongoing, but 
incorporates baseline characterization data from a previous post-doc, Dr. Rong Zhang. Lastly, 
data assessing endothelial cell separation and mRNA expression of Wnts after partial 
hepatectomy, described in section 5.4.6, was previously reported in Dr. Jing Yang’s thesis (280) 
and is currently part of our Hepatology Communications manuscript. As Hepatology 
Communications is an open access journal, as first-author, written permission for re-use in this 
dissertation was not required. 
5.1 ABSTRACT 
We have previously shown that hepatocyte-specific β-catenin regulates liver regeneration (LR) 
after partial hepatectomy (PH), and hepatic zonation at baseline, both under the control of 
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canonical Wnt signaling. This is true at early timepoints up to 40–72 hours. Using cell-specific 
Wntless (Wls) knockout mouse models, which lack Wls and prevent Wnt secretion, we have 
previously determined epithelial cells are not the source of these Wnts. However, macrophage-
specific Wls knockouts (MP-KO) have a marginal regeneration defect at 40 hours and displayed 
normal hepatic zonation. Removing Wls from all endothelial cells was embryonic lethal, 
therefore in this study we generated a liver-specific endothelial cell knockout model (EC-KO) 
and a hepatic stellate cell-specific knockout model (HSC-KO). Intriguingly, EC-KO demonstrate 
a marked reduction in hepatic zonation at baseline, and were protected from acetaminophen-
induced liver toxicity. After PH, EC-KO display less proliferation than littermate controls until 
72 hours, overall emphasizing the role of endothelial cell-specific Wnts in liver regeneration. We 
also noted no difference in zonation or regeneration in HSC-KO, and confirmed MP-KO do not 
secrete Wnts prior to 40 hours after PH, suggesting they are not the primary contributor of Wnts. 
We also questioned which Wnts are responsible for β-catenin activation, and identified Wnt2 and 
Wnt9b to be highly upregulated in endothelial cells after PH. Finally, we tested whether shear 
stress, evident immediately after PH due to increased portal pressure, can initiate Wnt production 
in vitro. We noted an increase in Wnt2 and Wnt9b mRNA in two separate endothelial cell types 
including primary liver endothelial cells. Our data suggests endothelial cells secrete Wnt2 and 
Wnt9b, initiated in part by shear stress early after PH, to temporally regulate hepatocyte-specific 
β-catenin activation and liver regeneration. 
 111 
5.2 BACKGROUND 
5.2.1 Introduction to liver zonation 
The liver is composed of thousands of liver lobules, consisting of a central vein (CV) surrounded 
by six portal triads in a hexagonal shape. The portal triad, made of the hepatic artery (HA), portal 
vein (PV), and bile duct, bring oxygenated blood (via PV) and deoxygenated blood (via HA) into 
the liver (281). Blood travels through hepatic sinusoids and exits through the CV (Fig.32A, B).  
Hepatocytes have heterogeneous functions and protein expression based on their location 
along the liver lobule, being defined as periportal (PP) near PV, midzonal (MZ), or pericentral 
(PC) near CV. Unsurprisingly, this is regulated in part by the oxygen gradient. For example, 
expression of hypoxia-inducible transcription factors are present in hepatocytes in the PC zone, 
where oxygen tension is low (282). Further, gluconeogenesis and urea synthesis are two 
processes requiring oxygen, and occur in the PP area where oxygenated blood is present (283). 
In addition to the oxygen gradient, morphogen gradients including Wnt, hedgehog, and HGF also 
result in differential hepatocyte signaling along the lobule (281). It is believed this 
compartmentalization, termed “zonation”, results from the liver’s requirement to perform often 
opposing functions simultaneously (284) (Fig.32B). 
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Figure 32: The liver is composed of zonated lobules. 
(A) The liver has thousands of lobules, consisting of one central vein surrounded by six portal 
veins, hepatic arteries, and bile ducts, known as the portal triad. The central vein is connected to 
the portal vein and hepatic artery through liver sinusoids. Blood flows from the portal vein and 
hepatic artery to the central vein. Bile flows into the bile duct from the bile canaliculi. (B) 
Schematic highlighting different zones of the liver. Hepatocytes near the portal vein are exposed 
to oxygen and perform functions including gluconeogenesis and urea synthesis, whereas 
hepatocytes near the central vein are not exposed to oxygen and perform functions including 
glycolysis and xenobiotic metabolism. The midzone consists of intermediate hepatocytes. LS, 
liver sinusoid; CV, central vein; HA, hepatic artery; PV, portal vein; BD, bile duct; BC, bile 
canaliculi; HP, hepatocyte. 
5.2.1.1 β-Catenin and liver zonation 
β-Catenin is considered a master regulator of zonation. Although β-catenin is expressed 
throughout the liver at hepatocyte membranes, signal transduction predominantly occurs in the 
PC area and regulates PC-centric gene activity (205, 285). Target genes include PC markers 
involved in glutamine metabolism (GS, ornithine aminotransferase, glutamate transporter-1), 
xenobiotic metabolism (Cytochrome P450 Cyp2e1 and Cyp1a2), and others discussed in Table 1. 
APC negatively regulates β-catenin expression and is localized in the PP region (281). 
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Using liver-specific β-catenin knockout animals (bKO), we and others have shown loss 
of β-catenin in hepatocytes leads to loss of zonation (89, 163). Moreover, we have shown liver-
specific Lrp5/6 knockout mice (5/6KO), which lack the Wnt co-receptor and prevent Wnt 
signaling while leaving β-catenin intact, phenocopy bKO (40). Similarly, mice deficient in the 
Wnt agonist Rspo3, lack hepatic zonation that is rescued by expression of Rspo1 (286). This 
suggests hepatic zonation is under the control of Wnt-dependent β-catenin activation. In an 
attempt to characterize the cellular source of Wnts, we generated a HP/BEC-specific Wntless 
knockout mouse (HP-KO) and a macrophage (MP)-specific Wntless knockout mouse (MP-KO), 
preventing Wnt secretion from either cell type, and noted no defects in hepatic zonation (40). 
Recent reports identify endothelial cells as the major Wnt-producing cells required for hepatic 
zonation and identified Wnt2 and Wnt9b to be highly expressed in these cells (20, 287). 
5.2.2 Introduction to liver regeneration 
There are over 500 million people worldwide suffering from liver disease (288). Mortality rates 
vary, with 7.3 in 100,000 patients in the US and 57.3 in 100,000 patients in Middle Eastern 
countries (289), making this a global concern. For many liver diseases, transplants or surgical 
resections are the only effective treatment (290, 291). A shortage of donor organs, poor 
regenerative capability, and high probability of recurrence makes these unlikely options for most 
patients, demonstrating the need for promising alternatives. The liver is unique in its capacity to 
regenerate after substantial loss, as evident through partial hepatectomy (PH) studies. In rodents, 
specific lobes are removed during PH which account for two-thirds of the liver, and the intact 
lobes grow to the full liver mass prior to surgery. Similar results are seen after surgical resection 
in larger mammals including humans (292), although the mouse is an appropriate model to study 
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regeneration kinetics as it is well characterized that peak proliferation occurs around 40 hours 
post-PH (293). Uncovering the mechanisms that initiate and propagate liver regeneration is an 
important step in developing alternatives to liver transplants, as the detailed mechanisms that 
coordinate hepatocyte repopulation are not well understood. In fact, impaired regeneration is the 
major cause of liver failure and liver-related death (294). 
Several primary and auxiliary mitogens have been identified to play significant roles 
during LR post-PH. Growth factors including hepatocyte growth factor (HGF), interleukin 6 
(IL6), and others are produced by nonparenchymal cells to induce HP proliferation early after 
PH. Noncoding RNAs, platelets, hypoxia, microbiome, immune cells, and other factors 
contribute to complete LR (295). Strikingly, the removal of one component may delay LR, 
however the liver employs compensatory mechanisms to complete regeneration, highlighting the 
redundancy available in maintaining hepatic homeostasis. In fact, the only known report of a 
complete lack of regeneration and subsequent animal death post-PH involves the concomitant 
inhibition of the HGF receptor Met and epidermal growth factor receptor (EGFR), while 
inhibiting Met or EGFR alone was not sufficient to prevent LR (296). 
5.2.2.1 Wnt/β-catenin in liver regeneration  
The importance of Wnt/β-catenin signaling in liver regeneration (LR) is undisputed (295). In 
2001, Monga et. al demonstrated β-catenin is increased 5 minutes after partial hepatectomy (PH) 
in rats, resulting from a decrease in β-catenin degradation (297). A follow up study treated rats 
with β-catenin targeted antisense morpholinos, resulting in impaired proliferation after PH at 24 
hours and 7 days, and liver weight/body weight ratios (LW/BW) were lower than controls at both 
timepoints (298). Additionally, bKO exhibit significantly decreased LW/BW as early as 15 days 
after birth, and the same trend is observed throughout the lifespan. After PH, proliferation in 
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bKO was compromised and Cyclin D1 levels were decreased at 40 hours, although LR 
rebounded after three days (89). Moreover, liver-specific transgenic mice (bTG) were generated 
with mutated β-catenin (serine 45 mutated to aspartic acid) under an Albumin promoter, which 
prevents β-catenin degradation. These mice had higher liver LW/BW than controls at 15 days 
and one month, but differences were absent at two months. After PH, bTG exhibited increases in 
mitotic cell count, PCNA-positivity, and Cyclin D1 expression at 40 hours, although control 
mice were eventually comparable (299), suggesting increased β-catenin activation creates a 
regeneration advantage at early timepoints. Furthermore, bTG mice led to the identification of 
Epidermal Growth Factor Receptor (EGFR) as a novel β-catenin target gene. EGFR is required 
for optimal liver regeneration after partial hepatectomy, as EGFR inhibition leads to increased 
mortality and delayed hepatocyte proliferation (31, 300). 
More recently, we confirmed the importance of Wnt-dependent β-catenin signaling. 
5/6KO, lacking the Wnt receptors LRP5/6, phenocopied bKO; LW/BW were decreased at 
baseline, and LR was impaired at 40 and 72 hours after PH (40). Taken together, these data 
suggest Wnt/β-catenin plays a pivotal role in LR during the first 40-72 hours.  
Our lab has also published that these Wnts do not originate from hepatocytes (HP) or 
biliary epithelial cells (BEC). Subjecting HP-KO to PH had no effect on LR, suggesting liver 
epithelial cells are not the source of Wnts. Next we performed PH on MP-KO and noted a 
marginal decrease in regeneration at 40 hours, to a lesser magnitude than bKO or 5/6KO (40), 
suggesting MP are a source of Wnts during LR, but likely not the primary source.  
Any additional Wnt sources, identities, and initiation mechanisms during LR are not fully 
understood. One report used in vitro Wnt2 knockout and rescue experiments to determine Wnt2 
is secreted by liver sinusoidal endothelial cells (LSECs) and acts in an autocrine manner to 
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stimulate LSEC proliferation and angiogenesis (301). Another group added LSECs transfected 
with Wnt2 and HGF into a mouse that had LSECs deficient for Wnt2 and HGF, and liver mass 
was restored after PH compared to mice that did not receive the transfected LSECs, suggesting 
LSECs secrete Wnt2 and HGF which together contribute to hepatocyte proliferation in a 
paracrine manner (19), although the role of Wnt2 alone was not assessed. The lack of consensus 
of the function of Wnt2, and the little known about other Wnts, suggests more needs to be done 
to fully understand the role of Wnt in LR (Fig.33).  
 
Figure 33: Schema of current understanding of Wnt/β-catenin kinetics after PH. 
5.2.2.2 Shear stress and liver regeneration 
Shear stress (SS) is the force acting on endothelial cells (ECs) as a result of blood flow across the 
endothelium, and variations in SS cause ECs to exhibit a range of responses (302, 303). Two 
types of SS are laminar and orbital. Laminar SS is characterized by unidirectional flow, whereas 
orbital SS is characterized by random speed and directional variations (304). The effect of SS on 
ECs has been studied for over 30 years. Early studies used novel shear loading devices to 
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produce fluid SS on cultured ECs (305-307), and noted increased migration, proliferation (307), 
and increased production of several mitogenic and vasculogenic mRNAs (305, 308), 
demonstrating that ECs may be activated in response to SS.  
It is also known that hepatic portal venous pressure increases immediately after PH (309), 
causing portal hypertension due to blood flow becoming constricted to one third of the original 
liver. This predictably causes SS in the liver sinusoids, and several models suggest SS induces 
LR after PH. For example, when rats underwent a portal vein branch ligation (PVL) where the 
left portal venous branch that supplies two thirds of the liver is ligated, portal hypertension is 
increased similarly to what is seen after PH. PH and PVL samples both had increased hepatocyte 
proliferation compared to sham, and were comparable to each other (308, 310). These data 
suggest SS may initiate or otherwise contribute to the early stages of LR. 
A recent study queried liver progenitor cells (LPCs), as it is posited LPCs differentiate 
into HP when HP proliferation is blocked, such as in the PH/2-N-acetylaminoflourene (2-AAF) 
model. Hypothesizing LPCs may be influenced by SS after PH/2-AAF, Nishii et al. established 
in vitro 3-dimensional LPC cultures and subjected them to SS comparable to physiological levels 
observed after PH. Intriguingly, after SS, LPCs increased transcript levels of Wnt1 and several 
immediate early genes upregulated during LR including cFos (311). While this is not applicable 
to the PH model as LPCs do not contribute to HP proliferation, this is the only known study 
suggesting a link between Wnt expression and SS. We sought to identify a further link, and 
hypothesized SS may induce Wnt secretion from nonparenchymal cells after PH. 
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5.3 METHODS 
5.3.1 Mice and breeding 
All animal husbandry and experimental procedures, including animal housing and diet were 
performed under the guidelines and approval of the National Institutes of Health and the 
Institutional Animal Care and Use Committee at the University of Pittsburgh. Mice were fed 
regular chow in standard caging and kept under 12 hour light-dark cycle with no enrichment. 
Lyve1-cre mice were purchased from Jackson Laboratories (312) and bred with Wntless 
(Wls)flox/flox mice (40, 240). Lyve1-cre+/-;Wlsflox/flox are referred hereon as EC-KO. Mice with 
Lyve1-cre-/-;Wlsflox/flox or Lyve1-cre+/-;Wls-/- genotypes were used as littermate controls (EC-
CON). Lyve1-cre mice were also bred to ROSA26-Stopflox/flox-EYFP mice to label cells 
effectively targeted by Lyve1-cre (313). To generate hepatic stellate cell-specific Wntless 
knockout mice (referred to as HSC-KO), Wlsflox/flox mice were bred with Lecithin retinol 
acyltransferase (Lrat)-Cre mice provided by Dr. Robert Schwabe (314). Mice with Lrat-cre-/-
;Wlsflox/flox or Lrat-cre+/-;Wls-/- genotypes were used as littermate controls (HSC-CON). MP-CON 
and MP-KO were generated as described elsewhere (40) and in section 4.3.1. 
5.3.2 Partial hepatectomy, liver perfusion, endothelial cell separation 
Two-month old male and female EC-KO and EC-CON were subjected to PH as 
described elsewhere (315). At 0 (n=2 male, n=3 female), 24h (n=2 male, n=2 female), 40h (n=3 
male, n=2 female), or 72h (n=3 male, n=2 female), mice were euthanized via isoflurane 
inhalation and cervical dislocation. HSC-CON and HSC-KO (n=6-7 for 0h, n=2 for 24h, 40h, 
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and 72h) and MP-CON and MP-KO (n=2 for 6h, n=4-5 for 24h and 40h) were subjected to PH 
similarly. Livers were harvested and lobes were flash frozen or paraffin embedded for further 
analysis.  
For liver perfusion prior to cell separation, two-month old C57BL/6 male mice were 
anesthetized with Nembutal and an incision was made to open the peritoneum. A 24-gauge 
catheter was inserted into the inferior vena cava and another in the portal vein. The inferior vena 
cava below the heart was clamped. Through the portal vein catheter, the liver was washed with 
100 ml calcium (-) magnesium (-) HBSS with 50mM HEPES (Gibco) and 25mM EGTA at 2-
3ml/min. Next the liver was digested with 0.3 mg/g collagenase type IV (Sigma) and 50mM 
HEPES in HBSS with calcium. Upon digestion, liver was removed and dispersed in 30ml HBSS. 
Dispersed cells were filtered by mesh (100μm) and centrifuged at 50g for 5min twice to isolate 
hepatocytes. Then supernatant is spun down at 1500 rpm for 10min to get non-parenchymal cells 
(NPCs). 
For cell separation studies, 2-month old male C57BL/6 mice (Jackson Laboratories) 
(n=2) were used for two-step liver perfusion, 12h after PH and parenchymal and non-
parenchymal cell fractions were separated. Magnetic bead separation was used to isolate EC and 
macrophages. Cell from 2 livers were pooled together for analysis. NPC fraction was incubated 
with anti-mouse biotin-F4/80 antibody (Biolegend) at 1:10 for 30 min on ice. Cells were washed 
and incubated with streptavidin-microbeads (Miltenyi Biotech) at 1:10 for 20 min on ice. 
Samples were passed through LS columns (Miltenyi Biotech) to obtain F4/80-positive cells. 
F4/80-negative fraction was processed further and incubated with anti-mouse biotin-CD31 
antibody (Biolegend) at 1:20 for 30 min on ice. They were washed once and incubated with 
streptavidin-microbeads at 1:20 for 20 min on ice. Then LD-columns (Miltenyi Biotech) were 
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used to obtain CD31-positive cells (ECs). CD31-positive fractions were then processed for RNA 
analysis. 
5.3.3 Acetaminophen toxicity studies 
Ten-week old EC-CON (n=3) and EC-KO (n=5), all males were fasted overnight and injected 
intraperitoneally with 450mg/kg acetaminophen in 0.9% saline. Animals were sacrificed 24h 
post-injection as described above. Blood was drawn through the inferior vena cava and serum 
submitted to the University of Pittsburgh Medical Center Clinical Chemistry laboratory, which is 
part of Pittsburgh Liver Research Center, for alanine aminotransferases (ALT) and aspartate 
aminotransferase (AST) testing. 
5.3.4 Immunofluorescence 
Liver sections were fixed in 2% PFA for 2 hours, then 30% sucrose in PBS overnight. For 
immunofluorescence (IF), sections were frozen in OCT compound and cut in 5μm sections. 
Samples were permeabilized with 0.1% Triton and blocked in 2% serum in PBST. Primary 
antibodies (information in Table 10) were incubated overnight. Secondary antibodies conjugated 
to Alexa Fluor 555 or 488 (Life Technologies) were incubated at 1:400 in PBST for 3 hours prior 
to Dapi. Confocal images were taken on a Nikon A1 Spectral Confocal Microscope located at the 
Center for Biological Imaging at the University of Pittsburgh. Epifluorescent images were taken 
on a Nikon Eclipse Ti microscope using NIS Elements software. 
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5.3.5 Protein isolation, western blot, immunoprecipitation 
Whole-cell protein lysate preparation was performed using RIPA buffer (40) and 30μg of protein 
was used for gel electrophoresis for Western blots (WB). Immunoprecipitation (IP) was 
performed using 750μg of pre-cleared protein and A/G agarose beads as described elsewhere 
(316). For a complete list of antibodies used see Table 10. Secondary antibodies conjugated to 
horse radish peroxidase were used at 1 to 10,000. 
Table 10:  List of antibodies used in section 5.0 
Name Company Catalog Number Use 
GFP Abcam Ab13970 IF: 1 to 200 
Lyve1 Abcam Ab14917 IF: 1 to 100 
EpCam DSHB  G8.8 IF: 1 to 10 (15µg/ml) 
GS Sigma G2781 IF: 1 to 500 
GS Santa Cruz SC-9067 IHC: 1 to 50 
WB: 1 to 1000 
Cyp2e1 Sigma Aldrich HPA009128 IHC: 1 to 500 
WB: 1 to 500 
Cyp1a2 Santa Cruz SC-53241 IHC: 1 to 50* 
WB: 1 to 200 
Active β-Catenin Cell Signaling 4270s WB: 1 to 750 
β-Catenin BD Biosciences 610154 WB: 1 to 1000 
Actin Millipore MAB1501 WB: 1 to 1000 
Gapdh Proteintech 60004-1-Ig WB: 1 to 10,000 
Cyclin D1 Neomarkers RB-9041-P IHC: 1 to 200 
WB: 1 to 200 
PCNA Santa Cruz SC-56 IHC: 1 to 50* 
WB: 1 to 200 
TCF4 Cell Signaling 2569s IP: 1 to 50 
TCF4 Sigma Aldrich T5817 WB: 1 to 750 
CD31 Abcam Ab28364 IF: 1 to 50 
*Use Mouse On Mouse kit (Vector Laboratories) 
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5.3.6 RNA isolation and qRT-PCR analysis 
RNA was obtained using RNeasy Mini Kit (Qiagen) and 1-2μg was reverse transcribed using 
Superscript III (Invitrogen). Real-time qPCR was performed using SYBR Green on an ABI 
Prism 7300 sequence Detection System (Applied Biosystems) and values were normalized to 
GAPDH. For a list of primer sequences, see Table 11. 
Table 11:  List and sequence of all primers used for qRT-PCR in section 5.0. 
Primer 
(Mouse) 
Forward Sequence Reverse Sequence 
Wnt2 TCTGTCTATCTTGGGCATTCTG TTCCTTCGCTATGTGATGTTTC 
Wnt9b GGGTGTGTGTGGTGACAATCT GGTCCTTGCTTCCTCTCTTG 
Gapdh AACTTTGGCATTGTGGAAGG ACACATTGGGGGTAGGAACA 
Wnt2b ACCTTCCTCTACCCTCAATCCT TCACTCAGCCTCCTAAATCCAT 
Wnt3 GTCTGCTAATGCTGGCTTGAC TAGGAAGGGATGGGAGGTGT 
Wnt4 AGAACTGGAGAAGTGTGGCTGT AAAGGACTGTGAGAAGGCTACG 
Wnt5a GTCCTTTGAGATGGGTGGTATC ACCTCTGGGTTAGGGAGTGTCT 
Wnt5b TGTCAGTTGTATCAGGAGCACA GTGAAGGCAGTCTCTCGGCTA 
Wnt9a ATGGTGTGTCTGGCTCCTG CAGTGGCTTCATTGGTAGTGCT 
Wnt10a TCCTGTTCTTCCTACTGCTGCT ACGCACACACACCTCCATC 
Wnt10b CCACTACAGCCCAGAACCTC GGAGAGACCCTTTCAACAACTG 
Wnt11 CCCTGGAAACGAAGTGTAAATG AGGTAGCGGGTCTTGAGGTC 
Wnt16 GCTGTAACCTCCTCTGCTGTG GTGGACATCGGTCATACTTTCA 
Cyclin D1 TTTCTTTCCAGAGTCATCAAGTGT TGACTCCAGAAGGGCTTCAA 
5.3.7 Histology and immunohistochemistry 
Hematoxylin and Eosin staining was performed on 4m paraffin sections for discerning 
histology. Mitotic figures were identified in hepatocytes. For quantification, hepatocytes with 
mitotic figures were counted in 3-5 random 200x fields from 3 livers from each group at 24h, 
40h and 72h. For IHC, paraffin sections were processed as described elsewhere (40, 89). A list of 
antibody dilutions is available in Table 10. Heat-mediated antigen retrieval was performed for 
IHC. Secondary antibodies conjugated to biotin were used at 1 to 400 and staining was detected 
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with DAB detection systems after incubation with avidin-biotin-complex (Vector). For 
quantification, PCNA-positive hepatocytes were counted in 3-5 random 200x fields from 3 livers 
from each group at 40h and 72h. For quantification of Cyclin D1-positive hepatocytes 
immediately bordering the central vein, we counted in both groups of mice at 24h, 40h and 72h 
after PH the number of Cyclin D1-positive hepatocytes lining the central vein over total 
hepatocytes lining that central vein and presented as a percentage. At least 5 central veins were 
randomly chosen for counting hepatocytes at 200x and at least 3 mice from each group and time 
were analyzed. 
5.3.8 Cell culture and shear stress analysis 
Primary murine liver sinusoidal endothelial cells (LSECs) and their culture medium Endothelial 
Cell Medium were purchased from Cell Biologics. Transformed Sinusoidal Endothelial Cells 
were a gift from Dr. Vijay Shah at the Mayo Clinic and Foundation (317) and cultured in 
Endothelial Cell Medium from Cell Biologics. Primary hepatocytes were isolated as described 
above and cultured in complete MHGM media described elsewhere (318). Raw Blue cells were 
obtained from InvivoGen and cultured in DMEM with 10% FBS. LSECs, and primary 
hepatocytes were cultured on 2% gelatin coated dishes. All cells were grown at 37°C in a 
humidified 5% CO2 incubator. 
Cells were cultured in 6-well plates and rotated on a cell culture incubator-appropriate 
orbital shaker (VWR) at 210 rotations per minute for 6 hours. RNA was then extracted using 
RNeasy mini kit (Qiagen). TSEC and LSEC were each cultured in triplicates and shear stress for 
6h. While we performed the studies in triplicates, these were performed once each as these cells 
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lose differentiation rapidly upon passaging and in prolonged culture (317, 319). Raw Blue cells 
and primary hepatocytes were cultured in triplicates and experiments were performed twice. 
5.3.9 Statistics 
Data are presented as mean, standard deviation, and/or individual data points. Graphs 
were generated using Graphpad or Microsoft Excel. P values were calculated using Two-tailed 
Student’s T-test or one-way ANOVA for multiple comparisons with either Tukey’s post-test 
correction or Fisher’s LSD test, and resulting P values less than 0.05 (*), less than 0.01 (**), less 
than 0.001 (***) or less than 0.0001 (****) were considered statistically significant. 
 
5.4 RESULTS 
5.4.1 Successful recombination of floxed alleles in hepatic sinusodial and central venous EC 
by Lyve1-Cre 
Since Lyve1 is a known lymphatic endothelial cell marker (320), we first wanted to 
confirm which EC in the liver undergo recombination. Lyve1-cre mice were crossed with 
ROSA26-Stopflox/flox-EYFP reporter mice. Confocal imaging showed YFP localization in 
sinusoidal EC as well as in EC lining central veins as highlighted by GS-expressing pericentral 
hepatocytes (Fig.34A). Since Lyve1 expression in adult liver has been reported in sinusoidal EC 
but not in EC lining central veins, we stained normal adult liver for Lyve1 (321, 322). Indeed, 
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Lyve1 localized to hepatic sinusoidal EC and not venous EC (Fig.34B). We also co-stained for 
Lyve1 and biliary marker EpCAM to distinguish portal from pericentral region (Fig.34C). 
Additional confirmation of Lyve1-cre driven recombination in hepatic sinusoidal and central 
venous EC was seen by co-localization of pan EC maker CD31 and YFP in ROSA26-Stopflox/flox-
EYFP; Lyve1+/- but not in ROSA26-Stopflox/flox-EYFP; Lyve1-/- controls (Fig.35). Thus, while 
Lyve1 was only expressed in hepatic sinusoidal EC in adult liver, it did recombine reporter gene 
in venous EC.  
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Figure 34: Lyve1-cre efficiently recombines floxed stop codon allowing expression of YFP in hepatic 
endothelia. 
(A) Two representative confocal images show immunofluorescence (IF) staining for YFP (red), 
GS (green) and DAPI (blue) revealing YFP positivity in EC lining the central vein flanked by 
GS-positive hepatocytes in addition to sinusoidal EC in livers from ROSA26-Stopflox/flox-EYFP; 
Lyve1-cre +/- mice. (B) Two representative confocal images for IF for Lyve1 and DAPI (blue) in 
control adult liver shows localization in predominantly hepatic sinusoidal EC but no staining in 
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EC lining central veins (*). (C) Two representative confocal images for IF for Lyve1 (red), 
EpCAM (green) and DAPI (blue) reveals predominant Lyve1 expression in sinusoidal EC in 
zones 1 and 2, and lack of Lyve 1 in EC lining central veins (*). EpCAM was used to outline bile 
ducts to help recognize periportal region.   
 
 
Figure 35: Confirmation of Lyve1-cre activity in sinusoidal and central venous EC in reporter mice 
via expression of YFP. 
Immunofluorescent imaging of staining for YFP (red), CD31 (green), DAPI (blue) shows co-
localization of YFP and CD31 in liver sections from ROSAeYFP+/+;Lyve1-Cre+/- but not in 
ROSAeYFP+/+;Lyve1-Cre-/- littermate controls (CON), shown at 100X magnification.  
5.4.2 EC cell derived Wnt proteins are required for expression of pericentral β-catenin 
targets and metabolic zonation 
To assess the role of EC Wnts in the liver, we conditionally deleted Wls using Lyve1-Cre 
through generation of EC-KO as described in the methods. Very similar to bKO and 5/6KO, we 
observed a significantly lower liver weight to body weight ratio (LW/BW) in EC-KO (40, 89, 
240) (Fig.36A). No additional phenotype at baseline was evident grossly.  
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A recent study showed the central vein EC cells are the source of Wnt2 and Wnt9b 
essential for pericentral -catenin activation (20). We next examined -catenin-dependent 
hepatic zonation targets in the EC-KO. While total β-catenin levels were comparable in EC-CON 
and EC-KO, levels of hypophosphorylated-active-β-catenin were notably reduced in the EC-KO 
at baseline by Western blot (WB) (Fig.36B). Likewise, a profound loss of -catenin targets 
including GS, Cyp2e1, and Cyp1a2 was also observed by WB and immunohistochemistry (IHC) 
(Fig.36B,C). To validate functionally the loss of metabolic zonation, we next administered high 
dose of acetaminophen (APAP) to EC-CON and EC-KO mice. Our lab and others have shown 
both bLKO and 5/6KO are protected from APAP-induced hepatic injury because they lack 
Cyp2e1 and Cyp1a2 and hence unable to convert APAP into N-acetyl-p-benzo-quinone imine 
(NAPQI), the metabolite critical for glutathione depletion and hepatocyte injury (40, 89, 90, 163, 
323). At 24h after APAP injection, EC-CON had expectedly high serum ALT and AST levels, 
while EC-KO showed normal transaminases demonstrating protection (Fig.36D). Thus, Wnts 
from central vein EC are essential for baseline -catenin activation and metabolic zonation. 
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Figure 36: Characterization of EC-KO reveals low liver weights and defective metabolic zonation. 
(A) EC-KO (n=6) have significantly lower LW/BW ratio at baseline as compared to littermate 
controls (n=7). (B) Representative WB shows noteworthy decreases in Cyp2e1, GS, Cyp1a2, and 
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active-β-catenin in ecWlsKO at baseline while total β-catenin is unaltered. (C) Representative 
IHC shows presence of GS, Cyp2e1, and Cyp1a2 in EC-CON in zone-3 hepatocytes, which is 
absence in EC-KO. (50X). (D) Significantly lower serum ALT and AST shows complete 
protection in EC-KO at 24h in response to a single intra-peritoneal injection of 450mg/kg of 
acetaminophen, as compared to EC-CON. (*p<0.05; ***p<0.001). 
5.4.3 β-Catenin-dependent delayed LR in EC-KO after PH 
EC-CON and EC-KO were next subjected to PH and regenerating livers harvested at various 
time-points as outlined in methods. PCNA labeling was assessed by IHC at 24h, 40h and 72h. As 
expected, no PCNA-positive hepatocytes were evident in both groups at 24h (Fig.37A). 
However, at 40h and 72h in EC-CON, several hepatocytes throughout the hepatic lobule were 
strongly PCNA-positive (Fig.37A,B). Intriguingly, we saw a consistent and complete lack of 
PCNA-positive hepatocytes in EC-KO at 40h (Fig.37A,B). At 72h, a noteworthy increase in the 
numbers of PCNA-positive hepatocytes was evident in EC-KO (Fig.37A).  
Decrease in PCNA-positive hepatocytes in EC-KO compared to EC-CON was significant 
at 40h but not at 72h (Fig.38A). Hepatocyte mitotic figures as index of cell division were 
counted and showed significantly lower mitotic figures in EC-KO at 40h (Fig.38B). Highest 
hepatocyte mitosis occurred at 40h in EC-CON whereas this peak was shifted to 72h in EC-KO 
(Fig.38B). These observations were consistent in both sexes. WB for PCNA also confirmed its 
absence at 24h in both EC-CON and EC-KO (Fig.38C) while its maximal levels were seen at 
40h in EC-CON with decline at 72h in both males and females (Fig.38C). PCNA was absent at 
40h in EC-KO and was highest at 72h in both males and females (Fig.38C). Thus, a notable 
delay in LR is evident in EC-KO in response to PH, which was similar to observations in bKO 
and 5/6KO.  
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To address if delay in LR in EC-KO is due to decreased β-catenin activation, we first 
examined β-catenin-TCF4 interaction by immunoprecipitation (IP). A dramatic decrease in 
TCF4-β-catenin association was observed in EC-KO at 24h after PH as compared to EC-CON in 
both sexes (Fig.38D). We concurrently assessed levels and localization of cyclin-D1, a β-
catenin-TCF4 target in LR. WB showed decreased cyclin-D1 in EC-KO at 24-40h in both sexes, 
although differences were less drastic in females likely due to higher basal cyclin-D1 (Fig.38C). 
At 72h, however, cyclin-D1 resurged in EC-KO and was almost comparable to EC-CON. GS, a 
known β-catenin target, continued to be absent all times in EC-KO indicating sustained loss of β-
catenin activity (Fig.38C). 
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Figure 37: IHC for PCNA in regenerating livers from EC-CON and EC-KO. 
(A) Representative IHC (100x and 200x) shows increased PCNA staining hepatocytes pan-
zonally at 40-72h in EC-CON, whereas EC-KO show positive staining only at 72h. (B) Larger 
panels (100x) highlighting differences in PCNA at 40h. 
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Figure 38: LR is notably delayed in the EC-KO mice as compared to controls. 
(A) Quantification of PCNA IHC shows significant decreases in number of hepatocytes staining 
positive at 40h after PH in EC-KO as compared to controls. No differences were evident at 72h. 
Each symbol represents average of 5 random images at 200x magnification from one mouse. 
Three or more mice from each group were used for each time-point. P value was calculated by 
one-way ANOVA for multiple comparisons with Tukey’s post-test correction.  (***p<0.001) (B) 
Number of hepatocytes showing mitotic figures were counted at 24h, 40h and 72h after PH in 
EC-KO and EC-CON. EC-KO showed a significant decrease at 24h and 40h while these number 
were comparable at 72h. Each symbol represents average of 5 random images at 200x 
magnification from one mouse. Three or more mice from each group were used for each time-
point. P value was calculated by ordinary one way ANOVA and multiple comparisons by 
uncorrected Fishers’s LSD. (*p<0.05; **p<0.01; ***p<0.001) (C) Representative WB showing 
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levels of cyclin-D1, PCNA, and GS in EC-CON versus EC-KO from 24-72h during LR. (D) 
Immunoprecipitation using anti-TCF4 and probing for β-catenin shows reduced TCF4-β-catenin 
association in EC-KO at 24h. 
5.4.4 LR begins pericentrally in EC-KO, unlike midzonal distribution in EC-CON 
IHC was performed next and showed Cyclin D1 staining in the EC-KO at 24h after PH in both 
periportal and midzonal hepatocytes while pericentral hepatocytes were negative (Fig.39A). At 
40h, Cyclin D1 localization expanded to additional hepatocytes in all zones sparing only some 
pericentral hepatocytes (Fig.39A). Cyclin D1-labeled hepatocytes were further increased at 72h 
including to a few pericentral hepatocytes (Fig.39A). EC-KO showed a prominent decrease in 
Cyclin D1 at 24h, but intriguingly, hepatocytes in the pericentral region showed positivity. At 
40h more layers of hepatocytes surrounding central vein became Cyclin D1-positive, in stark 
contrast to EC-CON (Fig.39A). Cyclin D1 labeling expanded further into the midzonal 
hepatocytes in EC-KO at 72h. These observations were evident in both male and female mice, 
although decreased Cyclin D1 was less prominent in females (IHC shown for males only). To 
further validate this observation, we quantified Cyclin D1-positive hepatocytes bordering the 
central vein only as described in online methods. At all 24h, 40h and 72H, EC-KO showed 
significantly greater cyclin D1-positive hepatocytes along the central vein than EC-CON. 
(Fig.39B). Thus, there were quantitative and qualitative differences in Cyclin D1 expression 
between the two groups. 
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Figure 39: Quantitative and qualitative differences in hepatocyte cyclin-D1 in EC-KO versus EC-
CON after PH. 
(A) Representative IHC shows a gradual increase in cyclin-D1 staining during LR in periportal 
and midzonal hepatocytes in EC-CON from 24-40h, and almost the entire lobule sparing a few 
pericentral hepatocytes at 72h. Cyclin-D1 staining was apparent in few pericentral hepatocytes in 
EC-KO livers at 24h after PH, and gradually increased in this zone at 40h, expanding further at 
72h. Black asterisk – portal triad; Red asterisk – central vein. (B) Quantification of cyclin-D1-
positive versus total hepatocytes lining only central veins is represented as a percentage for both 
EC-CON and EC-KO at 24h, 40h and 72h post-PH. Each symbol represents the average of at 
least 5 200x images around central vein from one mouse. Three or more mice from each group 
were used for each time-point. P value was calculated by ordinary one way ANOVA and 
multiple comparisons by uncorrected Fishers’s LSD. (**p<0.01; ***p<0.001; ****p<0.0001).  
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5.4.5 Hepatic stellate cells do not contribute to liver zonation or regeneration after PH 
Next we questioned whether hepatic stellate cells (HSC) contribute Wnts required for LR. We 
crossed Wls-floxed mice with mice expressing Cre under the Lecithin retinol acyltransferase 
(Lrat) promoter (HSC-KO) (314). Mice exhibited no phenotype at baseline, as liver weight to 
body weight ratios were comparable between HSC-KO and HSC-CON (Fig.40A). Further, 
hepatic zonation was comparable by immunohistochemistry of GS and western blotting of GS, 
Cyp2e1, and Cyp1a2 (Fig.40B, C). Intriguingly we observed decreased Cyclin D1 at baseline in 
HSC-KO, and this trend was sustained 40 hours after PH by western blot (Fig.40B). However, 
this trend was not observed by immunohistochemistry, as HSC-CON and HSC-KO had 
comparable Cyclin D1 and PCNA positivity at 40 hours and 72 hours (Fig.40D, E). The 
discrepancy in Cyclin D1 may result from western blot detection of nonparenchymal cell 
expression. Hence, we concluded HSC likely do not contributes Wnts required for LR.  
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Figure 40: HSC-KO have no notable phenotype at baseline or after PH compared to HSC-CON. 
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(A) Liver weight to body weight ratios of male and female HSC-KO and HSC-CON are 
comparable. (B) Western blot analysis at baseline (0 hour) and 40 hour post PH show no deficit 
in zonation, however HSC-KO have reduced cyclin D1 at 0 hour and 40 hour compared to HSC-
CON. (C) Representative immunohistochemistry images of glutamine synthetase show similar 
staining in HSC-CON and HSC-KO. (D) PCNA positivity was quantified. Three images were 
taken per sample and positive nuclei were counted, and the average of three images was 
considered. Images were taken blindly at 200x. (E) Immunohistochemistry of cyclin D1 and 
PCNA at 40 and 72 hours post PH show comparable staining in HSC-KO and HSC-CON. 
Images are taken at 100x. PCNA, proliferating cell nuclear antigen; 
5.4.6 EC-KO phenocopy bKO and 5/6KO, while MP-KO and HSC-KO do not 
Previous work suggested macrophages are a Wnt-secreting cell type after PH, although 
proliferation defects in MP-KO were marginal at 40h compared to bKO and 5/6KO (40). To 
confirm the primary source of Wnts are endothelial cells and not macrophages, we assessed 
Cyclin D1 transcription at various timepoints after PH in MP-CON and MP-KO. At 6hr and 24hr 
Cyclin D1 was comparable, and only at 40h was an insignificant but notable decrease in mRNA 
observed in MP-KO (Fig.41A). We verified this by comparing Cyclin D1 immunohistochemistry 
24h after PH in bKO, 5/6KO, EC-KO, MP-KO, and HSC-KO. Expectedly, bKO and 5/6KO had 
reduced Cyclin D1 compared to their respective controls, and EC-KO was the only cell-specific 
Wntless knockout model to phenocopy this finding (Fig.41B). MP-KO and HSC-KO had 
comparable Cyclin D1 levels to their controls, concluding that endothelial cells, but not 
macrophages or stellate cells, are the primary Wnt source after PH.  
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Figure 41: EC, but not MP or HSC, are the primary source of Wnts and phenocopy bKO and 5/6KO. 
(A) qPCR assessing Cyclin D1 expression of MP-CON and MP-KO at 6h, 24h, and 40h after 
PH. There is no reduction in Cyclin D1 until 40h. (B) Cyclin D1 immunohistochemistry at 24h 
after PH demonstrates decreased expression in bKO, 5/6KO, and EC-KO, with no deficit in MP-
KO or HSC-KO.  
5.4.7 Upregulation of Wnt2 and Wnt9b mRNA expression in endothelial cells hepatocytes 
in regenerating livers at 12h after PH 
Although unpublished, the data in section 5.4.7 has been previously described in a dissertation 
from a previous graduate student (280). Since our current study suggests EC are the major source 
of Wnts during LR and HSC and MP likely are not, we focused on EC-specific Wnt 
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contributions. We selected 12 hours after PH to query changes in Wnt expression in EC 
compared to baseline. 
Control mice were used to isolate hepatocytes and non-parenchymal cells by collagenase 
perfusion at 12h after PH, and cells were pooled from 2 mice (Fig.42A). Purity of isolated cells 
was confirmed by qPCR analysis for cell-specific markers. EC fraction was concluded to be pure 
judging by expression of Tie2 and Vegfr2, and absence of Albumin, CD68, and Lysozyme. MP 
fraction had marginal increase in EC-specific markers (Fig.42B), suggesting EC contamination 
and MP were discarded from further analysis. Analysis of hepatocyte fraction showed no 
appreciable changes in Wnt expression at 12h versus baseline (Fig.42C). Around 45-fold 
upregulation in the expression of Wnt2 and around 18-fold upregulation in the expression of 
Wnt9b was observed in EC at 12h after PH (Fig.42A). Lastly, at baseline, highest transcript 
levels of Wnt2 and Wnt9b were observed in EC, which increased significantly after PH 
(Fig.43B,C).  
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Figure 42: Cell isolation and purity validation from regenerating livers at 12h after PH. 
(A) Schematic summarizing the process of cell isolation and separation at 12h after PH. 
Hepatocytes were obtained from parenchymal cell (PC) fraction. Non-parenchymal cell (NPC) 
fraction was used to separate Macrophages (Mac) and endothelial cells (EC) using magnetic 
columns as outlined in supplemental methods. (B) Each fraction was tested for purity using qRT-
PCR for cell-specific gene expression. qRT-PCR for mouse albumin shows expression only in 
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hepatocytes (Hep) only, macrophage marker CD68 and Lysozyme in Mac fraction only, 
endothelial cell marker Vegfr2 and Tie2 in EC fraction, and small enrichment in Mac fraction, 
suggesting EC contamination of Mac. (C) Insignificant changes in selected Wnt genes by qRT-
PCR in hepatocytes at 12h after PH when compared to their respective baseline expression.  
 
 
Figure 43: Upregulation of Wnt2 and Wnt9b mRNA in EC during LR. 
(A) qRT-PCR analysis for selected Wnt genes in EC isolated from regenerating livers at 12h after 
PH. Y-axis denotes fold-change at 12h over baseline. Wnt2 mRNA increased 45-fold and Wnt9b 
around 15-fold. (B) Changes in Wnt2 and Wnt9b mRNA in hepatocytes (Hep) and EC. EC 
express highest levels of Wnt2 and Wnt9b mRNA both at baseline and after PH. 
5.4.8 Shear stress can induce Wnt2 and Wnt9b transcripts in endothelial cells in vitro 
Finally, to address the basis of Wnt upregulation in EC, which triggers β-catenin activation in 
hepatocytes thus contributing to LR, we investigated if shear stress on EC may be the major 
inciting mechanism. Portal pressure increase immediately after PH exerts shear stress along the 
sinusoids (324). There is evidence suggesting shear stress can influence EC signaling and is 
sufficient to induce LR (308). We cultured two liver-relevant EC, primary murine liver 
sinusoidal EC (LSEC) and a transformed murine liver sinusoidal EC line (TSEC) (317) and 
subjected them to orbital shear stress for 6h. Response of the two cells to shear stress was 
verified by a significant, approximate 80-fold induction of interleukin-6 (IL6) in both cells and 
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around 350-fold increase in endothelin-1 (ET1) in LSEC and around 200-fold increase in TSEC, 
two genes known to be highly shear-stress responsive (325, 326) (Fig.44A, B). In LSECs, orbital 
shear stress led to approximately 140-fold increase in expression of Wnt2 and 40-fold increase in 
Wnt9b (Fig.44C). In TSECs exposed to shear stress, Wnt2 and Wnt9b were upregulated 15- and 
40-fold, respectively (Fig.44D). Primary murine hepatocytes showed no change in expression of 
either Wnts when subjected to orbital shear stress (Fig.44E). Raw blue macrophage cell line 
showed no effect of shear stress on Wnt2 expression, but did induce Wnt9b marginally 
(Fig.44F). Thus, hepatic sinusoidal EC are highly responsive to shear stress, which led to 
profound upregulation of Wnt2 and Wnt9b mRNA expression. 
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Figure 44: Effect of in vitro shear stress on hepatic endothelial cells. 
(A) qRT-PCR results assessing expression of Interleukin-6 (IL6) and Endothelin-1 (ET1), 
following orbital shear stress generated by shaking primary liver EC (LSECs) and (B) 
transformed liver endothelial cell line (TSECs) at 210 rpm for 6h, which were profoundly 
induced. (****p<.0.001). (C) qRT-PCR on LSECs shows a significant increase in Wnt2 and 
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Wnt9b expression after shear stress. Y-axis denotes fold-change in mRNA expression during 
shear stress over static culture. (D) qRT-PCR on TSECs shows a significant increase in Wnt2 
and Wnt9b expression after shear stress. Y-axis denotes fold-change in mRNA expression during 
shear stress over static culture. (E) No change in mRNA expression of Wnt2 and Wnt9b in 
primary hepatocytes exposed to shear stress. (F) No change in mRNA expression of Wnt2 but a 
marginal but significant increase in Wnt9b expression in Raw blue macrophage cell line 
subjected to 6h of orbital shear stress. (*p<0.05; **p<0.01; ***p<0.005; ****p<0.001). 
5.5 DISCUSSION 
The current study is a continuation of our previous work identifying hepatocyte-specific 
β-catenin as a major driver of hepatic zonation and LR after PH (89). Further, β-catenin in both 
zonation and LR is under the control of paracrine Wnt signaling (40). In the same study, we 
ruled out hepatocytes, cholangiocytes and macrophages as sources of Wnts in regulating 
pericentral -catenin activation. However, macrophages were identified as one source of Wnts 
during LR, as macrophage-specific Wls knockout mice showed marginal and temporal decrease 
in Cyclin D1 and a resulting 20% deficit in hepatocyte proliferation at 40h.  
We previously used Tie2-Cre to ablate Wls from all EC, which led to embryonic 
lethality, thus precluding assessment of EC contribution to -catenin signaling in liver 
pathophysiology (40). We also employed PDGFi-Cre-ERT2 to generate EC-KO, which led to 
mosaic recombination insufficient for drawing concrete conclusions (data not shown) (327). 
Eventually, we employed transgenic mice expressing Cre recombinase under the lymphatic 
vessel endothelial hyaluronic acid receptor 1 (Lyve1) promoter. Lyve1 is expressed in lymphatic 
EC and intriguingly is also expressed in hepatic sinusoidal EC (321). Our careful fate tracing 
studies utilizing ROSA-YFP reporter mice also unveil Lyve1-dependent YFP expression in 
vascular EC in the liver including cells lining central veins, therefore enabling the removal of 
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Wls from most hepatic EC. This likely suggests vascular EC and sinusoidal EC may come from 
a common Lyve-1-positive progenitor cell, allowing for Cre activation in both cell types during 
embryonal development. 
EC-KO mice at baseline showed lower LW/BW ratios than their controls. This 
observation is consistent with lack of appropriate baseline -catenin activation in hepatocytes 
during early postnatal stages, which also led to lower LW/BW ratios in bKO and 5/6KO (40, 89). 
Indeed, our previous study has also shown -catenin activation to be imperative in hepatocyte 
proliferation during early postnatal hepatic growth (328). Our study now suggests that Wnts from 
EC in the liver are indeed responsible for driving -catenin activation during these early stages 
since livers show minimal basal proliferation after around 4-6 weeks of age. 
EC-KO mice at baseline also lacked pericentral -catenin targets like GS, Cyp2e1, and 
Cyp1a2 indicating disruption of metabolic zonation. This observation also phenocopied bKO and 
5/6KO (40, 89, 163). Recently, EC lining the central vein have been shown to be the primary 
source of Wnts required for -catenin activation in pericentral hepatocytes (20). This study also 
identified Wnt2 and Wnt9b to be two major Wnts responsible for this process. Since Lyve1-cre 
led to recombination of Wls alleles in central venous EC as well, -catenin dependent metabolic 
zonation was abrogated in EC-KO. The limited movement of Wnts in general owing to their 
hydrophobicity secondary to palmitoylation, which is essential for their biological activity, likely 
restricts -catenin activation to a few hepatocyte layers around central vein. Further, high APC 
expression in hepatocytes in periportal region also deters basal -catenin activity in that region 
(329). The basis of constitutive Wnt2 and Wnt9b release from EC lining central veins remains 
unknown.  
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EC-KO mice, like bKO and 5/6KO also show a comparable delay in LR (40, 89, 330). 
This was secondary to decreased expression of known -catenin target Cyclin D1 in hepatocytes 
after EC-KO were subjected to PH. This led to reduced numbers of hepatocytes entering S-phase 
as detected by PCNA IHC, also evident in bKO and 5/6KO during LR. However, at 72h, there 
was a rebound increase in both Cyclin D1 and PCNA in EC-KO, just like bKO and 5/6KO. 
Further analysis in EC-CON mice showed Cyclin D1 appearance in periportal and midzonal 
hepatocytes at 24h after PH and later expanding to all zones barring the most distal zone-3 
hepatocyte layer neighboring the central vein EC. Based on these observations, and proximity to 
hepatocytes, sinusoidal EC are likely the major source of Wnts during LR. This was affirmed by 
lack of Cyclin D1 until 40h and PCNA until 72h after PH in EC-KO. Intriguingly, the location 
where Cyclin D1 appears in EC-KO during LR was distinct in that it was evident most 
prominently in pericentral hepatocytes and extended towards other zones. We are unable to 
address the basis of this difference but posit this is due to activation of compensatory signaling to 
ensure LR during continually absent -catenin signaling. Indeed, redundancy in signaling 
pathways to ‘guarantee’ LR is well recognized (331).  
Both males and females mice lacking Wls in EC showed similar defect in LR. 
Intriguingly, PCNA-deficiency is evident in females at 40h despite higher basal Cyclin D1 
expression in EC-CON, suggesting that de novo Cyclin D1 expression and not the pre-existing 
pool is critical for initiating hepatocyte proliferation after PH. The pre-existing Cyclin D1 pool in 
females may be a function of estrogen since Cyclin D1 promoter has an estrogen-response 
element and known to control its expression (332). However, because of known pleiotropic 
functions of Cyclin D1 beyond proliferation such as in metabolism, it is likely that estrogen-
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dependent Cyclin D1 may be performing additional functions in female livers at baseline 
contributing to sexual dimorphism (333). 
Although convinced EC are the major source of Wnts during zonation and LR, we 
queried stellate cells (SC) in order to complete our assessment of liver cell populations. Our 
HSC-KO had no deficit in liver weight to body weight ratios or hepatic zonation at baseline. We 
also noted no difference in PCNA positivity at 40 hours or 72 hours. Oddly, HSC-KO displayed 
decreased Cyclin D1 at baseline and 40 hours by western blot, although these differences were 
not reconciled by immunohistochemistry (IHC), which showed comparable Cyclin D1. While we 
cannot conclusively state the reason for this discrepancy, one speculation is IHC is not sensitive 
enough to notice small differences that western blotting can identify. Alternatively, western blot 
accounts for all Cyclin D1 present, whereas IHC focuses on nuclear staining. However, Cyclin 
D1 has cytoplasmic roles regulating cell adhesion, mitosis, and migration under physiological 
and abnormal conditions (334, 335). Lastly, it is possible western blot accounts for 
nonparenchymal cell Cyclin D1 expression, while we emphasized hepatocyte-specific staining 
using IHC. Therefore, it would be of interest to identify whether HSC produce Wnts that regulate 
nonparenchymal cell proliferation after PH. 
We also vetted MP-CON and MP-KO more extensively, and found no differences in 
Cyclin D1 expression at early timepoints including 6 and 24h. Further, by qPCR, Cyclin D1 
decrease at 40h in MP-KO was statistically insignificant. To further confirm EC-KO as the only 
Wntless knockout animal model to phenocopy bKO and 5/6KO, we established a side-by-side 
comparison of Cyclin D1 via IHC at 24h to conclusively show EC-KO, bKO, and 5/6KO had 
similar decreases in Cyclin D1, unlike MP-KO and HSC-KO. It will be of interest to discover the 
mechanism by which MP-specific Wnts contribute to LR at 40h, but not before or after 40h. 
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The overall close resemblance of the mouse models of -catenin activity loss in 
hepatocytes including bKO, 5/6KO and EC-KO underscores the existence of a Wnt--catenin 
paracrine axis composed of EC and hepatocytes in contributing to normal LR after PH. Once the 
cell sources of Wnts during LR were identified, we next focused on discerning their identity. 
Intriguingly Wnt2 and Wnt9b, the same Wnts involved in zonation, were most profoundly 
upregulated in both EC and macrophages at the time before -catenin activation and Cyclin D1 
expression was apparent.  
In rats, nuclear translocation of β-catenin occurs almost immediately after PH (297). In 
mice, the kinetics of nuclear translocation is slower but is evident as 3-6h, with -catenin-TCF4 
complex formation observed at 4h persisting for 24-40h, and Cyclin D1 mRNA and protein 
expression increasing steadily from 12-72h (35, 40, 89, 336-338). Therefore, it is likely that there 
are preexisting stores of Wnt2 and Wnt9b proteins in hepatic sinusoidal EC, which get dumped 
towards hepatocytes for immediate -catenin activation which however would need to be 
sustained for successful hepatocyte proliferation at 40h. To conclusively prove such phenomenon 
would require labeled Wnts and intravital imaging. Previously, genetic ablation of vascular 
endothelial growth factor (VEGF)-A receptor-2 (VEGFR2) in the hepatic sinusoidal EC 
impaired hepatocyte proliferation after PH due to diminution of EC-specific transcription 
factor Id1 (19). In fact, Id1-deficient mice also showed defective LR initiation that was 
associated with decreased expression of hepatocyte growth factor (HGF) and Wnt2 in sinusoidal 
EC. We theorized that ongoing Wnt secretion from EC for sustained -catenin activation in 
hepatocyte would be a rather dynamic process and further conjectured enhanced sinusoidal 
pressure secondary to increased portal pressure, and its effect on sinusoidal EC, as the regulator 
of Wnt expression. Indeed, portal venous pressure is induced after PH which could be 
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recapitulated solely by portal vein branch ligation, triggering LR seen via immediately enhanced 
c-fos mRNA expression (308). Subjecting two EC from liver – primary LSECs and TSECs, a 
profound upregulation of both Wnt2 and Wnt9b was observed along with known shear-stress 
responsive genes like IL6 and ET-1 (325, 326). It is important to note that for both hepatic EC 
cell lines, only freshly isolated and plated cells were responsive to shear stress and became 
rapidly resistant upon passaging and prolonged plating, likely due to their de-differentiation, 
which is well known (317, 319). Nonetheless, strong induction in Wnt genes was unique to EC 
and not hepatocytes or macrophages. Interestingly, macrophage cell line showed mild 
upregulation of Wnt9b by 2.5-fold following exposure to shear stress. As macrophages also line 
sinusoids, it is possible increased portal pressure may initiate Wnt secretion in this cell type, 
albeit to a lesser extent. Alternatively, shear stress induced production of cytokines such as IL6 
or TNFα in EC, may influence Wnt expression in macrophages. While IL6 and TNF are not 
direct hepatocyte mitogens (331), these may influence hepatocyte proliferation by facilitating 
expression of Wnt genes in non-parenchymal cells. Recently, TNFα treatment was shown to 
induce Wnt2 mRNA in Raw Blue cells (338). Further confirmation is needed to elucidate 
whether shear stress-induced mitogen production can trigger Wnt production in resident liver 
macrophages or EC in vivo.  
In summary, we validate the paracrine function of Wnt--catenin pathway in regulating 
hepatic zonation and characterize the complex cell-molecule circuitry of the Wnt--catenin 
pathway during the process of LR after PH (Fig.8). We show that hepatic sinusoidal EC secrete 
Wnt2 and Wnt9b in response to enhanced shear stress, to act through Wnt-LRP5/6 to stabilize β-
catenin, enhance its nuclear translocation and complex with TCF to contribute to normal zone 1 
and zone 2 expression of Cyclin D1, which is critical for normal progression of hepatocytes into 
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S-phase of proliferation. Termination of Wnt/-catenin signaling upon accomplishment of 
hepatocyte proliferation is at least in part achieved by Wnt5a secretion from regenerated 
hepatocytes (21). See Figure 45 for working summary.  
 
Figure 45: Schema of Wnt/beta-catenin activation after LR, induced in part by shear stress. 
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6.0  CONCLUDING REMARKS AND GENERAL DISCUSSION 
6.1.1 Beta-catenin in hemochromatosis 
6.1.1.1 Current questions and future directions 
We have shown β-catenin is required for protection against hepatic iron overload in mice, in part 
due to its role in antioxidant production (108). There are many exciting questions that remain to 
be answered to further elucidate the mechanism and implications of β-catenin in iron-induced 
injury, and the molecular consequences that occur from loss of β-catenin in bKO. After chronic 
iron overload for three months, bKO had greater hepatic fibrosis, steatosis, inflammation, and 
oxidative stress. Further, we noted β-catenin target gene expression including GS and Cyp2e1 in 
bKO, mainly in areas of steatosis. This correlated with a resurgence of β-catenin expression 
evident by IHC. We speculated these β-catenin-positive cells were hepatocytes, but this should 
be confirmed. We also can confirm β-catenin reappearance is driving this ectopic GS and 
Cyp2e1 expression. β-Catenin was present homogenously throughout bKO+Fe livers, therefore 
we would expect zonation markers present at central veins, which was not the case. Yap has also 
been shown to upregulate GS, although a conflicting report demonstrated increased GS in Yap 
knockout mice (339, 340). Moreover, Yap is localized periportally, however this landscape likely 
changes after hepatic injury including iron overload seen in bKO, highlighting the importance of 
linking β-catenin resurgence to GS and Cyp2e1 expression in bKO+Fe. 
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 Additionally, there is an opportunity to identify the source of β-catenin-positive 
hepatocytes. The liver stem cells, also called “oval cells”, often arise when the liver must 
regenerate but hepatocytes and cholangiocytes are unable to proliferate (341). There is a positive 
correlation with the presence of ductular reaction, which was evident in bKO+Fe, and oval cell 
appearance in hepatic injury (151). However, if oval cells differentiate into liver epithelial cells, 
they will express Albumin and activate Cre, leading to loss of β-catenin. Therefore, it would be 
of interest to utilize a fate tracing model, such as a fluorescent reporter under the Forkhead Box 
L1 (FoxL1) promoter, to determine where these hepatocyte-like cells originate. FoxL1 is a bona 
fide hepatic progenitor marker (342). Alternatively, hepatic stellate cells may also be a source of 
these β-catenin-positive cells, as some data suggests if hepatocyte proliferation is blocked such 
as in the partial hepatectomy and 2-acetylaminofluorene model, stellate cells can 
transdifferentiate into progenitors and then into hepatocyte-like cells (343). Regardless of the cell 
source, the β-catenin-positive hepatocytes were unable to rescue the injury seen in bKO, 
suggesting their functionality is impaired or absent compared to bCON. 
Future directions also include determining whether β-catenin is under the control of Wnt, 
by analyzing whether 5/6KO phenocopy bKO after iron overload. Additionally, the role of 
macrophages should be assessed. We noted in bKO+Fe, large iron-laden cells that are likely 
macrophages engulfing dead hepatocytes and excess iron. Intriguingly, in patients, activation of 
Kupffer cells correlated with intercellular adhesion molecule 1 (ICAM) expression on 
hepatocytes, and lead to heightened disease severity including increased steatosis and fibrosis 
(129). It will be of interest to deplete macrophages using clodronate liposomes and identify 
whether the phenotype is improved. We did not see a macrophage response in bCON comparable 
to bKO, so elucidating the mechanism of macrophage recruitment in absence of β-catenin is 
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important. We can consider ICAM1, and the alternatively activated pathways we noticed in 
bKO+Fe, including AKT, ERK, and NFkB, and their potential roles in macrophage recruitment 
and activation. 
6.1.1.2 Clinical implications 
To our knowledge, this is the first animal model to physiologically recapitulate the most severe 
forms of hereditary hemochromatosis. We show that hepatic injury in bKO+Fe can be protected 
by the administration of antioxidants which raises the opportunity of using antioxidants for 
patients. Antioxidants such as vitamin C would sequester free iron and prevent conversion to 
toxic ferric iron and thus prevent free radical production. However, vitamin C acts as a pro-
oxidant in many pathological conditions (344), and in chronic iron overload, ferric iron 
paradoxically causes oxidation of antioxidants (345-347), preventing their efficacy as therapies. 
Therefore, our model will serve to identify and test new therapeutic options targeted for 
the most severe cases of HH.  
6.1.2 Cell-specific Wnts in HCC 
6.1.2.1 Current questions and future directions 
The role of the microenvironment in HCC is undisputable. We have tried to dissect the role of 
various relevant cellular elements in contributing to HCC development using a relevant injury 
and fibrosis model. We focus on Wnts from hepatocytes and macrophages in this model.  
A. Role of HP Wnts during DEN/CCl4 (Section 3.0) 
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At 5 months, we noted HP-KO had CK19-positive foci absent in HP-CON. Further, HP-KO had 
less E-cadherin expression than HP-CON at 5 months. E-cadherin inversely correlates with 
aggressive HCC and epithelial to mesenchymal transition (249). These findings together suggest 
the development of more aggressive stem-like tumors in HP-KO, however this was not evident at 
6 months. In fact, HP-KO and HP-CON had comparable tumor burden including CK19-
positivity and E-cadherin at this timepoint. We rationalized the DEN/CCl4 model is too 
hepatotoxic to appreciate contributions of HP Wnts, however further confirmation is possible. In 
this current study, the development of small, aggressive foci at 5 months in HP-KO are unable to 
grow and flourish after an additional month of CCl4 because the livers are continuously hit with 
toxins, allowing for additional oncogenic drivers and passengers to overshadow HP Wnt 
contributions. Therefore it will be advantageous to submit HP-CON and HP-KO to DEN/CCl4 
for 5 months, then let them “recover” for an additional month. This way, the oncogenic 
mutations and landscape present at 5 months can drive tumor advancement into late stages. 
CK19-positive foci in HP-KO may develop into full tumor nodules that undergo EMT, and we 
may observe more advanced tumors in HP-KO compared to HP-CON at 6 months like we 
initially predicted.  
B. Role of MP Wnts during DEN/CCl4 (Section 4.0) 
The definitive cause of two distinct phenotypes deserves further elucidation. While MP-CON A 
and MP-CON B had similar tumor burden, MP-CON A had increased cMyc, P38 MAPK, AR, 
and others, while MP-CON B had increased GS, M1 macrophages, and leukocytes. Although we 
predicted these differences resulted from MP-CON A and MP-CON B having different 
epigenetic signatures consequentially from different breeding pairs, this should be conclusively 
studied. To address whether epigenetic sexual dimorphism explains these two phenotypes, 
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multiple cohorts from breeders of male Wntless-floxed mice and female lysozyme-Cre mice, and 
of the reverse, should be subjected to DEN/CCl4. Ideally, Group A would result from one 
breeding scheme, and Group B would result from the other. Unbiased methylation arrays, such 
as LC-MS/MS (348), can then be used to assess whether general methylation differences exist in 
pups from different breeders. Animals with and without DEN/CCl4 should be considered. 
Further, we will ask whether increased protein expression of cMyc, P38 MAPK, and others, is 
due to increased activated histone modifications. We can use histone-modification-specific 
antibodies to test the presence of specific modifications such as activating methylation marks, 
and perform chromatin immunoprecipitation and sequencing (ChIP-seq) to test whether the 
promoters of specific genes like cMyc are activated in MP-CON A versus MP-CON B. DNA 
methylation and histone methylation are strongly linked (349), enabling us to correlate our 
findings to LC-MS/MS data. We will assess tumors and adjacent non-tumor tissue, as it is 
possible changes in epigenetics will be observed only in tumors. 
If we are unable to explain our two phenotypes via epigenetics, we predict differences in 
gut microbiota may lead to two different HCC types. Microbiota depletion via antibiotics 
protects mice against DEN/CCl4-induced HCC (225). Further, strains including C57BL/6 mice 
have considerable variability in their microbial composition (350). Predictably, litters housed in 
the same cage may have comparable microbiomes resulting from maternal transfer and 
coprophagy (351).  
While we show MP Wnts can suppress or promote tumorigenesis, further studies are 
required to fully characterize the environment that determines MP Wnts role. In particular, does 
the presence of overexpressed cMyc or P38 MAPK, as seen in MP-CON A, predict MP Wnts are 
tumor suppressive? While cMyc is “undruggable”, liver epithelial cell-specific cMyc knockout 
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mice are viable (352) and could be crossed with MP-KO to determine whether these double 
knockouts have less tumors than controls. Several P38 MAPK inhibitors exist such as SB203580 
(353), and could be administered to MP-KO as well. Moreover, does more leukocyte infiltration 
and M1 macrophage polarization drive Group B tumors? By taking MP-CON and littermate MP-
KO, subjecting them to DEN/CCl4 while providing anti-CD47 treatment to stimulate M1 
macrophage polarization (354), we can attempt to shift all animals towards a Group B phenotype 
and identify whether MP-KO reduces tumor burden.  
6.1.2.2 Clinical implications 
Several studies suggest inhibiting Wnt signaling alone or in combination will have significant 
therapeutic value (221, 355-357). However, these studies are performed in vitro or with 
xenograft models, and therefore do not recapitulate the tumor microenvironment or disease 
progression seen in patients. In our study, we used a clinically relevant chemical model to assess 
HP Wnt contributions and MP Wnt contributions. Our results suggest inhibiting HP-specific 
Wnts may not have any patient benefit, as tumors still develop and progress in their absence, 
albiet via distinct mechanisms. Once we delineate the specific molecular and immunological 
patterns that determine whether MP Wnts will contribute to or inhibit tumor growth based on 
epigenetic or other mechanisms, we can use this information to predict whether a patient will 
benefit from MP-Wnt suppression, provided a tumor biopsy is accessible.  
6.1.3 Role of Wnt/beta-catenin in LR after PH 
6.1.3.1 Current questions and future directions 
 
 158 
We undisputedly show the role of endothelial cell Wnts in both hepatic zonation and Cyclin D1-
dependent hepatocyte regeneration after partial hepatectomy. Future directions include 
confirming the mitogenic roles of Wnt2 and Wnt9b during LR and in homeostatic zonation. We 
are currently generating Wnt2-floxed mice and are obtaining Wnt9b-floxed mice to create cell-
specific conditional knockouts. Further, using rats we can confirm in vivo that shear stress can 
induce Wnt secretion from EC using a portal vein branch ligation model which increases portal 
pressure while leaving the liver intact (308, 310). Lastly, we plan to further scrutinize our HSC-
KO animals after PH to further confirm SC do not play a role in LR. 
To continue developing a complete kinetic profile of Wnt/-catenin signaling in LR, 
there are many variables to consider. The role of the Rspondin (Rspo) axis will be of importance. 
Rspo ligands signal through LGR receptors to augment Wnt signaling by preventing 
internalization of Wnt receptors (26). Loss of LGR4/5 or Rspo3 was shown to ablate β-catenin-
dependent zonation at baseline, and addition of Rspo1 to increase pericentral fate (286, 358). 
Moreover, LGR4/5 KO showed delayed LR after PH (358). Preliminary data not shown suggests 
Wnt2 and Wnt9b are unable to induce -catenin-TCF-dependent transcription in vitro, unless 
Rspo3 is present, but further studies in primary hepatocytes will be relevant. Considering current 
literature suggesting Rspo is required for Wnt signaling during LR, future studies can elucidate 
the cellular source and identity of Rspo required after PH.  
The identity of Fzd receptors required during LR will also be of interest. Whole liver 
expresses eight of ten Fzd receptors with several of them expressed in hepatocytes (11). While 
Fzd7 and Fzd6 have defined roles in hepatic carcinogenesis (44, 217), to our knowledge no one 
has determined the receptors that interact with Wnt2 and/or Wnt9b during LR, which would 
greatly enhance our understanding of canonical Wnt signaling. 
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Another interesting question is the role of macrophage-specific Wnts during LR. As 
mentioned, we previously reported MP-KO have a slight regeneration deficit and hepatic 
zonation is unaffected. While this could suggest MP are a secondary contributor of Wnts, we 
speculate MP-Wnts indirectly contribute to LR through their interactions with EC. Indeed, MP 
depletion studies have concluded MPs are required for viable EC and to activate them during 
different hepatic injury models (359, 360), so it would be of interest to assess EC phenotype in 
MP-KO to determine if MP-Wnts are required for healthy EC.  
An important unanswered question that requires further investigation is the molecular 
basis of regeneration in the three genotypes that lack ‘physiological’ β-catenin activation 
including bKO, 5/6KO, and EC-KO. A simplest explanation is that the liver has a common 
redundant mechanism that is activated when β-catenin activation via Wnts is hampered in the 
three genotypes based on similarly decreased Cyclin D1 at 24h-40h, lack of PCNA at 40h and 
increased Cyclin D1 and PCNA at 72h. Also, lack of GS-positivity in EC-KO at 72h despite 
resurgence of Cyclin D1 and initiation and expansion of Cyclin D1 expression at 24-72h that 
occurs from pericentral zone to periportal zone (as opposed to periportal to pericentral zone in 
control mice), suggests activation of a non-Wnt, non-β-catenin mechanism. However, the 
molecular basis of LR could also be distinct due to disruption of non-β-catenin signaling at 
different levels, in these three models. β-Catenin activation through any mechanism is precluded 
only in the bKO since they lack β-catenin in hepatocytes and hence redundant signaling has to be 
β-catenin-independent. β-Catenin activation through any Wnt is not possible in both bKO as 
well as 5/6KO, since the latter lack Wnt co-receptors, although β-catenin can be activated in the 
latter via non-Wnt-dependent mechanisms since β-catenin is still present in the hepatocytes. β-
Catenin activation in hepatocytes cannot occur via Wnts from EC in either bKO, 5/6KO, or EC-
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KO, but only in the latter can Wnts from non-EC sources activate β-catenin to eventually drive 
LR at 72h. A direct comparison of the three strains at various time points after PH is ongoing to 
elucidate the basis of LR in both biased and unbiased analysis. By identifying pathways that 
create redundancy for loss of canonical Wnt signaling during LR, we will contribute to overall 
knowledge of the “hepatostat” and mechanisms required for liver homeostasis. 
6.1.3.2 Clinical implications 
Currently the only effective treatments for most liver diseases are liver transplant or surgical 
resection (290, 291), which are often unrealistic due to lack of donor organs and poor 
regenerative capabilities of injured or transplanted livers, frequently causing hepatocyte 
dysfunction and “small-for-size syndrome” (361). Not surprisingly, impaired liver regeneration 
(LR) is the major cause of liver failure and liver-related death worldwide (294). Therefore, by 
understanding what initiates and propagates LR in a healthy model, we can develop alternative 
therapies utilizing the natural regenerative potential of the liver.  
While the major goal of this study is to further understand upstream mechanisms of β-
catenin signaling during LR, these and future results have therapeutic implications for liver 
disease patients. If we can activate β-catenin in hepatocytes after surgical resection, for example, 
possibly through stimulating Wnt production in endothelial cells, we could improve LR and 
patient survival. We can stimulate Wnt production during living donor transplants to decrease 
recovery time and improve regeneration, or to prevent “small-for-size syndrome”. Our lab has 
shown thyromimetics such as T3 and GC-1 initiate hepatocyte proliferation dependent on β-
catenin activation (362). Currently more physiological means are being pursued such as use of 
surrogate Wnt agonists (363). 
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APPENDIX A 
LIST OF ANIMALS USED IN STUDY 
 
 
Table 12: All animals used in study 
 
 
 
 
 
 
 
Animal Abbreviation  Description Reference 
Alb-Cre+/-;Ctnnb1fl/fl bKO Hepatocyte and 
cholangiocyte-specific 
β-catenin knockout 
(89) 
Lrp5fl/flLrp6fl/fl;Alb-
Cre+/- 
5/6KO Hepatocyte and 
cholangiocyte-specific 
Lrp5/6 double 
knockout 
(40) 
Wntlessfl/fl;Alb-Cre+/- HP-KO Hepatocyte and 
cholangiocyte-specific 
Wntless knockout 
(40) 
Wntlessfl/fl;Lyz-Cre+/- MP-KO Macrophage Wntless 
knockout 
(40) 
Wntlessfl/fl;Lyve1-
Cre+/- 
EC-KO Endothelial cell 
Wntless knockout 
(312) 
Wntlessfl/fl;Lrat-Cre+/- HSC-KO Hepatic stellate cell 
Wntless knockout 
(314) 
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